

CTAD^{Alzheimer} 2024

Clinical Trials on Alzheimer's Disease

Final program



In-Person



Remote

October 29 – November 1, 2024

Madrid, Spain

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11 / Monte Carlo '12
San Diego '13 / Philadelphia '14 / Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18
San Diego '19 / Virtual '20 / Boston '21 / San Francisco '22 / Boston '23

www.ctad-alzheimer.com

Email: ctad@ant-congres.com



SUMMARY

Organizing & Scientific Committees	3
Lifetime Achievement Award	4
Keynotes	5
Onsite Program	8
Tuesday, October 29	9
Wednesday, October 30	11
Thursday, October 31	15
Friday, November 1	20
Poster presentations	26
Sponsors	60
Practical details	61



CTAD National Organizing Committee

Leocadio Rodriguez-Manas, MD, PhD (Hospital Universitario de Getafe - Getafe, Spain)

Pascual Sanchez-Juan, MD, PhD (Centro Alzheimer Fundacion Reina Sofia - Madrid, Spain)

Merce Boada, MD, PhD (ACE Alzheimer Center - Barcelona, Spain)

Organizing and Scientific Committees

Susan ABUSHAKRA (San Francisco, USA); Paul AISEN* (San Diego, USA); Rebecca E. AMARIGLIO (Boston, USA); Davide ANGIONI (Toulouse, France); Laura D. BAKER (Winston-Salem, USA); Randall J. BATEMAN (St. Louis, USA); Karim BENNY (Montpellier, France); Kaj BLENNOW (Molndal, Sweden); Merce BOADA (Barcelona, Spain); Marc CANTILLON (Livingston, USA); Maria CARRILLO (Chicago, USA); Suzanne CRAFT (Winston-Salem, USA); Lucia CRIVELLI (Buenos Aires, Brazil); Steven DEKOSKY (Miami, USA); Michael C. DONOHUE (San Diego, USA); Rachelle DOODY (Houston, USA); Bruno DUBOIS (Paris, France); Howard FELDMAN (San Diego, USA); Howard FILLIT (New-York, USA); Nick FOX (London, UK); Kristian Steen FREDERIKSEN (Copenhagen, Denmark); Giovanni B. FRISONI (Brescia, Italy); Serge GAUTHIER (Montreal, Canada); Joshua GRILL (Los Angeles, USA); Michael GRUNDMANN (San Diego, USA); Harald HAMPEL (Nutley, USA); Oskar HANSSON (Lund, Sweden); Tobias HARTMANN (Hamburg, Germany); Jakub HORT (Prague, Czech Republic); Takeshi IWATSUBO (Tokyo, Japan); Frank JESSEN (Cologne, Germany); Ara KHACHATURIAN (Washington DC, USA); Zaven KHACHATURIAN (Washington DC, USA); Miia KIVIPELTO (Stockholm, Sweden); Yan LI (St. Louis, USA); Jorge J. LLIBRE GUERRA (St. Louis, USA); Constantine G. LYKETSOS (Baltimore, USA); Gad A. MARSHALL (Boston, USA); Lefkos T. MIDDLETON (London, UK); José Luis MOLINUEVO (Valby, Denmark); Claire PAQUET (Paris, France); Robert PERNECZKY (Munich, Germany); Ronald PETERSEN (Minnesota, USA); Michael S. RAFFI (San Diego, USA); Rema RAMAN (San Diego, USA); Craig W. RITCHIE (Edinburgh, UK); Robert RISSMAN (San Diego, USA); Marwan SABBAGH (Phoenix, USA); Stephen SALLOWAY (Providence, USA); Pascual SANCHEZ-JUAN (Madrid, Spain); Nikolaos SCARMEAS (New York, USA); Rachel SCHINDLER (New York, USA); Philip SCHELTENS (Amsterdam, NL); Lon SCHNEIDER (Los Angeles, USA); Eric SIEMERS (Philadelphia, USA); Sietske SIKKES (Amsterdam, NL); Yong SHEN (Hefei, China); Jiong SHI (Hefei, China); Heather SNYDER (Chicago, USA); Reisa SPERLING (Boston, USA); Yaakov STERN (New York, USA); Duygu TOSUN (San Francisco, USA); Jacques TOUCHON* (Montpellier, France); Christopher H. VAN DYCK (New Haven, USA); Bruno VELLAS* (Toulouse, France); Prashanthi VEMURI (Rochester, USA); Michael W. WEINER* (San Francisco, USA); Donna M. WILCOCK (Indianapolis, USA); Bengt WINBLAD (Stockholm, Sweden); Jin-Tai YU (Shanghai, China)

*Organizing Committee Member

CTAD 2024

Lifetime Achievement Award

This year the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research, is awarded to Lars Lannfelt MD, PhD in recognition for his pioneering work in Alzheimer's Disease Scientific Discoveries and Drug Development.



Lars Lannfelt, MD, PhD
Professor, Uppsala University, Uppsala (Sweden)

Professor of Molecular Geriatrics at Uppsala University since 2001, elected to the Royal Swedish Academy of Sciences in 2004. A major scientific achievement was the detection of the "Swedish" mutation. This genetic mutation causes Alzheimer's disease in a large family and leads to 3-5 times increased production of amyloid β ($A\beta$). Another major scientific breakthrough was the detection of the "Arctic" mutation, found in a family from northern Sweden. The pathogenic effect of the mutation was a propensity to generate soluble aggregated $A\beta$, protofibrils. These species of $A\beta$ are toxic. This inspired him to target $A\beta$ protofibrils with immunotherapy and they developed an antibody selective for $A\beta$ protofibrils, mAb158. In 2003, he co-founded BioArctic, based on the discovery of the Arctic mutation. BioArctic has signed a long-term license agreement with Eisai Pharmaceuticals of Japan on the clinical development of lecanemab. Results from phase 3 came in September 2022, and primary and all key secondary end-points were being met.

He was awarded the Bengt Winblad's prize for increased understanding of the pathogenesis of Alzheimer's disease (2022), the Rudbeck Medal for scientific discoveries, Uppsala University (2021), the Khalid Iqbal Lifetime Achievement Award in Alzheimer's Disease Research and the Swedish Alzheimer's Foundation (Alzheimerfonden) Grand Research Prize (2019).

Keynotes



“Next Generation of Clinical Trials for Alzheimer’s Disease and Related Disorders”

Catherine Mummery, MD, PhD

Neurologist, Head of Clinical Trials, Dementia Research Center, University College London, London (United Kingdom)

Cath Mummery is a consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, building a national unified trials network for early phase clinical trials and working with the Mission to accelerate and enhance dementia translational research in novel treatments. She is Head of Clinical Trials at the Dementia Research Centre at University College London, and Deputy Director for the Leonard Wolfson Experimental Neurology Centre. She has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer’s disease (AD), and genetic forms of AD and frontotemporal dementia. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a program of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer’s, but that we can deliver them promptly, safely and equitably.



“Lecanemab: from a mutation to a treatment for Alzheimer’s disease”

Lars Lannfelt, MD, PhD

Professor, Uppsala University, Uppsala (Sweden)

Professor of Molecular Geriatrics at Uppsala University since 2001, elected to the Royal Swedish Academy of Sciences in 2004. A major scientific achievement was the detection of the “Swedish” mutation. This genetic mutation causes Alzheimer’s disease in a large family and leads to 3-5 times increased production of amyloid β (A β). Another major scientific breakthrough was the detection of the “Arctic” mutation, found in a family from northern Sweden. The pathogenic effect of the mutation was a propensity to generate soluble aggregated A β , protofibrils. These species of A β are toxic. This inspired him to target A β protofibrils with immunotherapy and they developed an antibody selective for A β protofibrils, mAb158. In 2003, he co-founded BioArctic, based on the discovery of the Arctic mutation. BioArctic has signed a long-term license agreement with Eisai Pharmaceuticals of Japan on the clinical development of lecanemab. Results from phase 3 came in September 2022, and primary and all key secondary end-points were being met. He was awarded the Bengt Winblad’s prize for increased understanding of the pathogenesis of Alzheimer’s disease (2022), the Rudbeck Medal for scientific discoveries, Uppsala University (2021), the Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research and the Swedish Alzheimer’s Foundation (Alzheimerfonden) Grand Research Prize (2019).



“Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?”

Rachelle Doodu, MD, PhD

Houston, TX (USA)

Rachelle Doodu is a distinguished neurodegeneration expert with a profound commitment to advancing treatments for neurodegenerative diseases. Extensive industry, clinical and academic medicine experience have shaped her views of personalized care and meaningful outcomes for patients. As the Global Head of Neurodegeneration and Alzheimer's disease and Neurodegeneration Franchise Head at Roche Pharmaceuticals and the US affiliate, Genentech (2016-Feb. 2024), she successfully created and led late-stage development programs for Alzheimer's, Parkinson's, and Huntington's diseases, aiming to provide comprehensive solutions from diagnostics to therapeutics. Board certified in Neurology and Psychiatry, Dr. Doodu trained at Baylor College of Medicine in Houston, Texas and McGill University in Montreal. While at Baylor College of Medicine, she founded and directed the Alzheimer's Disease and Memory Disorders Center and was the Effie Marie Cain Chair in AD Research. She also holds an MA/PhD in cognitive anthropology from Rice University. Dr. Doodu has served on steering committees for the National Institutes of Health-funded Alzheimer's Disease Cooperative Study and Alzheimer's Disease Neuroimaging Initiative, and the executive committee for the Alzheimer's Therapeutic Research Institute. Dr. Doodu was the Principal Investigator for the Phase 2 and 3 development of donepezil (Aricept), the most widely-used AD therapy globally, and contributed to the development of most of the other approved AD treatments as well as several under development. For over 30 years, Dr. Doodu has worked with biotech and pharma companies in the design and execution of trials for cognitive and behavioral treatment of AD. She has contributed to efforts to globalize approaches to AD, advising on guidelines in China, Malaysia, South Korea and the Philippines, and educating investigators throughout Europe and Asia on study design and outcome measures to support global studies. Dr. Doodu has published over 235 original articles in this field, has been awarded with a Lifetime Achievement Award by the Clinical Trials in Alzheimer's Disease group in 2018, and is Immediate Past-Chair of the US Alzheimer's Association Research Roundtable. She is a Distinguished Alumna from Rice University and Distinguished Faculty Award winner from Baylor College of Medicine.



“Fluid biomarkers in research, clinical trials, and clinical practice”

Suzanne E. Schindler MD, PhD

Associate Professor of Neurology, Washington University School of Medicine, St. Louis, MO (USA)

Dr. Suzanne Schindler is a clinical neurologist and neuroscientist focused on improving the diagnosis and treatment of Alzheimer disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E metabolism. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia. Currently Dr. Schindler sees patients with memory concerns and coordinates biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center. She received a large R01 to evaluate novel fluid biomarkers. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare.

ONSITE PROGRAM

in Madrid

Available via livestream
on the CTAD24
digital platform

Demographics and baseline disease

Amyloid PET SUVR, mean composite \pm SD

Age in years, mean \pm SD

Female, n (%)

AD medications used, n (%)

ApoE ϵ 4, n (%)

Carrier

Non-carrier

Clinical stage, n (%)

MCI due to AD

Mild AD

CDR-SB score, mean \pm SD

MMSE score, mean \pm SD

ADAS-Cog13 score, mean \pm SD

ADCS-ADL-MCI score, mean \pm SD

Patients that reached amyloid plaque negative status at Week

- Lower baseline amyloid burden
- A higher proportion of ApoE ϵ 4 noncarriers; this finding is a protocol amendments²

Program at a glance

● Tuesday, OCTOBER 29

- 2:45 p.m. POSTER WALKING TOUR
- 3:15 p.m. TAKING CARE – A movie
- 4:00 p.m. Opening Ceremony
- 4:20 p.m. CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research
- 4:30 p.m. KEYNOTE 1: Lecanemab: from a mutation to a treatment for Alzheimer's disease
- 4:55 p.m. ORAL COMMUNICATIONS
- 6:10 p.m. LATE BREAKING SYMPOSIUM: The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial
- 7:00 p.m. CTAD Networking Event with the Support of the Alzheimer's Association

● Wednesday, OCTOBER 30

- 7:30 a.m. POSTER WALKING TOUR
- 8:30 a.m. LATE BREAKING COMMUNICATIONS
- 9:15 a.m. KEYNOTE 2: Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders
- 9:40 a.m. SYMPOSIUM 1: Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?
- 10:20 a.m. Coffee break and poster session
- 10:50 a.m. LATE BREAKING COMMUNICATIONS
- 11:35 a.m. ORAL COMMUNICATIONS
- 12:45 p.m. Lunch and poster sessions
- 1:45 p.m. ROUNDTABLE: Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments
- 2:15 p.m. ORAL COMMUNICATIONS
- 3:30 p.m. LATE BREAKING SYMPOSIUM: One-Year Experience on the Use of Lecanemab in Clinical Practice
- 4:10 p.m. Coffee break and poster session
- 4:40 p.m. ORAL COMMUNICATIONS
- 6:10 p.m. End of the Conference Day

● Thursday, OCTOBER 31

- 7:30 a.m. POSTER WALKING TOUR
- 8:30 a.m. LATE BREAKING COMMUNICATIONS
- 9:45 a.m. KEYNOTE 3: Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?
- 10:10 a.m. ORAL COMMUNICATIONS
- 10:55 a.m. Coffee break and poster session
- 11:25 a.m. ORAL COMMUNICATIONS: Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease
- 12:00 p.m. LATE BREAKING COMMUNICATIONS
- 12:30 p.m. Lunch and poster sessions
- 1:30 p.m. LATE BREAKING COMMUNICATIONS
- 2:00 p.m. KEYNOTE 4: Fluid biomarkers in research, clinical trials, and clinical practice
- 2:25 p.m. ORAL COMMUNICATIONS
- 3:10 p.m. LATE BREAKING COMMUNICATIONS
- 3:55 p.m. Coffee break and poster session
- 4:25 p.m. ORAL COMMUNICATIONS
- 5:10 p.m. LATE BREAKING SYMPOSIUM: Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal-mild AD
- 5:50 p.m. End of the Conference Day

● Friday, NOVEMBER 1

- 7:30 a.m. POSTER WALKING TOUR
- 8:30 a.m. LATE BREAKING COMMUNICATIONS
- 9:30 a.m. ORAL COMMUNICATIONS
- 10:30 a.m. Coffee break and poster session
- 11:00 a.m. LATE BREAKING ORAL COMMUNICATIONS
- 12:00 p.m. LATE BREAKING ROUNDTABLE
- 12:30 p.m. Lunch and poster sessions
- 1:30 p.m. LATE BREAKING SYMPOSIUM: Cannabinoid based medications for neuropsychiatric symptoms in Alzheimer's dementia
- 2:10 p.m. ORAL COMMUNICATIONS
- 3:10 p.m. Coffee break and poster session
- 3:40 p.m. LATE BREAKING ORAL COMMUNICATIONS
- 5:10 p.m. End of the Conference Day

● Tuesday, OCTOBER 29

2:45-3:15 p.m.

POSTER WALKING TOUR

3:15 p.m.

TAKING CARE – A movie

Directed and produced by award-winning filmmaker James Keach, and produced by Seth Rogen and Lauren Miller Rogen. This 40-minute documentary featuring the story of Lauren and Seth's courtship and marriage as their family faces the complexities and heartbreak of Lauren's mother's advancing early-onset Alzheimer's disease.

4:00 p.m.

Opening Ceremony

Pascual Sánchez-Juan, and Jacques Touchon on behalf of the CTAD Organizing Committee
Paul Aisen, Sandrine Andrieu, Lefkos Middleton, Reisa Sperling, Bruno Vellas and Mike Weiner and the National Organizing committee, Merce Boada and Leocadio Rodríguez Mañas

4:20 p.m.

CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research

Presented to Lars Lannfelt, MD, PhD in recognition for his pioneering work in Alzheimer's Disease Scientific Discoveries and Drug Development
Introduction by Lefkos Middleton, Imperial College London, London (United Kingdom)

4:30 p.m.

KEYNOTE 1

Lecanemab: from a mutation to a treatment for Alzheimer's disease

Lars Lannfelt, Uppsala University, Uppsala (Sweden)

4:55 p.m.

ORAL COMMUNICATIONS

Chairs: Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States), Suzanne Craft, Wake Forest School of Medicine - Winston Salem (United States)

4:55 p.m.

OC1 - The Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer's Disease: Primary Outcome Results from TRAILBLAZER-ALZ 6

Hong Wang¹, Emel S. Nery¹, Paul Ardayfio¹, Dunlei Cheng¹, Rashna Khanna¹, Diana Otero Svaldi¹, Paula Hauck¹, Sergey Shcherbinin¹, Dawn A. Brooks¹, Emily C. Collins¹, Mark A. Mintun¹, John R. Sims¹

¹Eli Lilly and Company - Indianapolis (United States)

5:10 p.m.

OC2 - Fosgonimeton for the Treatment of Alzheimer's Disease; Efficacy and Safety Results from the LIFT-AD Trial

Anton P Porsteinsson², Kevin J Church¹, Javier San Martin¹, Michael D Hale¹, Len B Walt⁴, Simon Daggett¹, Hans J Moebius³

¹Athira Pharma, Inc., Bothell, WA (United States); ²Alzheimer's Disease Care, Research and Education Program, University of Rochester School of Medicine and Dentistry, Rochester, NY (United States); ³moebius-consult GmbH, Baar ZG (Switzerland); ⁴SSI Strategy, Parsippany-Troy Hills, New Jersey (United States)

5:25 p.m.

OC3 - Immunometabolic and Vascular Modulators for Combination Therapy in AD: Results of a Phase II Trial of Intranasal Insulin and the SGLT2 Inhibitor Empagliflozin

Jennifer Erichsen¹, Thomas Register¹, Courtney Sutphen¹, James R. Bateman¹, Melissa Rundle¹, Marc Rudolph¹, Samuel Lockhart¹, Suzanne Craft¹

¹Wake Forest School of Medicine - Winston-Salem (United States)

5:40 p.m.

OC4 - Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD

Kristin Wildsmith¹, Kanta Horie^{1,2}, Arnaud Charil¹, Nicolas Barthelemy², David Verbel¹, Anthonin Reihac-laborde¹, Brian Gordon², Peter Boyd³, Robert Bell¹, Sumit Rawal¹, Erica Andreozzi¹, Tammie Benzinger², Randall Bateman², Jin Zhou¹, Larisa Reyderman¹

¹Eisai Inc. - Nutley (United States), ²Washington University School of Medicine - St Louis (United States), ³Eisai Europe Ltd. - Hatfield (United Kingdom)

● Tuesday, OCTOBER 29

5:55 p.m.

OC5 - Results from COGO201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer's Disease

Michael Woodward¹, Everard Vijverberg^{2,3}, Susan Catalano⁴, Theresa Devins⁵, Valentina Di Caro⁵, Michael Grundman⁶, Mary Hamby⁵, Jennifer Iaci⁵, Anthony Caggiano⁵

¹Austin Health - Melbourne, Victoria (Australia), ²Brain Research Center - Amsterdam (Netherlands), ³UMC - Amsterdam (Netherlands), ⁴Capsida Therapeutics - Thousand Oaks (United States), ⁵Cognition Therapeutics, Inc., New York (United States), ⁶Global R&D Partners, LLC - La Jolla (United States)

6:10 p.m.

Late breaking Symposium 1 - The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial

Chair: Rema Raman, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States)

Presentation 1: The AHEAD 3-45 Study: Adaptation to Challenges

Paul Aisen, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States)

Presentation 2: Screening Plasma Biomarkers, Amyloid and Tau PET Imaging in the AHEAD 3-45 Study

Reisa Sperling, Brigham and Women's Hospital, Harvard Medical School and Massachusetts General Hospital, Harvard Medical School, Boston (United States)

Presentation 3: Racial and Ethnic Differences in Plasma P-tau217 Biomarker Eligibility Rates in a Preclinical AD Trial

Doris Molina Henry, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego (United States)

7:00 - 8:00 p.m.

CTAD Networking Event with the Support of the Alzheimer's Association



● Wednesday, OCTOBER 30

7:30 a.m.

POSTER WALKING TOUR

8:30 a.m.

LATE BREAKING COMMUNICATIONS

Chairs: Merce Boada, *Ace Alzheimer Center - Barcelona (Spain)*, Gil Rabinovici, *UCSF - San Francisco (United States)*

8:30 a.m.

LB1 - Donanemab: Appropriate Use Recommendations

Gil Rabinovici¹, Stephen Salloway², Suzanne Schindler³, Paul Aisen⁴, Liana Apostolova⁵, Alireza Atri⁶, Steven Greenberg⁷, Suzanne Hendrix⁸, Ron Petersen⁹, Michael Weiner¹, Dennis Selkoe⁷, Jeffrey Cummings¹⁰

¹UCSF - San Francisco (United States), ²Brown - Providence (United States), ³Washington University - St. Louis (United States), ⁴USC - San Diego (United States), ⁵Indiana University - Indianapolis (United States), ⁶Banner Health - Phoenix (United States), ⁷Harvard - Boston (United States), ⁸Pentara - Millcreek (United States), ⁹Mayo Clinic - Rochester (United States), ¹⁰UNLV - Las Vegas (United States)

8:45 a.m.

LB2 - Latest Interim Results from the Brainshuttle™ AD Study, a Phase Ib/Ia Study of Trontinemab in People with Alzheimer's Disease

Luka Kulic¹, Fabien Alcaraz¹, Gregory Klein¹, Carsten Hofmann¹, Stella Yilmaz¹, João A. Abrantes¹, Denise Sickert¹, Maddalena Marchesi¹, Jakub Wojtowicz¹, Ruth Croney¹, David Agnew¹, Silke Ahlers², Paul Delmar¹, Hanno Svoboda³, Iris Wiesel¹

¹F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ²Excelya Germany GmbH - Freiburg (Germany), ³F. Hoffmann-La Roche Ltd. - Penzberg (Germany)

9:00 a.m.

LB3 - Diagnostic performance of capillary pTau217 in Alzheimer's disease: The Drop-AD project

Hanna Huber¹, Laia Montoliu-Gaya¹, Wagner S. Brum¹, Jakub Vavra¹, Yara Yakoub¹, Silke Kern¹, Haley Weninger¹, Barbara Borroni², Anne Corbett³, Oskar Hansson⁴, Xavier Morató⁵, Henrik Zetterberg¹, Kaj Blennow¹, Nicholas J. Ashton¹

¹University of Gothenburg - Gothenburg (Sweden), ²University of Brescia - Brescia (Italy), ³University of Exeter - Exeter (United Kingdom), ⁴University of Lund - Lund (Sweden), ⁵Ace Alzheimer Center Barcelona - Barcelona (Spain)

9:15 a.m.

KEYNOTE 2

Next Generation of Clinical Trials for Alzheimer's Disease and Related Disorders

Introduction: Reisa Sperling, *Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston (United States)*

Catherine Mummery, *Dementia Research Center, University College London, London (United Kingdom)*

9:40 a.m.

SYMPOSIUM 1

Does the Current Evidence Base Support Continued Dosing with Lecanemab for Early Alzheimer's Disease?

Chair: Christopher van Dyck, *Yale University, New Haven (United States)*

Presentation 1: Mechanistic Rationale for Continued Lecanemab Dosing

Michael Irizarry, *Eisai Inc. - Nutley (United States)*

Presentation 2: Pharmacologic Support for a Maintenance Dosing Regimen with Lecanemab: An Update on the Latest Clinical Pharmacology Data and Modeling

Larisa Reyderman, *Eisai Inc. - Nutley (United States)*

Presentation 3: Evidence for a Continued Benefit for Long-Term Lecanemab Treatment: A Benefit/Risk Update from Long-Term Efficacy, Safety and Biomarker Data

Christopher van Dyck, *Yale University, New Haven (United States)*

10:20 a.m.

Coffee break and poster session



Early career investigators showcase: flash session presentations in the Poster Hall



● Wednesday, OCTOBER 30

10:50 a.m.

LATE BREAKING COMMUNICATIONS

Chairs: Kim Johnson, *Duke University - Durham (United States)*, Pascual Sánchez-Juan, *Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII - Madrid (Spain)*

10:50 a.m.

LB4 - Safety and Preliminary Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer's Disease – Interim Data from a Phase 1/2, Open-Label, 52-Week, Multicenter Study

Kim Johnson¹, Michael Kaplitt², Stephen Kaminsky², Gianni Amato³, Nithya Selvan³, Richie Khanna³, Sandi See Tai³, Ronald Crystal²

¹Duke University - Durham (United States), ²Cornell Medical College - New York (United States), ³Lexeo Therapeutics - New York (United States)

11:05 a.m.

LB5 - Cognitive and behavioral outcomes in patients with dementia with Lewy bodies treated with nilotinib

Fernando Pagan¹, Yasar Torres-Yaghi¹, Michaeline Hebron¹, Barbara Wilmarth¹, Raymond Scott Turner¹, Charbel Moussa¹

¹Georgetown - Washington (United States)

11:20 a.m.

LB6 - Lecanemab for the Treatment of Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease in Adults that are Apolipoprotein E ε4 (ApoE ε4) Heterozygotes or Non-Carriers

Richard Perry¹, Christopher Kipps², Rob McMurray³, Shobha Dhadda⁴, Michio Kanekiyo⁴, Michael Irizarry⁴, Lynn Kramer⁴

¹Imperial College London - London (United Kingdom), ²University Hospital Southampton NHS Foundation Trust - Southampton (United Kingdom), ³Eisai Europe Ltd - Hatfield (United Kingdom), ⁴Eisai Inc. - Nutley (United States)

11:35 a.m.

ORAL COMMUNICATIONS

Chairs: Sandrine Andrieu, *IHU HealthAge - Toulouse (France)*, Michael Schöll, *University of Gothenburg - Gothenburg (Sweden)*

11:35 a.m.

OC6 - Screening and baseline results from the donanemab preclinical Alzheimer's disease TRAILBLAZER-ALZ 3 study

Karen C. Holdridge¹, Roy Yaari¹, Melissa Williamson¹, Alette M. Wessels¹, Sergey Shcherbinin¹, Vikas Kotari¹, Naohisa Hatakeyama¹, Pierre N. Tariot², Robert Alexander², Eric M. Reiman², Jessica B. Langbaum², John Sims¹

¹Eli Lilly and Company - Indianapolis (USA), ²Banner Alzheimer's Institute - Phoenix (United States)

11:50 a.m.

OC7 - Efficacy, Cardiovascular Safety and Adverse Events Associated with Escitalopram in Alzheimer's Dementia: Results from the S-CitAD Trial

Hamid Okhravi¹, Manisha Parulekar², Sheriza Baksh³, Emily Clark⁴, Ismail Zahinoor⁵, David M. Shade³, Constantine G. Lyketsos^{6,7}, Anton P. Porsteinsson⁴

¹Goldrich Neurohealth Institute, Eastern Virginia Medical School - Norfolk (United States), ²Hackensack Meridian School of Medicine, Division of Geriatrics - Hackensack (United States), ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health - Baltimore (United States), ⁴Department of Psychiatry, University of Rochester School of Medicine and Dentistry - Rochester (United States), ⁵University of Calgary - Calgary (Canada), ⁶Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine - Baltimore (United States), ⁷Johns Hopkins Bayview Medical Center - Baltimore (United States)

12:05 a.m.

OC8 - Differences in Amyloid PET Results and Social Determinants of Health by Race/Ethnicity: Results from New IDEAS

Gil Rabinovici¹, Peggie Dilworth-Anderson², Lucy Hanna³, Jon Steingrimsson³, Ilana Gareen³, Emily Glavin⁴, Bruce Hillner⁵, Andrew March⁴, Barry Siegel⁶, Christopher Weber⁷, Charles Windon¹, Rachel Whitmer⁸, Constantine Gatsonis³, Maria Carrillo⁷, Consuelo Wilkins⁹

¹University of California San Francisco - San Francisco (United States), ²University of North Carolina - Chapel Hill (United States), ³Brown University - Providence (United States), ⁴American College of Radiology - Reston (United States), ⁵Virginia Commonwealth University - Richmond (United States), ⁶Washington University - St. Louis (United States), ⁷Alzheimer's Association - Chicago (United States), ⁸University of California Davis - Sacramento (United States), ⁹Vanderbilt University - Nashville (United States)

12:20 p.m.

OC9 - First results from the REAL AD study: Validation of a realistic screening approach for early Alzheimer's disease

Kaj Blennow^{1,2}, Silke Kern^{1,2}, Iris Bosch², Henrik Zetterberg^{1,3,4,2}, Michael Schöll^{1,3,2}

¹University of Gothenburg - Gothenburg (Sweden), ²Västra Götaland Region - Gothenburg (Sweden), ³University College London - London (United Kingdom), ⁴University of Wisconsin-Madison (United States)

12:45 p.m.

Lunch and poster session

● Wednesday, OCTOBER 30

1:45 p.m.

ROUNDTABLE

Advancing Combination Therapy: Discussion on Key Considerations, Perspectives, and Promising Avenues for the Future of Alzheimer's Treatments

Howard Fillit¹, Jeffrey Cummings², Suzanne Hendrix³, Jin Zhou⁴, Mark Mintun⁵

¹Alzheimer's Drug Discovery Foundation - New York (United States), ²UNLV - Nevada, Las Vegas (United States), ³Pentara - Salt Lake City (United States), ⁴Eisai - Nutley (United States), ⁵Eli Lilly and Company

2:15 p.m.

ORAL COMMUNICATIONS

Chairs: Gilda Ennis, University of Wisconsin-Madison - Madison (United States), Patrick Oeckl, Ulm University Hospital- Ulm (Germany)

2:15 p.m.

OC10 - PROSPECT-ALZ: Results of the phase 2 study of ceperognastat, an orally available O-linked N-acetyl glucosaminidase inhibitor for the treatment of early symptomatic Alzheimer's disease

Adam S. Fleisher¹, Leanne Munsie¹, Michele Mancini¹, Eden Yun-Ju Cheng¹, Sergey Shcherbinin¹, Tomomi Nakamura¹, William Kielbasa¹, Hugh Nuthall¹, Dustin Mergott¹, Mark Mintun¹, Miroslaw Brys¹

¹Eli Lilly and Company - Indianapolis (United States)

2:30 p.m.

OC11 - Biomarkers of neurodegeneration and synaptic dysfunction differentiate cognitively unimpaired individuals with high levels of Alzheimer's disease (AD) neuropathology from individuals with AD dementia

Sara Fernandes-Taylor¹, Matthew Glittenberg¹, Ira Frahmmand¹, Brianne Breidenbach¹, Tobey Betthauser¹, Sanjay Asthana¹, Sterling Johnson¹, Gwendlyn Kollmorgen², Clara Quijano-Rubio³, Henrik Zetterberg⁴, Kaj Blennow⁴, Ozioma Okonkwo¹

¹University of Wisconsin - Madison (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³Roche Diagnostics International Ltd. - Rotkreuz (Switzerland), ⁴Neurochemistry Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden)

2:45 p.m.

OC12 - Study Design and Screening Experience from the Phase 2 AUTONOMY Trial of Anti-P-tau Monoclonal Antibody Posdinemab for Early Alzheimer's Disease

Dave Henley^{1,2}, Jennifer Bogert³, Ziad S Saad⁴, Gallen Triana-Baltzer⁴, Tina Wang⁴, Hartmuth C Kolb⁴, Maggie Fedgchin¹

¹Janssen Research & Development, LLC - Titusville (United States), ²Indiana University School of Medicine, Psychiatry - Indianapolis (United States), ³Janssen Research & Development, LLC - Bridgewater (United States), ⁴Janssen Research & Development, LLC - La Jolla (United States)

3:00 p.m.

OC13 - Performance of plasma p-tau217 in an African American cohort: Findings from the African Americans Fighting Alzheimer's in Midlife study

Gilda Ennis¹, Derek Norton¹, Fabu Carter¹, Diane Gooding¹, Alexander Gee², Tracy Smith¹, Hector Salazar¹, Rachael Wilson¹, Rebecca Langhough¹, Megan Zuelsdorff¹, Shenikqua Bouges¹, Sanjay Asthana¹, Sterling Johnson¹, Henrik Zetterberg¹, Carey Gleason¹

¹University of Wisconsin-Madison - Madison (United States), ²Nehemiah Center for Urban Leadership Development - Madison (United States)

3:15 p.m.

OC14 - Early increase of the synaptic blood marker β -synuclein in asymptomatic individuals with autosomal dominant Alzheimer's disease

Patrick Oeckl^{1,2}, Randall J. Bateman³, Gregory S. Day⁴, Nick C. Fox⁵, Laura Ibanez³, Mathias Jucker^{6,7}, Jae-Hong Lee⁸, Johannes Levin^{9,10,11}, Jorge J. Llibre-Guerra³, Eric Mc Dade³, John C. Morris³, Jee Hoon Roh¹², Raquel Sánchez-Valle¹³, Peter R. Schofield^{14,15}, Markus Otto¹⁶

¹Ulm University Hospital- Ulm (Germany), ²DZNE Ulm - Ulm (Germany), ³Washington University School of Medicine - Saint Louis (United States), ⁴Mayo Clinic in Florida - Jacksonville (United States), ⁵UCL Queen Square Institute of Neurology - London (United Kingdom), ⁶DZNE Tübingen - Tübingen (Germany), ⁷University of Tübingen - Tübingen (Germany), ⁸Asan Medical Center - Seoul (Korea, Republic of), ⁹LMU Munich - Munich (Germany), ¹⁰DZNE Munich - Munich (Germany), ¹¹Munich Cluster for Systems Neurology (SyNergy) - Munich (Germany), ¹²Korea University College of Medicine - Seoul (Korea, Republic of), ¹³University of Barcelona - Barcelona (Spain), ¹⁴Neuroscience Research Australia - Sydney (Australia), ¹⁵University of New South Wales - Sydney (Australia), ¹⁶Martin-Luther-University Halle-Wittenberg - Halle (saale) (Germany)

● Wednesday, OCTOBER 30

- 3:30 p.m.** **LATE BREAKING SYMPOSIUM 2 - One-Year Experience on the Use of Lecanemab in Clinical Practice**
Co-chairs: Lefkos Middleton, *ICL - London (United Kingdom)*, Bruno Vellas, *IHU HealthAge - Toulouse (France)*
Presentation 1: Lecanemab Treatment in Real World Settings in the United States
Marwan Sabbagh, *Department of Neurology Barrow Neurological Institute - Phoenix, Arizona (United States)*
Presentation 2: Lecanemab Use in Clinical Practice at an Academic Medical Center
Lawrence Honig, *Columbia University - New York (United States)*
Presentation 3: Latest data from the clinic use of Lecanemab in Japan
Takeshi Iwatsubo, *University of Tokyo - Tokyo (Japan)*
- 4:10 p.m.** Coffee break and poster session 
Early career investigators showcase: flash session presentations in the Poster Hall 
- 4:40 p.m.** **ORAL COMMUNICATIONS**
Chairs: Maria Carrillo, *Alzheimer's Association - Chicago (United States)*, Oskar Hansson, *Gothenburg University - Gothenburg (Sweden)*
- 4:40 p.m.** **OC15 - Advancing Patient Outcomes with Real-World Evidence**
Ann Hartry¹, Helmut Butzkueven^{2,3}, Robert Perneczky⁴, Craig Ritchie⁵
¹Eli Lilly and Company - Indianapolis (United States), ²MSBase Foundation - Melbourne (Australia), ³Monash University - Melbourne (Australia),
⁴Ludwig-Maximilians-Universität Munich - Munich (Germany), ⁵University of St. Andrews - St. Andrews (United Kingdom)
- 4:55 p.m.** **OC16 - Longitudinal trajectories of plasma p-tau217 in early Alzheimer's Disease: Implications for use in clinical trials**
Bjørn-Eivind Kirsebom¹, Fernando Gonzalez-Ortiz², Lene Pålhaugen³, Per Selnes³, Jonas Alexander Jarholm³, Berglind Gísladóttir³, Arvid Rongve⁴, Ragnhild Eide Skogseth⁵, Geir Bråthen⁶, Dag Aarsland⁷, Michael Turton⁸, Peter Harrison⁸, Henrik Zetterberg², Kaj Blennow², Tormos Fladby³
¹University Hospital of North Norway - Tromsø (Norway), ²University of Gothenburg - Gothenburg (Sweden), ³Akershus University Hospital- Lørenskog (Norway), ⁴Helse Fonna - Haugesund (Norway), ⁵Haraldsplass Deaconess Hospital- Bergen (Norway), ⁶University Hospital of Trondheim - Trondheim (Norway), ⁷King's College London - London (United Kingdom), ⁸Bioventix Plc- Surrey (United Kingdom)
- 5:10 p.m.** **OC17 - Precision Neuroscience: Rationale And Design For The RETAIN Phase 2b Study With A Tau Active Immunotherapy In Preclinical Alzheimer's Disease**
Lennert Steukers¹, Iva Kezic¹, Cathy Bleys¹, Lingjue Li², Clara Theunis¹, Athena Beckers¹, Gallen Triana-Baltzer³, Tricia Thornton-Wells⁴, TAU PE³, David Henley², Fiona Elwood⁴, María Cristina López López⁵
¹Johnson & Johnson - Beerse (Belgium), ²Johnson & Johnson - Titusville (United States), ³Johnson & Johnson - La Jolla (United States), ⁴Johnson & Johnson - Cambridge (United States), ⁵Johnson & Johnson - Allschwil (Switzerland)
- 5:25 p.m.** **OC18 - Blood biomarkers to detect Alzheimer's disease in clinical practice - a cross-sectional study in primary & secondary care**
Sebastian Palmqvist¹, Pontus Tideman¹, Niklas Mattsson-Carlgrén¹, Ruben Smith¹, Rik Ossenkoppele¹, Suzanne Schindler², Mark Monane³, Tim West³, Kaj Blennow⁴, Philip Verghese³, Joel Braunstein³, Shorena Janelidze¹, Erik Stomrud¹, Gemma Salvadó¹, Oskar Hansson¹
¹Lund University - Malmö (Sweden), ²Washington University School of Medicine - Saint Louis (United States), ³C2N Diagnostics - Saint Louis (United States), ⁴Gothenburg University - Gothenburg (Sweden)
- 5:40 p.m.** **OC19 - Clinical Progression on CDR-SB: Residence Time at Each Level in the DIAN and ADNI Cohorts**
Guoqiao Wang¹, Yan Li¹, Eric Mcdade¹, John Morris¹, Lon Schneider²
¹School of Medicine, Washington University in St Louis - St Louis (United States), ²Keck School of Medicine, University of Southern California, Los Angeles - Los Angeles (United States)
- 5:55 p.m.** **LB6bis - The Global Neurodegeneration Proteomics Consortium - Biomarker and Drug Target Discovery Across >40,000 Biosamples for AD, PD, ALS, FTD, and Aging**
Farhad Imam¹, Martin Bringmann², Varsha Krish¹
¹Gates Ventures - Seattle (United States), ²Johnson&Johnson - Spring House (United States)
- 6:10 p.m.** **End of the Conference Day**

● Thursday, OCTOBER 31

7:30 a.m.

POSTER WALKING TOUR

8:30 a.m.

LATE BREAKING COMMUNICATIONS

Chairs: David Knopman, *Mayo Clinic - Rochester (United States)*, Michael Weiner, *UCSF, San Francisco (United States)*

8:30 a.m.

LB7 - Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer's disease

Hayley Shanks¹, Kiran Pandey², Madison Bangs³, Venky Venkatesh⁴, Matthew Meyer⁴, Manfred Windisch⁵, Nicholas Seyfried^{2,3}, Stephen Massa^{6,7}, Frank Longo⁸, Taylor Schmitz¹

¹Western University - London (Canada), ²Emtherapro Inc. - Atlanta (United States), ³Emory University - Atlanta (United States), ⁴C2N Diagnostics - St. Louis (United States), ⁵NeuroScios GmbH - St. Radegund (Austria), ⁶San Francisco Veterans Affairs Health Care System - San Francisco (United States), ⁷University of California, San Francisco - San Francisco (United States), ⁸Pharmatrophix - Menlo Park (United States)

8:45 a.m.

LB8 - Bridging the gap: parahippocampal tau-PET improves detection of the transition from age-related tauopathy to Alzheimer's disease

Emma G. Thibault¹, Michelle E. Farrell², Jessie Fanglu Fu³, Justin S. Sanchez¹, Brian C. Healy^{2,4}, Bernard J. Hanseeuw^{1,5}, Heidi I.I. Jacobs³, Julie C. Price³, J. Alex Becker¹, Reisa A. Sperling^{2,6}, Keith A. Johnson^{1,6}

¹Department of Radiology, Massachusetts General Hospital - Boston (United States), ²Department of Neurology, Massachusetts General Hospital - Boston (United States), ³Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital - Boston (United States), ⁴Biostatistics Center, Massachusetts General Hospital - Boston (United States), ⁵Department of Neurology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain - Bruxelles (Belgium), ⁶Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital - Boston (United States)

9:00 a.m.

LB9 - Phase IIb/III Trial of Blarcamesine in Early Alzheimer Disease Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation

Marwan Sabbagh¹, Juan-Carlos Lopez-Talavera², Kun Jin², William Chezem², Christopher Missling²

¹Barrow Neurological Institute - Phoenix (United States), ²Anavex - New York (United States)

9:15 a.m.

LB10 - Discrepancies between CSF and PET determinations of elevated brain amyloid and their prognostic significance

David Knopman¹, Stephen Weigand¹, Heather Wiste¹, Jonathan Graff-Radford¹, Neill Graff-Radford¹, Ronald Petersen¹, Clifford Jack¹, Mary Machulda¹, Julie Fields¹, Vijay Ramanan¹, Hugo Botha¹, Stuart McCarter¹, David Jones¹, Bryan Neth¹, Gregory Day¹, Alicia Algeciras-Schimmich¹, Joshua Bornhorst¹, Val Lowe¹, Derek Johnson¹, Bradley Boeve¹

¹Mayo Clinic - Rochester (United States)

9:30 a.m.

LB11 - ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer's Disease

Todd Feaster¹, Karen Sundell¹, Maddelyn Hyland¹, Gopalan Sethuraman¹, Vladimir Skljarevski¹, June Kaplow¹, Robert A. Dean¹, Jasna Jerecic¹, Eric Siemers¹

¹Acumen Pharmaceuticals, Inc - Newton (United States)

9:45 a.m.

KEYNOTE 3

Interim observations on developing drugs for people living with AD: What do they want, what can they have, and how can we do better?

Introduction: Bruno Vellas, *IHU HealthAge - Toulouse (France)*

Rachelle Doody, *Houston, TX (USA)*

● Thursday, OCTOBER 31

10:10 a.m.

ORAL COMMUNICATIONS

Chairs: Miia Kivipelto, *Karolinska Institutet - Stockholm (Sweden)*, Leocadio Rodríguez Mañas, *Hospital Universitario de Getafe - Getafe (Spain)*

10:10 a.m.

OC20 - Initial results from remote speech-based screening in the first 900 digitally recruited participants in ADNI-4

Caroline Skirrow¹, Jack Weston¹, Melanie J. Miller^{2,3}, Rachel L. Nosheny^{2,4}, Bruce Albala^{5,6}, Michael W. Weiner^{2,3,4}, Emil Fristed¹
¹*Novoic Ltd - London (United Kingdom)*, ²*Northern California Institute for Research and Education (NCIRE) - San Francisco (United States)*,
³*Department of Veterans Affairs Medical Center - San Francisco (United States)*, ⁴*University of California, San Francisco - San Francisco (United States)*, ⁵*University of California Irvine - Irvine (United States)*, ⁶*Veterans Administration Long Beach Healthcare System - Long Beach (United States)*

10:25 a.m.

OC21 - Validating speech-based biomarkers for measuring disease progression in AD: A head-to-head comparison of three biomarker development strategies

Michael Spilka¹, Mengdan Xu¹, Bali Toth², Somaye Hashemifar², Rainier Amora², Jessica Robin¹, Edmond Teng², Cecilia Monteiro², William Simpson¹
¹*Winterlight Labs (Cambridge Cognition) - Toronto (Canada)*, ²*Genentech, Inc. - South San Francisco (United States)*

10:40 a.m.

OC22 - Eligibility for anti-amyloid treatment in real world memory clinic populations

Anna Matton^{1,2}, Makrina Daniilidou^{1,2}, Anette Hall^{3,1}, Ulf Öhlund-Wistbacka^{4,1}, Urban Ekman¹, Anna Rennie¹, Linus Jönsson¹, Göran Hagman⁴, Alina Solomon^{3,1}, Anna Rosenberg^{3,1}, Miia Kivipelto^{4,1,2}
¹*Karolinska Institutet - Stockholm (Sweden)*, ²*FINGERS Brain Health Institute - Stockholm (Sweden)*, ³*University of Eastern Finland - Kuopio (Finland)*, ⁴*Karolinska University Hospital - Stockholm (Sweden)*

10:55 a.m.

Coffee break and poster session ☕

Early career investigators showcase: flash session presentations in the Poster Hall



11:25 a.m.

ORAL COMMUNICATIONS: Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease

Chair: Howard Fillit, *Alzheimer's Drug Discovery Foundation, New York (USA)*

11:30 a.m.

OC23 - Transcranial Magnetic Stimulation (TMS) for MCI: Trials using advanced stimulation and precision approaches

Joy Taylor¹, Ying-Hui Chou², Andreana Benitez³
¹*Stanford University - Palo Alto (United States)*, ²*University of Arizona - Tucson (United States)*, ³*Medical University of South Carolina - Charleston (United States)*

11:45 a.m.

OC24 - Results of a 52-Week Phase II Trial of Repetitive TMS of the Default Mode Network in Mild to Moderate Alzheimer's Disease

Elias Casula¹, Sonia Bonni¹, Michele Maiella¹, Martina Assogna¹, Emiliano Santarnecchi², Allessandro Martorana³, Giacomo Koch³
¹*Santa Lucia Foundation IRCCS - Rome (Italy)*, ²*Massachusetts General Hospital - Boston (United States)*, ³*University of Rome Tor Vergata - Rome (Italy)*

12:00 p.m.

LATE BREAKING COMMUNICATIONS

Chairs: Catherine Mummery, *Dementia Research Center, University College London - London (United Kingdom)*, Suzanne Schindler, *Washington University in St. Louis - St. Louis (United States)*

12:00 p.m.

LB12 - A Phase I Clinical Trial of BDNF Gene Therapy in Alzheimer's Disease and MCI

Brad Elder¹, Krys Bankiewicz¹, Russell Lonser¹, Gabriel Leger², Doug Scharre¹, Susan Landau³, William Jagust³, Mark Tuszynski²
¹*Ohio State University - Columbus (United States)*, ²*UC San Diego - La Jolla (United States)*, ³*UC Berkeley - Berkeley (United States)*

12:15 p.m.

LB13 - Plasma pTau217 alone is not enough for staging Alzheimer's disease

James D Doecke¹, Edwin Stage², Christopher J Fowler³, Vincent Dore⁴, Nils Boehm², Christoph Kleinert², Azadeh Feizpour⁵, Larry Ward^{6,7,8}, Jurgen Mejan-Fripp¹, Colin L Masters³, Christopher Rowe⁵, Anthony Bannion²
¹*Australian E-Health Research Centre, CSIRO - Herston (Australia)*, ²*Abbvie Inc - North Chicago (United States)*, ³*The Florey Institute of Neuroscience and Mental Health - Parkville (Australia)*, ⁴*Australian E-Health Research Centre, CSIRO - Melbourne (Australia)*, ⁵*Department of Molecular Imaging & Therapy, Austin Health - Melbourne (Australia)*, ⁶*Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) - Parkville (Australia)*, ⁷*Australian Dementia Network (ADNeT) - Parkville (Australia)*, ⁸*Faculty of Medicine, Dentistry and Health Sciences - Parkville (Australia)*

● Thursday, OCTOBER 31

12:30 p.m.

Lunch and poster session

1:30 p.m.

LATE BREAKING COMMUNICATIONS

Chairs: Catherine Mummery, *Dementia Research Center, University College London - London (United Kingdom)*, Suzanne Schindler, *Washington University in St. Louis - St. Louis (United States)*

1:30 p.m.

LB14 - Not all plasma tau biomarkers are equally associated with tau tangles and affected by co-pathologies

Laia Montoliu-Gaya¹, Elizabeth Valeriano-Lorenzo², Nicholas J Ashton¹, Alberto Rábano², Henrik Zetterberg¹, Johan Gobom¹, Kaj Blennow¹, Pascual Sánchez-Juan²

¹University of Gothenburg - Mölndal (Sweden), ²Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII - Madrid (Spain)

1:45 p.m.

LB15 - Study design for TRAILRUNNER-ALZ 3: A double-blind, placebo-controlled, Phase 3 clinical trial investigating subcutaneous remternetug in early Alzheimer's disease

Kevin Biglan¹, Erum Rizvi¹, Tongrong Wang¹, Matthew Hufford¹, Mausumi Lidogoster¹, Christina Dickson¹, Susan Warner¹, Ivelina Gueorguieva¹, Yvonne Vandenburg¹, Matan Dabora¹

¹Eli Lilly and Company - Indianapolis (United States)

2:00 p.m.

KEYNOTE 4

Fluid biomarkers in research, clinical trials, and clinical practice

Introduction: Mike Weiner, *UCSF, San Francisco (United States)*

Suzanne Schindler, *Washington University in St. Louis - St. Louis (United States)*

2:25 p.m.

ORAL COMMUNICATIONS

Chairs: Jacques Touchon, *Montpellier University - Montpellier (France)*, Christopher Van Dyck, *Yale School of Medicine, New Haven (United States)*

2:25 p.m.

OC25 - TargetTau-1: A phase 2 trial designed to evaluate the efficacy, safety, and tolerability of the anti-MTBR tau monoclonal antibody, BMS-986446, in patients with early Alzheimer's disease

Oskar Hansson¹, Anja Kahl², Grigor Abelian², Mark Donovan², Manuj Ahuja², David Watson³, Rik Ossenkoppele⁴, Takeshi Iwatsubo⁵, Christopher Van Dyck⁶

¹Lund University and Skåne University Hospital - Malmö (Sweden), ²Bristol Myers Squibb, Princeton (United States), ³Alzheimer's Research and Treatment Center, Wellington (United States), ⁴Lund University, Skåne University Hospital - Malmö (Sweden), ⁵University of Tokyo - Tokyo (Japan), ⁶Yale School of Medicine, New Haven (United States)

2:40 p.m.

OC26 - A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial

Richard Joules¹, Robin Wolz^{1,2}, Lynne Hughes^{1,2}, Richard Mohs², John Dwyer², Douglas Beauregard²

¹IXICO - London (United Kingdom), ²Global Alzheimer's Platform Foundation - Washington (United States)

2:55 p.m.

OC27 - Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of pepinemab, SEMA4D antibody to block reactive astrogliosis, in patients with mild AD dementia

Elizabeth Evans¹, Eric Siemers¹, Terrence Fisher¹, Megan Boise¹, Amber Foster¹, John Leonard¹, Vikas Mishra¹, Crystal Mallow¹, Raymond Turner², John Huffaker³, Anton Porsteinsson⁴, Maurice Zauderer¹

¹Vaccinex - Rochester (United States), ²Georgetown University - Washington (United States), ³Neuropsychiatric Research Center of Southwest Florida - Stuart (United States), ⁴University of Rochester - Rochester (United States)

3:10 p.m.

LATE BREAKING COMMUNICATIONS

Chairs: Alireza Atri, *Banner Health - Phoenix (United States)*, Reisa Sperling, *Massachusetts General Hospital / Harvard Medical School - Boston (United States)*

3:10 p.m.

LB16 - The anatomy of tau PET associations with biomarkers and cognitive decline in the A4 study

Justin Sanchez¹, Michael Properzi¹, Aaron Schultz¹, Emma Thibault¹, Michelle Farrell¹, Alex Becker¹, Bernard Hanseeuw¹, Paul Aisen², Rema Raman², Michael Donohue², Reisa Sperling¹, Keith Johnson¹

¹Massachusetts General Hospital / Harvard Medical School - Boston (United States), ²University of Southern California - Los Angeles (United States)

● Thursday, OCTOBER 31

3:25 p.m.

LB18 - AI-derived prognostic covariates enhance the precision of lecanemab efficacy assessments and optimize Alzheimer's disease clinical trials

Viswanath Devanarayan¹, Yuanqing Ye¹, Liang Zhu¹, Lu Tian², Lynn Kramer¹, Michael Irizarry¹, Shobha Dhadda¹
¹Eisai Inc. - Nutley (United States), ²Stanford University - Stanford (United States)

3:40 p.m.

LB19 - Comparison of one-step and two-step workflows for determining phosphorylated tau 217 cut-off points for amyloid positivity in different subgroups

Jehyun Ahn¹, Eun Hye Lee², Heejin Yoo¹, Boram Park³, Henrik Zetterberg^{4,5,6,7}, Kaj Blennow^{4,5,8,9}, Fernando Gonazalez-Ortiz^{4,5}, Nicholas J Ashton^{4,10,11,12}, Kyunga Kim^{3,13,14}, Sang Won Seo^{1,2,14,15}

¹Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of), ³Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul (Korea, Republic of), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Goteborg (Sweden), ⁵Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Goteborg (Sweden), ⁶Department of Neurodegenerative Disease, UCL Institute of Neurology, London (United Kingdom), ⁷UK Dementia Research Institute at UCL, London (United Kingdom), ⁸Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris (France), ⁹Neurodegenerative Disorder Research Center, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei (China), ¹⁰King's College London, Institute of Psychiatry, London (United Kingdom), ¹¹NIHR Biomedical Research Centre for Mental Health London (United Kingdom), ¹²Centre for Age-Related Medicine, Stavanger (Norway), ¹³Department of Data Convergence and Future Medicine, Seoul (Korea, Republic of), ¹⁴Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul (Korea, Republic of), ¹⁵Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul (Korea, Republic of)

3:55 p.m.

Coffee break and poster session



Early career investigators showcase: flash session presentations in the Poster Hall



4:25 p.m.

ORAL COMMUNICATIONS

Chairs: Frank Jessen, University of Cologne - Cologne (Germany), Lon Schneider, Keck School of Medicine, USC, Los Angeles (United States)

4:25 p.m.

OC28 - Design and Rationale of cAPPricorn-1, A Phase 2 Study of Mivelsiran in Patients with Cerebral Amyloid Angiopathy

Jin-Moo Lee¹, Ellis S. Van Etten², M. J. P. Van Osch², Catharina J. M. Klijn³, Alexandre Sostelly⁴, Sasikiran Goteti⁴, Farshid Sepehrband⁵, Andreja Avbersek⁵, Robert W. Deering⁴, Neal S. Parikh⁴, Steven M. Greenberg⁶

¹Washington University School of Medicine - St. Louis (United States), ²Leiden University Medical Center - Leiden (Netherlands), ³Radboud University Medical Centre - Nijmegen (Netherlands), ⁴Alnylam Pharmaceuticals, Inc. - Cambridge (United States), ⁵Regeneron Pharmaceuticals, Inc. - Tarrytown (United States), ⁶Harvard Medical School, Massachusetts General Hospital - Boston (United States)

4:40 p.m.

OC29 - Use of plasma p-tau217 to identify Aβ-positive cognitively unimpaired participants for clinical trials: A multicohort study

Gemma Salvadó¹, Shorena Janelidze¹, Divya Bali¹, Joseph Therriault², Tammie L.s. Benzinger³, Kaj Blennow⁴, Pedro Rosa-Neto⁵, Sterling C Johnson⁶, Christopher C Rowe⁷, Sylvia Villeneuve⁸, Cliff R Jack Jr.⁹, Marc Suárez-Calvet¹⁰, Suzanne E Schindler³, Rik Ossenkoppele^{1,11}, Oskar Hansson¹

¹Lund University - Lund (Sweden), ²McGill University - Montréal (Canada), ³Washington University School of Medicine and Knight Alzheimer Disease Research Center - St. Louis (United States), ⁴Sahlgrenska University Hospital - Mölndal and University of Gothenburg - Gothenburg (Sweden), ⁵McGill University - Montréal (Canada), ⁶University of Wisconsin-Madison and Wisconsin Alzheimer's Institute - Madison (United States), ⁷CSIRO Health and Biosecurity- Victoria and Austin Health - Melbourne (Australia), ⁸Douglas Mental Health University Institute - Montréal (Canada), ⁹Mayo Clinic and Foundation - Rochester (United States), ¹⁰BarcelonaBeta Brain Research Center and Hospital del Mar Research Institute - Barcelona (Spain), ¹¹UMC and Vrije Universiteit Amsterdam - Amsterdam (Netherlands)

4:55 p.m.

OC30 - PreventE4: a double-blind placebo-controlled clinical trial testing high dose DHA in APOE4 carriers before the onset of dementia

Hussein Yassine¹, Michael Harrington¹, Jackson Park¹, Isabella Cordova¹, Naoko Kono¹, Wendy Mack¹, Meredith Braskie¹, Lon Schneider¹

¹USC - Los Angeles (United States)

● Thursday, OCTOBER 31

5:10 p.m.

LATE BREAKING SYMPOSIUM 3: Results from TOGETHER, a double-blind, placebo-controlled Phase II study evaluating efficacy, safety and tolerability of bepranemab in prodromal–mild AD

Chair: Randall J Bateman, *Washington University School of Medicine - St Louis (United States)*

Presentation 1: Identification and development of bepranemab, an antibody targeting the mid-region of tau
Martin Citron, *UCB - Braine-l'Alleud (Belgium)*

Presentation 2: Results from TOGETHER, a Phase II study of bepranemab in prodromal–mild AD
Matthew E Barton, *UCB - Raleigh (United States)*

Presentation 3: Bepranemab, the tau mid-region hypothesis, and future implications
Randall J Bateman, *Washington University School of Medicine - St Louis (United States)*

5:50 p.m.

End of the Conference Day

● Friday, NOVEMBER 1

7:30 a.m. POSTER WALKING TOUR

8:30 a.m. LATE BREAKING COMMUNICATIONS

Chairs: Giovanni Frisoni, *UniGE - Geneva (Switzerland)*, Henrik Zetterberg, *University of Lund - Lund (Sweden)*

8:30 a.m. LB21 – The Role of pTau217 in Integrated Amyloid and Tau Staging: Implications for Cognitive Trajectories in Alzheimer's Disease

Daeun Shin ¹, Hyemin Jang ², Kyoungmin Kim ¹, Heejin Yoo ¹, Henrik Zetterberg ^{3,4,5,6}, Kaj Blennow ^{3,4,7,8}, Fernando Gonzalez-Ortiz ^{3,4}, Nicholas J. Ashton ^{4,9,10,11}, Theresa A. Day ¹², Eun Hye Lee ¹, Jihwan Yun ¹³, Duk L Na ¹⁴, Hee Jin Kim ^{14,15,16,17}, Sung Hoon Kang ¹⁸, Ko Woon Kim ¹⁹, Si Eun Kim ²⁰, Yeo Jin Kim ²¹, Yeshin Kim ²², Jaeho Kim ²³, Chi-Hun Kim ²⁴

¹Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ²Seoul National University Hospital, Seoul National University College of Medicine - Seoul (Korea, Republic of), ³University of Gothenburg - Gothenburg (Sweden), ⁴Sahlgrenska University Hospital - Gothenburg (Sweden), ⁵UCL Institute of Neurology - London (United Kingdom), ⁶UK Dementia Research Institute at UCL - London (United Kingdom), ⁷ICM, Pitié-Salpêtrière Hospital, Paris (France), ⁸University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (China), ⁹King's College London, London (United Kingdom), ¹⁰NIHR Biomedical Research Centre for Mental Health - London (United Kingdom), ¹¹Stavanger University Hospital - Stavanger (Norway), ¹²Eli Lilly and Company, Indianapolis (United States), ¹³Soonchunhyang University Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), ¹⁴Samsung Medical Center, Seoul (Korea, Republic of), ¹⁵Alzheimer's Disease Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), ¹⁶SAIHST, Sungkyunkwan University - Seoul (Korea, Republic of), ¹⁷Neuroscience Center, Samsung Medical Center - Seoul (Korea, Republic of), ¹⁸Korea University Guro Hospital, Seoul (Korea, Republic of), ¹⁹Jeonbuk National University Jeonju (Korea, Republic of), ²⁰Inje University College of Medicine, Haeundae Paik Hospital - Busan (Korea, Republic of), ²¹Kangdong Sacred Heart Hospital, Seoul (Korea, Republic of), ²²Kangwon National University Hospital, Chuncheon (Korea, Republic of), ²³Dongtan Sacred Heart Hospital, Hwaseong (Korea, Republic of), ²⁴Hallym University Sacred Heart Hospital - Anyang (Korea, Republic of)

8:45 a.m. LB22 – Timing of changes in Alzheimer's disease plasma biomarkers using amyloid and tau PET clocks

Marta Milà-Alomà ¹, Duygu Tosun ¹, Suzanne E. Schindler ², Yan Li ², Kellen K. Petersen ², Leslie M. Shaw ³, Jeffrey L. Dage ^{4,5}, Ziad S. Saad ⁶, David L. Raunig ⁷, Lei Du-Cuny ⁸, Carrie E. Rubel ⁹, Janaky Coomaraswamy ⁷, Erin G. Rosenbaugh ¹⁰, Anthony W. Bannion ¹¹, William Z. Potter ¹²

¹University of California San Francisco - San Francisco (United States), ²Washington University School of Medicine - St. Louis (United States), ³Perelman School of Medicine, University of Pennsylvania - Philadelphia (United States), ⁴Department of Neurology, Indiana University School of Medicine - Indianapolis (United States), ⁵Stark Neurosciences Research Institute - Indianapolis (United States), ⁶Johnson and Johnson Innovative Medicine - San Diego (United States), ⁷Takeda Pharmaceutical Company Ltd. - Cambridge (United States), ⁸AbbVie - Rheinland-Pfalz (United States), ⁹Biogen - Cambridge (United States), ¹⁰Foundation for the National Institutes of Health - North Bethesda (United States), ¹¹AbbVie - North Chicago (United States), ¹²Philadelphia (United States)

9:00 a.m. LB23 – Effects of initial medial temporal lobe tauopathy and amyloid-beta on the timeline to caTAAustrophe

Michelle E. Farrell ¹, Emma G. Thibault ¹, Grace Del Carmen Montenegro ¹, Jessie Fanglu Fu ¹, Julie C. Price ¹, Bernard J. Hanseuw ¹, John R. Sims ², Roy Yaari ², Sergey Shcherbinin ², Karen C. Holdridge ², Rema Raman ³, Michael C. Donohue ³, Paul Aisen ³, Reisa A. Sperling ¹, Keith A. Johnson ¹

¹Massachusetts General Hospital, Harvard Medical School - Boston (United States), ²Eli Lilly and Company - Indianapolis (United States), ³Keck School of Medicine, University of Southern California - Los Angeles (United States)

9:15 a.m. LB24 – Updating Diagnostic Criteria for Alzheimer's Disease: Recommendations of the International Working Group (IWG)

Howard Feldman ¹, Nicolas Villain ², Giovanni Frisoni ³, Alexis Moscoso ⁴, Bruno Dubois ²

¹Department of Neurosciences, University of California San Diego, San Diego (United States), ²Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau - Paris (France), ³UniGE - Geneva (Switzerland), ⁴Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden)

● Friday, NOVEMBER 1

9.30 a.m.

ORAL COMMUNICATIONS

Chairs: Karim Bennys, *Montpellier University Hospital - Montpellier (France)*, Rema Raman, *ATRI, University of Southern California - San Diego (United States)*

9.30 a.m.

OC31 - The Alzheimer's Tau Platform (ATP) and Progressive Supranuclear Palsy Trial Platform (PTP): a combination amyloid and tau therapy trial for early AD, and a tau monotherapy trial for mild-moderate PSP

Adam Boxer¹, Keith Johnson², Irene Litvan³, Julio Rojas¹, Anne-Marie Wills², Reisa Sperling², Paul Aisen⁴, Ron Petersen⁵, Randall Bateman⁶, Chihiro Sato⁶, Michael Donohue⁴, Rema Raman⁴, Eden Barragan³

¹University of California, San Francisco - San Francisco (United States), ²MGH - Boston (United States), ³UCSD - San Diego (United States), ⁴USC - San Diego (United States), ⁵Mayo Clinic - Rochester (United States), ⁶Washington University - St. Louis (United States)

9.45 a.m.

OC32 - An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study

Joel Braunstein¹, Demetrius Maraganore², Robert Carlile³, Kim Johnson⁴, David Merrill⁵, Darren Gitelman⁶, Kenneth Sharlin⁷, Lawren Vandevrede⁸, Kristi George⁹, Jimin Wang¹⁰, Tim West¹, Philip Verghese¹, Leslie Jacobs¹, Mark Monane¹

¹C2N Diagnostics, LLC - St Louis (United States), ²Tulane University - New Orleans (United States), ³Palmetto Primary Care Physicians - Summerville (United States), ⁴Duke University - Durham (United States), ⁵Pacific Brain Health Center - Santa Monica (United States), ⁶Advocate Lutheran General Hospital - Park Ridge (United States), ⁷Sharlin Health and Neurology - Ozark (United States), ⁸University of California - San Francisco (United States), ⁹JWM Neurology - Indianapolis (United States), ¹⁰Stat4ward - Pittsburgh (United States)

10.00 a.m.

OC33 - The role of trials in health-economic evaluation of anti-amyloid treatment for early Alzheimer's disease

Ron Handels¹, Anders Wimo², Bengt Winblad², Linus Jönsson²

¹Maastricht University - Maastricht (Netherlands), ²Karolinska Institutet - Stockholm (Sweden)

10.15 a.m.

OC34 - An ultra-fast MRI protocol to aid diagnosis and treatment of Alzheimer's disease

Miguel Rosa-Grilo¹, Haroon R Chughtai^{2,3}, Dave Thomas^{1,4}, Christopher R S Belder¹, Millie Beament¹, Nicholas Magill⁵, Moona Mazher², Emma Lim^{6,7}, Dermot Mallon⁷, H Rolf Jäger⁷, Geoff J M Parker^{2,8,9}, Daniel C Alexander², Nick Fox¹, Cath Mummery¹, Frederik Barkhof^{1,10}

¹Dementia Research Centre, UCL Queen Square Institute of Neurology - London (United Kingdom), ²Centre for Medical Image Computing, Medical Physics & Biomedical Engineering, UCL - London (United Kingdom), ³Advanced Research Computing Centre, UCL - London (United Kingdom), ⁴Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology - London (United Kingdom), ⁵Department of Medical Statistics, London School of Hygiene and Tropical Medicine - London (United Kingdom), ⁶Department of Imaging, Imperial College Healthcare NHS Trust - London (United Kingdom), ⁷Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery - London (United Kingdom), ⁸NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology - London (United Kingdom), ⁹Bioxydyn Limited - Manchester (United Kingdom), ¹⁰Department of Radiology and Nuclear Medicine, Amsterdam UMC - Amsterdam (Netherlands)

10.30 a.m.

Coffee break and poster session



Early career investigators showcase: flash session presentations in the Poster Hall



● Friday, NOVEMBER 1

11:00 a.m.

LATE BREAKING ORAL COMMUNICATIONS

Chairs: Anton P. Porsteinsson, *University of Rochester - Rochester (United States)*, Charlotte Teunissen, *Amsterdam UMC, location Vrije Universiteit - Amsterdam (Netherlands)*

11:00 a.m.

LB25 - Plasma biomarker data indicates clinical activity of neflamapimod in dementia with Lewy bodies (DLB) is mediated through effects on the basal forebrain cholinergic system

John Alam¹, Charlotte Teunissen²

¹CervoMed Inc. - Boston (United States), ²Amsterdam UMC, location Vrije Universiteit - Amsterdam (Netherlands)

11:15 a.m.

LB26 - Sex Moderates Relationships Between P-Tau217 and Longitudinal Tau-PET: Findings from the A4 and LEARN studies

Gillian Coughlan¹, Hannah Klinger¹, Mabel Seto¹, Colin Birkenbihl¹, Michelle Farrell¹, Robert Rissman², Michael Properzi¹, Diana Townsend¹, Hyun-Sik Yang¹, Keith Johnson¹, Oliver Langford², Michael Donohue², Reisa Sperling¹, Rachel Buckley¹

¹Mass General Hospital/Harvard Medical School - Boston (United States), ²Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)

11:30 a.m.

LB27 - Performance of the Lilly SPX P-tau217 blood-based immunoassay (LDT) in clinical validation cohort subpopulations

Michael E. Hodsdon¹, Samantha C. Burnham¹, Amanda Morris¹, Michael J. Pontecorvo¹, Rose C. Beck¹

¹Eli Lilly and Company - Indianapolis (United States)

11:45 p.m.

LB28 - Timing and Duration of Adverse Events During 24 Weeks of Brexpiprazole Treatment in Patients With Agitation Associated With Dementia due to Alzheimer's Disease: Results From a Randomized Trial and an Extension Trial

Anton P. Porsteinsson¹, Malaak Brubaker², Sanjeda R. Chumki², Anton M. Palma², David Wang³, Zhen Zhang², Pedro Such⁴, C. Brendan Montano⁵

¹University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE) - Rochester (United States), ²Otsuka Pharmaceutical Development & Commercialization Inc. - Princeton (United States), ³Lundbeck LLC - Deerfield (United States), ⁴H. Lundbeck A/S - Copenhagen (Denmark), ⁵Connecticut Clinical Research - Cromwell (United States)

12:00 p.m.

LATE BREAKING ROUNDTABLE: Plasma P-tau217 assays in clinical practice: Current uses and future considerations for diagnosing Alzheimer's disease

Chair: Marc Suárez-Calvet¹

Presentation and Roundtable Discussion

Joel B. Braunstein², Rose Beck³, Manu Vandijck⁴, Margherita Carboni⁵, Rebecca M. Edelmayer⁶, Marwan Sabbagh⁷, Jonathan M. Schott⁸, Jim Hendrix³

¹Barcelona Beta Brain Research Centre; Hospital del Mar - Barcelona (Spain), ²C2N Diagnostics - St Louis (United States), ³Eli Lilly and Company - Indianapolis (United States), ⁴Fujirebio Europe N.V. - Gent (Belgium), ⁵Roche Diagnostics International Ltd. - Rotkreuz (Switzerland), ⁶Alzheimer's Association - Chicago (United States), ⁷Barrow Neurological Institute - Phoenix (United States), ⁸Dementia Research Centre, UCL, Queen Square Institute of Neurology - London (United Kingdom)

12:30 p.m.

Lunch break and poster sessions

1:30 p.m.

LATE BREAKING SYMPOSIUM 4: Cannabinoid based medications for neuropsychiatric symptoms in Alzheimer's dementia

Chair: Sagnik Bhattacharyya, *King's College London, London (United Kingdom)*

Presentation 1: Heterogeneity of treatment response: A post hoc analysis of clinical factors from a randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease

Krista L. Lancot^{1,2,3,4}

¹Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto (Canada) ²Department of Pharmacology and Toxicology, University of Toronto (Canada) ³Hurvit Brain Sciences Program, Sunnybrook Research Institute, Toronto (Canada) ⁴Department of Psychiatry, Sunnybrook Health Sciences Centre Toronto (Canada)

● Friday, NOVEMBER 1

Presentation 2: The THC-AD Study: The Efficacy and Safety of Dronabinol treatment for Agitation in Alzheimer's Dementia

Brent Forester

Tufts Medical Center, Tufts University School of Medicine, Boston (United States)

Presentation 3: Cannabidiol for behaviour symptoms in Alzheimer's dementia

Latha Velayudhan

King's College London, London (United Kingdom)

Presentation 4: The Use of THC and CBD in the Treatment of Agitated Persons Living with Dementia at the End of Life

Olga Brawman-Mintzer^{1,2}

¹Ralph H. Johnson VA Health Care System and ²Medical University of South Carolina, Charleston (United States)

2:10 p.m.

ORAL COMMUNICATIONS

Chairs: Claire Paquet, *APHP, Hospital Lariboisière Fernand Widal- Paris (France)*, Sharon Sha, *Stanford University - Palo Alto (United States)*

2:10 p.m.

OC35 - Anti-amyloid antibody preference for vascular A β aggregates does not explain ARIA rates

Anna Francis ¹, Angela Meunier ¹, Amirah Anderson ¹, Elizabeth Hennessey ¹, Michael Miller ¹, Cynthia Lemere ¹, Dennis Selkoe ¹, Andrew Stern ¹

¹Brigham and Women's Hospital - Boston (United States)

2:25 p.m.

OC36 - Artificial Intelligence-enabled Safety Monitoring in Alzheimer's Disease Clinical Trials

Gustavo Jimenez-Maggiora ¹, Michael Donohue ¹, Michael Rafii ¹, Rema Raman ¹, Paul Aisen ¹

¹Keck School of Medicine of USC - San Diego (United States)

2:40 p.m.

OC37 - First-in-human AV-1980R/A tau vaccine for Alzheimer's prevention (IND 29644)

Lon Schneider ¹, Anahit Ghochikyan ², Robert Alexander ³, Duygu Tosun-Turgut ⁴, Michael Agadjanyan ²

¹Keck School of Medicine, University of Southern California - Los Angeles (United States), ²Institute for Molecular Medicine - Huntington Beach (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴University of California, San Francisco - San Francisco (United States)

2:55 p.m.

OC38 - Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker-guided diagnostics: head-to-head comparison among an Asian population

Hyemin Jang ¹, Daeun Shin ², Heejin Yoo ², Henrik Zetterberg ^{3,4,5,6}, Kaj Blennow ^{3,7,8,9}, Fernando Gonzalez-Ortiz ^{3,4}, Nicholas J. Ashton ^{3,10,11,12}, Theresa A. Day ¹³, Eun Hye Lee ², Jihwan Yun ¹⁴, Duk L Na ², Hee Jin Kim ^{2,15,16}, Sung Hoon Kang ¹⁷, Jun Pyo Kim ², Sang Won Seo ^{2,15,16}

¹National University College of Medicine - Seoul (Korea, Republic of), ²Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³University of Gothenburg - Gothenburg (Sweden), ⁴Sahlgrenska University Hospital - Gothenburg (Sweden), ⁵UCL Institute of Neurology - London (United Kingdom), ⁶UK Dementia Research Institute - London (United Kingdom), ⁷Sahlgrenska University Hospital - Gothenburg (Sweden), ⁸ICM - Paris (France), ⁹First Affiliated Hospital of USTC - Hefei (China), ¹⁰King's College London - London (United Kingdom), ¹¹NIHR and NHS Foundation - London (United Kingdom), ¹²Stavanger University Hospital - Stavanger (Norway), ¹³Eli Lilly and Company - Indianapolis (United States), ¹⁴Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), ¹⁵Samsung Medical Center - Seoul (Korea, Republic of), ¹⁶Sungkyunkwan University - Seoul (Korea, Republic of), ¹⁷Korea University College of Medicine - Seoul (Korea, Republic of)

3:10 p.m.

Coffee break and poster session



3:40 p.m.

LATE BREAKING COMMUNICATIONS

Chairs: Francesca De Simone, *Fujirebio Diagnostics, Inc - Malvern (United States)*, Jacques Touchon, *Montpellier University - Montpellier (France)*

3:40 p.m.

LB29 - The use of plasma biomarkers for the prediction of Amyloid positivity

Francesca I De Simone ¹, Luna Buitrago ¹, Natalya Benina ¹, Rachel R Radwan ¹, Douglas Hawkin ², Abhay Moghekar ³, Marilyn Albert ³, Oskar Hansson ^{4,5}, Erik Stomrud ^{4,5}, Pallavi Sachdev ⁶, Diana Dickson ¹

¹Fujirebio Diagnostics, Inc. - Malvern (United States), ²Scottsdale Scientific LLC - Austin (United States), ³Department of Neurology, Johns Hopkins School of Medicine - Baltimore (United States), ⁴Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), ⁵Memory Clinic, Skane University Hospital - Malmö (Sweden), ⁶Eisai Inc. - Nutley (United States)

● Friday, NOVEMBER 1

- 3:55 p.m. **LB30 - Amyloid modifies the association between late-life BMI and longitudinal cognition in cognitively unimpaired individuals**
Wai-Ying Wendy Yau^{1,2}, Rema Raman³, Shunran Wang³, Neelum Aggarwal⁴, Adam Brickman⁵, Jasmeer Chhatwal^{6,1,2}, Petrice Cogswell⁷, Jonathan Graff-Radford⁷, Jay Pillai⁷, Prashanthi Vemuri⁷, Michael Rafii³, Paul Aisen³, Reisa Sperling^{6,1,2}, The A4 And Learn Study Teams⁸
¹Massachusetts General Hospital - Boston (United States), ²Harvard Medical School - Boston (United States), ³University of Southern California - San Diego (United States), ⁴Rush University Medical Center - Chicago (United States), ⁵Columbia University - New York (United States), ⁶Brigham and Women's Hospital - Boston (United States), ⁷Mayo Clinic - Rochester (United States), ⁸Alzheimer Clinical Trials Consortium
- 4:10 p.m. **LB31 - Retinal Hyperspectral Imaging and Blood-Based Biomarkers Demonstrate Comparable Performance for Predicting Brain Aβ Pathology: A Head-to-Head Comparison from the Bio-Hermes-001 Study**
Sophie Grapentine¹, Alon Hazan¹, Eliav Shaked¹, Jennifer Giordano¹, Catherine Bornbaum¹, Doug Beauregard²
¹RetiSpec - Toronto (Canada), ²Global Alzheimer's Platform Foundation - Washington (United States)
- 4:25 p.m. **LB32 - Participants enrolled in the RewinD-LB clinical trial: a large cohort of patients with dementia with Lewy bodies (DLB) without temporal lobe neurodegeneration, as defined by absence of elevation in plasma ptau181**
Stephen Gomperts¹, John-Paul Taylor², Paul Maruff³, Gardner Amanda⁴, Blackburn Kelly⁴, Alam John⁴, Galvin James⁵
¹Massachusetts General Hospital - Charlestown (United States), ²Newcastle University - Newcastle Upon Tyne (United Kingdom), ³Cosgstate Ltd - London (United Kingdom), ⁴CervoMed - Boston (United States), ⁵U. of Miami Miller School of Medicine - Boca Raton (United States)
- 4:40 p.m. **LB33 - Variations in incidence, progression, and risk factors across mild cognitive impairment (MCI) subtypes**
Chao-Yi Wu¹, Kevin Duff², Cierra Guerrero², Sarah Gothard², Raina Croff², Hiroko Dodge¹, Jeffrey Kaye²
¹Massachusetts General Hospital/ Harvard Medical School - Charlestown (United States), ²Oregon Health & Science University - Portland (United States)
- 4:55 p.m. **LB34 - Diagnostic accuracy and added value of [18F]APN-1607 PET in the clinical workup of patients with cognitive symptoms**
Yu Jin-Tai¹, Wang Jun²
¹Huashan Hospital, Fudan University - Shanghai (China), ²Daping Hospital, Third Military Medical University - Chongqing (China)
- 5:10 p.m. **End of the Conference Day**



POSTER PRESENTATIONS
presented in Madrid
and available on the CTAD24
digital platform

CTAD24 POSTER LISTING

All posters are available in Pdf format
at all times on the CTAD24 digital platform.

Posters presented **remotely**
are indicated with this icon :



From Tuesday, October 29 - 3:00 p.m. to Wednesday, October 30 - 5:00 p.m.

POSTER SESSION 1

THEME 01: Clinical Trials: Methodology	P001 to P020 / LP001 to LP015
THEME 02: Clinical Trials: Results	P021 to P040 / LP016 to LP024
THEME 11: New Therapies and Clinical Trials	P042 to P062 / LP025 to LP035
THEME 14: Beyond Amyloid and Tau	P063 to P075 / LP036 to LP041bis
THEME 15: Clinical Trials Early Career Investigator Showcase	P076 to P078 / LP042 to LP043

From Thursday, October 31 - 7:15 a.m. to 5:00 p.m.

POSTER SESSION 2

THEME 03: Clinical Trials: Imaging	P079 to P101 / LP044 to LP047
THEME 04: Clinical Trials: Biomarkers including plasma	P102 to P144 / LP048 to LP077
THEME 12: Proof of Concept/Translational research for AD Development interventions	P145 to P161 / LP078 to LP081
THEME 15: Clinical Trials Early Career Investigator Showcase	P162 / LP082 to LP084

From Friday, November 1 - 7:15 a.m. to 5:00 p.m.

POSTER SESSION 3

THEME 05: Clinical Trials: cognitive and functional endpoints	P163 to P177 / LP085 to LP092
THEME 06: Cognitive assessment and clinical trials	P178 to P201 / LP093 to LP096
THEME 07: Behavioral disorders and clinical trials	P202 to P205
THEME 08: Health economics and clinical trials	P206 to P209 / LP097 to LP098
THEME 09: Epidemiology and clinical trials	P210 to P220 / LP099 to LP103
THEME 10: Animal Model	P221 to P225
THEME 13: Digital health/E-trials	P226 to P249 / LP104 to LP111
THEME 15: Clinical Trials Early Career Investigator Showcase	P250 to P253 / LP112

POSTER PRESENTATIONS

Poster presentations presented **remotely**
are indicated with this icon: 

POSTER SESSION 1: From Tuesday, October 29 - 3:00 p.m. to Wednesday, October 30 - 5:00 p.m.

THEME 01: Clinical Trials: Methodology


- P001 Screening for Cognitive Impairment across Four Different European Dementia Cohorts Using an Automatic Digital Cognitive Assessment**
Johannes Tröger¹, Elisa Mallick¹, Nicklas Linz¹, Gonzalo Sánchez Benavides², Inez Ramakers³, Silke Kern⁴, Ingmar Skoog⁴, Stefanie Köhler⁵, Stefan Teipel⁵, Alexandra König¹
¹ki elements GmbH - Saarbrücken (Germany), ²BarcelonaBeta Brain Research Center (BBRC), Hospital del Mar Research Institute - Barcelona (Spain), ³Maastricht University Medical Center (MUMC+) - Maastricht (Netherlands), ⁴Institute of Neuroscience and Physiology at the Sahlgrenska Academy University of Gothenburg - Gothenburg (Sweden), ⁵Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) - Rostock (Germany)
- P002 Increasing statistical power of early Alzheimer's disease clinical trials with the AD-PxTM prognostic model**
Angela Tam¹, César Laurent¹, Christian Dansereau¹
¹Perceiv AI - Montreal (Canada)
- P003 Clinical Trials in Chronic Traumatic Encephalopathy: are we there yet?**
Charles Bernick¹, Guogen Shan², Dawn Matthews³, Aaron Ritter⁴
¹Cleveland Clinic - Las Vegas (United States), ²University of Florida - Gainesville (United States), ³ADMDx - Chicago (United States), ⁴Hoag Medical Center - Newport Beach (United States)
- P004 Storyteller as a Recruitment and Pre-Screening tool for Alzheimer's Disease Clinical Trials**
Sarah Hollingshead¹, Jeffrey Norton¹, Isabella Hernandez¹, Jack Weston², Emil Fristed², Caroline Skirrow²
¹Charter Research - The Villages (United States), ²Novoic Ltd - London (United Kingdom)
- P005 Novel pilot Phase 1 clinical trial with PV-1950R/A vaccine for Lewy Body Dementia (LBD)**
James Galvin¹, Michael Agadjanyan²
¹University of Miami Miller School of Medicine - Boca Raton (United States), ²Institute for Molecular Medicine - San Diego (United States)
- P006 Key stakeholder engagement and protocol development for the IHI-funded public-private partnership project PREDICTOM**
Zunera Khan¹, Anna-Katherine Brem¹, Mark Ashworth¹, Nick Ashton¹, Sigurd Brandt², Anne Corbett³, Ellie Pickering³, Ana Diaz⁴, Holger Fröhlich⁵, Martha Therese Gjesten⁶, Gaby Marquardt⁷, Matthias Müllenborn⁸, Spiros Nikolopoulos⁹, Timo Schirmer¹⁰, Dag Aarsland¹¹
¹IOPPN, King's College London - London (United Kingdom), ²GN Hearing - Copenhagen (Denmark), ³University of Exeter - London (United Kingdom), ⁴Alzheimer's Europe - Luxembourg (Luxembourg), ⁵Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Bonn (Germany), ⁶Stavanger Hospital - Stavanger (Norway), ⁷Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Erlangen (Germany), ⁸Novo Nordisk - Copenhagen (Denmark), ⁹CERTH - Thessaloniki (Greece), ¹⁰GE Healthcare - Greater Munich (Germany), ¹¹IOPPN - London (United Kingdom)
- P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials**
Viswanath Devanarayan¹, Pallavi Sachdev¹, Arnaud Charil¹, Yuanqing Ye¹, Todd Nelson¹, Harald Hampel¹, Lynn Kramer¹, Shobha Dhadha¹, Michael Irizarry¹
¹Eisai Inc. - Nutley (United States)
- P008 Utilizing a Patient Burden Scoring Tool to Improve the Patient and Caregiver Experience in Clinical Research in Patients with Alzheimer's Disease and Other Forms of Dementia**
Jessica Sheldon¹, Ana Manera², Andreas Lysandropoulos³
¹Parexel - Boston (United States), ²Parexel - Quebec (Canada), ³Parexel - Brussels (Belgium)
- P009 Assessing the feasibility of implementing blood-based biomarkers as confirmatory diagnostic tools for early Alzheimer's disease in real-world clinical practice: a prospective, multi-clinic implementation science and observational study**
Leah Zullig¹, Jo Vandercappellen², Marwan N Sabbagh³, Soeren Mattke⁴, Harald Hampel², Richard Batrla², Daryl Jones²
¹Department of Population Health Sciences, Duke University School of Medicine - Durham, (United States), ²Eisai Inc., Nutley - New Jersey (United States), ³Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center - Phoenix (United States), ⁴Center for Economic and Social Research, University of Southern California - Los Angeles (United States)
- P010 A new precision-prevention approach combining lifestyle changes and metformin repurposing for the prevention of cognitive decline: MET-FINGER trial protocol and update**
Alina Solomon^{1,2,3}, Mariagnese Barbera^{1,2}, Dinithi Perera^{2,4}, Arzish Haqqee², Jenni Lehtisalo^{1,5}, Malin Aspö^{3,6}, Mary Cross², Celeste De Jager², Emanuela Falaschetti², Naomi Friel², Jack Message², Geraint Price², Charlotta Thunborg^{3,6}, Francesca Mangialasche^{3,4}, Lefkos Middleton^{2,7}, Tiia Ngandu^{5,3}, Miia Kivipelto^{3,6,2,4}
¹University of Eastern Finland - Kuopio (Finland), ²Imperial College London - London (United Kingdom), ³Karolinska Institutet - Stockholm (Sweden), ⁴FINGERS Brain Health Institute - Stockholm (Sweden), ⁵The Finnish Institute for Health and Welfare - Helsinki (Finland), ⁶Karolinska University Hospital - Stockholm (Sweden), ⁷Imperial College Healthcare NHS Trust Hospitals - London (United Kingdom)
- P011 Evidence-Based Reporting of Ethnicity in Clinical Trials**
Zunera Khan¹, Daniel Kramarczyk², Miguel Vasconcelos Da Silva², Kamara Mcleish Israel², Dag Aarsland², Clive Ballard³
¹Psychological Medicine - London (United Kingdom), ²Psychological Medicine - 6 De Crespigny Park, London (United Kingdom), ³University of Exeter - Exeter (United Kingdom)

POSTER PRESENTATIONS

- P012** **Diversity in a Registrational Trial for AriBio's AR1001 for Treatment of Early Alzheimer's Disease**
 Sharon Sha¹, Yaneicy Gonzalez², Marshall Nash³, James Rock⁴, Fred Kim⁴, Adam Schindler⁴, Tianyang Xi⁴, Jai Jun Choung⁴
¹Neurology & Neurological Sciences, Stanford University - Palo Alto (United States), ²Verus Clinical Research Corp - Miami (United States), ³Alcanza Research Site Network- NeuroStudies - Decatur (United States), ⁴AriBio Co., Ltd. - San Diego (United States)
- P013** **Estimating the benefits of pre-screening Alzheimer's trials using blood-based biomarkers and digital cognitive assessments**
 Nicklas Linz¹, Raphael Ullmann², Johannes Tröger¹, Alexandra König¹, Ruth Croney³, Tobias Bittner⁴, Thanneer Perumal²
¹ki:elements GmbH - Saarbrücken (Germany), ²Roche Pharma Research and Early Development, Roche Innovation Center Basel - Basel (Switzerland), ³Roche Products Ltd - Welwyn Garden City (United Kingdom), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland)
- P014** **Comparison of the screen failure rate in Alzheimer's clinical trials of immunotherapies between the clinical research center of Toulouse and the overall rate over the past 5 years.**
 Delphine Penneret¹, Davide Angioni¹, Isabelle Carrie¹, Nathalie Sastre¹, Julien Delrieu¹, Bruno Vellas¹, Pierre Jean Ousset¹
¹Centre de Recherche Clinique du Gerontopole, IHU Healthage - Toulouse (France)
- P015** **Comparing In-study Performance of Experienced and Naive Raters in Early AD Clinical Trials**
 Xingmei Wang¹, Alan Kott², David Miller¹
¹Signant Health - Blue Bell, Pa (United States), ²Signant Health - Prague (Czech Republic)
- P016** **Automatic Screening for CDR Stages in the Swedish H70 Birth Cohort Using a Digital Speech Biomarker for Cognition SB-C**
 Elisa Mallick¹, Fredrik Öhman², Nicklas Linz¹, Alexandra König¹, Michael Schöll², Silke Kern², Johannes Tröger¹, Ingmar Skoog²
¹ki:elements GmbH - Saarbrücken (Germany), ²Institute of Neuroscience and Physiology at the Sahlgrenska Academy University of Gothenburg - Gothenburg (Sweden)
- P017** **Enhancing Clinical Trial Efficiency in Alzheimer's Disease: An Application of Prognostic Scoring Adjustments to Address Heterogeneity**
 Harry Parr¹, Jeffrey Lin², Doug Thompson¹, Dave Inman¹, Aris Perperoglou¹
¹GSK - London (United Kingdom), ²GSK - Philadelphia (United States)
- P018** **Impact of Travel Distance and Participant Age on Potential Alzheimer's Disease Trial Participant Attendance and Clinical Trial Eligibility**
 Sarah Starling¹, Ashli Pratt², Adam Rosen², Sophie Barr², Bryanna Billy², Gaby Munoz², Mark Rapp²
¹Adams Clinical - Watertown (United States), ²Berman Clinical - New York (United States)
- P019** **Integrating a Speech-based Prescreening Tool in Central Recruitment Strategies for Alzheimer's Disease Clinical Trials: A Pilot Study**
 Caroline Skirrow¹, Allan Block², Nicole Hank², Jack Weston¹, Emil Fristed¹, James Rock³
¹Novoic Ltd - London (United Kingdom), ²Perseverance Research Center - Scottsdale, Az (United States), ³AriBio - San Diego, Ca (United States)
- P020** **Impact of screening call duration on initial evaluation attendance rate for Alzheimer's Disease drug trials**
 Yu-Jay Huoh¹, Brenda Martinez¹, Sydney Hopkins¹, Elizabeth Sosa¹, Jade Sanchez¹, Jennifer Mitolo¹, Tara Parnitvithikul¹, Elly Lee¹, Ralph Lee¹
¹Irvine Clinical Research - Irvine (United States)
- LP001** **Frequency of SAE and mortality rate in Alzheimer's Disease [AD] clinical trials: Data from Medical and Statistical reports from US FDA including seven approved medications consisting of a total database of 19,921 Subjects**
 Anshu Arora¹, Arun Arora¹, Arif Khan¹
¹Northwest Clinical Research Center - Bellevue (United States)
- LP002** **The importance of rigorous data quality assurance and management in clinical studies of the AI era: The innovative AI-Mind Study**
 Vebjørn Andersson¹, Christoffer Hatlestad-Hall¹, Ainar Drews², Hanna Renvall^{3,4}, Fernando Maestú^{5,6}, Camillo Marra^{7,8}, Ira Hebold Haraldsen¹, Paolo Maria Rossini⁹
¹Oslo University Hospital - Oslo (Norway), ²University of Oslo - Oslo (Norway), ³Helsinki University Hospital - Helsinki (Finland), ⁴Aalto University - Helsinki (Finland), ⁵Universidad Complutense Madrid - Madrid (Spain), ⁶San Carlos University Hospital - Madrid (Spain), ⁷Università Cattolica del Sacro Cuore - Rome (Italy), ⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁹IRCCS San Raffaele Pisana - Rome (Italy)
- LP003** **GAN-synthesized resting-state EEG and its clinical relevance in dementia studies**
 Vebjørn Andersson¹, Christoffer Hatlestad-Hall¹, Hanna Renvall², Fernando Maestú³, Camillo Marra⁴, Paolo Maria Rossini⁵, Anis Yazidi⁶, Ira H. Haraldsen¹, Ramesh Upreti¹
¹Oslo University Hospital - Oslo (Norway), ²Helsinki University Hospital - Helsinki (Finland), ³Universidad Politécnica de Madrid - Madrid (Spain), ⁴Università Cattolica del Sacro Cuore - Milan (Italy), ⁵the Scientific Institute for Research, Hospitalization and HealthCare - Rome (Italy), ⁶Oslo Metropolitan University - Oslo (Norway)
- LP004** **SHIMMER: Baseline Data and Early Lessons from the Ongoing Phase 2 Signal-finding Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (DLB)**
 James Galvin¹, Magdalena Tolea¹, Jennifer Iaci², Anthony Caggiano², Michael Grundman³
¹Comprehensive Center for Brain Health, Dept of Neurology, University of Miami Miller School of Medicine - Miami (United States), ²Cognition Therapeutics - Purchase (United States), ³Global R&D Partners - San Diego (United States)
- LP005** **Clinical Trial Enrichment Strategy for Participant Selection in the Phase 3 HOPE study of Alzheimer's disease: Progress towards personalized medicine**
 Lily Lee¹, Celine Houser¹, Alex Konisky¹, Evan Hempel¹, Chandran Seshagiri¹, Mihaly Hajos¹, Christian Howell¹, Ralph Kern¹
¹Cognito Therapeutics - Cambridge, Ma (United States)

POSTER PRESENTATIONS

Poster presentations presented **remotely**
are indicated with this icon : 

- LP007** International Registry for Alzheimer's Disease and Other Dementias (InRAD): Application of longitudinal practice-based data to augment and conduct clinical trials in early-stage Alzheimer's disease
Robert Perneczky^{1,2,3}, Johan Van Beek⁴, Robert Hyde⁴, Ignacio Illán-Gala⁵, Frank Jessen^{6,7}
¹Department of Psychiatry, LMU Hospital, LMU Munich - Munich (Germany), ²German Center for Neurodegenerative Diseases - Munich (Germany), ³University of Sheffield, Department of Neurosciences - Sheffield (United Kingdom), ⁴TW1 Healthcare Consulting Ltd. - London (United Kingdom), ⁵Hospital de La Santa Creu i Sant Pau, Department of Neurology, Memory Unit - Barcelona (Spain), ⁶Department of Psychiatry, University of Cologne - Cologne (Germany), ⁷German Center for Neurodegenerative Diseases - Cologne (Germany)
- LP008** Partners in Care Intervention for Persons with dementia and multimorbidity. A clinical trial feasibility study
Ingelin Testad^{1,2}, Lise Birgitte Holteng¹, Marthe Therese Gjestsén^{1,3}
¹Stavanger University Hospital - Stavanger (Norway), ²University of Exeter Medical School - Exeter (United Kingdom), ³University of Bergen - Bergen (Norway)
- LP009** The Patient Voice in Drug Reviews: Learnings from Older Adult Engagement on Disease-Modifying Treatments for Dementia in Ontario, Canada
Adam Morrison¹, Jessica Hogle¹
¹Alzheimer Society of Ontario - Toronto (Canada)
- LP010** AI-guided patient stratification improves efficiency of Alzheimer's disease clinical trial
Zoe Kourtzi¹, Delshad Vaghari¹, Gayathri Mohankumar², Peter Tino³, Craig Shering⁴, Andrew Lowe², Keith Tan²
¹University of Cambridge - Cambridge (United Kingdom), ²AstraZeneca - Cambridge (United Kingdom), ³University of Birmingham - Birmingham (United Kingdom), ⁴AstraZeneca - Boston (United States)
- LP011** Combination Therapy Phase 3 Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Study the Safety and Efficacy of NA-831 in Combination with Lecanemab in Subjects with Early Alzheimer's Disease
Lloyd Tran¹, Fern Vu¹, Zung Tran¹
¹BioMed Industries, Inc. - San Jose (United States)
- LP012** Minimizing Screen Failure Rates and Accelerating Clinical Trial Recruitment with a Prognostic Model
Angela Tam¹, César Laurent¹, Adrián Noriega¹, Christian Dansereau¹
¹Perceiv AI - Montreal (Canada)
- LP013** Enhancing Clinical Trial Efficiency: Increasing Screening and Randomization Rates Using RetiSpec's AI-Based Eye Scan for Pre-Screening in Eye Care Settings
John Lehr¹, Sophie Grapentine², Brandon Lenox³, Stephanie Cassidy³, Rozana Naureen², Brittany Pendarvis¹, Jennifer Giordano², Alon Hazan², Eliav Shaked², Catherine Bornbaum²
¹Magruder Eye Institute - Orlando (United States), ²RetiSpec - Toronto (Canada), ³K2 Medical Research - Maitland (United States)
- LP014** Development of Edaravone tablets for the treatment of Alzheimer's disease---Phase I trials in healthy volunteers and Phase II design in early AD
Xin-Fu Zhou¹, Jun Wang², Yan-Jiang Wang²
¹Suzhou Auzone Biotech - Suzhou (China), ²Department of Neurology, Daping Hospital, Third Military Medical University - Chongqing (China)
-  **LP015** Clinical Trials Using Music Interventions for Alzheimer's Disease and Related Disorders in Ethnically Diverse Communities
Tara Rose¹
¹University of Southern California - Los Angeles (United States)

THEME 02: Clinical Trials: Results

- P021** Phase 1 clinical trial of Leucettinib-21, a DYRK1A kinase inhibitor aiming at the correction of cognitive disorders in Alzheimer's disease and Down syndrome
Laurent Meijer¹, Emilie Chrétien¹, Emmanuel Deau¹, Gaëlle Hogrel¹, Mattias F. Lindberg¹
¹Perha Pharmaceuticals - Roscoff (France)
- P022** Phase 1a Single Ascending Dose Study of PMN310, a monoclonal antibody directed against toxic Aβ oligomers
Larry Altstiel¹
¹ProMIS Neurosciences - Cambridge, Ma (United States)
- P024** Comprehensive analysis of phase 2 trial results and post-hoc findings of ABvac40, an anti-Aβ40 vaccine
María Pascual-Lucas¹, Ana María Lacosta¹, María Montañés¹, Jesús Canudas¹, Jorge Loscos¹, José Antonio Allué¹, Leticia Sarasa¹, Noelia Fandos¹, Judith Romero¹, Manuel Sarasa¹, Gerard Piñol-Ripoll², Jose Terencio^{3,1}, Merce Boada^{4,5}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Cognitive Disorders Unit, Cognition and Behaviour Study Group, Hospital Universitari Santa Maria - Lleida (Spain), ³Grifols - Barcelona (Spain), ⁴Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain), ⁵Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III - Madrid (Spain)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon: 

- P037** Analysis of the cardiovascular safety of choline alphoscerate treatment in the ASCOMALVA trial
Enea Traini¹, Anna Carotenuto¹, Angiola Fasanaro², Francesco Amenta¹
¹University of Camerino - Camerino (Italy), ²Neurology and Stroke Unit-Neurology, A. Cardarelli Hospital - Napoli (Italy)
- P038** Exploring the effect of baseline characteristics on the efficacy of multidomain dementia prevention in late-life: a pooled analysis of individual participant data from the MAPT and preDIVA trials
Nicola Coley^{1,2,3}, Marie Hoevenaer-Blom^{4,5}, Jason Shourick^{1,2,3}, Eric Moll Van Charante^{4,5}, Jan-Willem Van Dalen^{6,7}, Willem Van Gool⁵, Edo Richard^{5,6}, Sandrine Andrieu^{1,2,3}
¹Aging Research Team, Centre for Epidemiology and Research in Population health (CERPOP), INSERM-University of Toulouse UPS - Toulouse (France), ²Department of Epidemiology and Public Health, Toulouse University Hospital - Toulouse (France), ³IHU HealthAge - Toulouse (France), ⁴Department of General Practice, Amsterdam UMC, University of Amsterdam - Amsterdam (Netherlands), ⁵Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam - Amsterdam (Netherlands), ⁶Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center - Nijmegen (Netherlands), ⁷Department of Neurology, Amsterdam University Medical Center, Location AMC - Amsterdam (Netherlands)
- P039** Online advertising resulted in more educated participants and non inferior screen fail rates when compared to offline methods in an Alzheimer's disease clinical trial
Yu-Jay Huoh¹, Ralph Lee¹, Colin Sholes¹, Brenda Martinez¹, Sydney Hopkins¹, Jennifer Mitolo¹, Tara Parnitvithikul¹, Edward Zamrini¹, Elly Lee¹
¹Irvine Clinical Research - Irvine (United States)
- P040** Potential Efficacy of Oral Nicotinamide Riboside (NR) Supplementation in Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment
Chao-Yi Wu¹, Ashley Kupferschmid¹, Alison Mcmanus¹, Pia Kivisakk¹, Jake Galler¹, Nadine Schwab¹, Libby Desruisseaux¹, Victoria Williams¹, Jessica Gerber¹, Misha Riley¹, Cathrine Young¹, Hiroko Dodge¹, Rudolph Tanzi¹, Clifford Singer², Steven Arnold¹
¹Massachusetts General Hospital/ Harvard Medical School - Boston (United States), ²Northern Light Health - Bangor (United States)
- LP016** Effects of sensory-evoked gamma oscillation on neurophysiological signals of visual and cognitive processing in Alzheimer's disease
Roberto Fernández Romero¹, David Grant¹, Brennan Jackson², Chandran Seshagiri², Mihály Hajós²
¹The University of Tennessee Medical Center - Knoxville (United States), ²Cognito Therapeutics - Cambridge (United States)
- LP017** Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease Treatment Center
David Watson¹, Michael Neam¹, Mark Stafford¹, Cynthia Bouchard¹, Venessa Ranney¹, Sydney Werner¹
¹Alzheimer's Research and Treatment Center - Wellington (United States)
- LP018** Additional Analysis of a 52-Week Phase II Trial of Neuromodulation of the Default Mode Network to Optimize Design of a Phase 3 Trial to Demonstrate Clinical Meaningfulness
Suzanne Hendrix¹, Lisa Fosdick², Garrett Duncan¹, Samuel Dickson¹, Giacomo Koch^{2,3}
¹Pentara Corporation - Salt Lake City (United States), ²Sinaptica Therapeutics - Cambridge (United States), ³University of Rome Tor Vergata - Rome (Italy)
- LP019** Intracerebroventricular injection of autologous adipose-derived stem cells for the treatment of Alzheimer's Disease: Experience with the first of three 3-patient cohorts in a "First in Human" Phase I FDA trial.
Christopher Duma¹, Gustavo Alva², Hans Keirstead¹, Gabriel Nistor¹, Robert Lynn¹, Jessica Buxton¹, Sawyer Farmer¹, Karlyssa Chung¹, Ashley Harris¹, Zoe Hareng¹
¹Regeneration Biomedical, Inc., Newport Beach, CA - Newport Beach (United States), ²Hoag Memorial Hospital, Newport Beach, CA - Newport Beach (United States)
- LP020** Treatment of Moderate Alzheimer's Disease Subjects with Expanded Non- genetically Modified Natural Killer Cells (trocleucel; SNK01) With Enhanced Activity —Report of the Phase I results of the Phase I/IIa study
Paul Song¹, Lucia Hui¹, Hank Lee¹, Juan Mata¹, Katia Betito¹, Harry Chung², Jesse Carr²
¹NKGen Biotech - Santa Ana (United States), ²Behavioral Research Specialists LLC - Glendale (United States)
- LP021** Post-marketing Study of Sodium Oligomannate: Long-Term Safety and Effectiveness of an Agent Targeting the Gut Microbiome for the Treatment of Alzheimer's Disease
Xianliang Xin¹, Jinhe Li¹, Xia Li², Meiyu Geng³, Qihao Guo⁴
¹Green Valley (Shanghai) Pharmaceuticals Co., Ltd. - Shanghai (China), ²Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine - Shanghai (China), ³State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Shanghai (China), ⁴Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine - Shanghai (China)
- LP022** Regional variation of amylin, β amyloid and amylin- β amyloid in sporadic, late-onset AD brains
Deepak Kotiya¹, Peter T. Nelson¹, Gregory A. Jicha¹, Larry B. Goldstein¹, Florin Despa¹
¹University of Kentucky - Lexington (United States)
- LP023** APOE4 and Buntanetap in Phase II/III Alzheimer's patients
Cheng Fang¹, Maria Maccacchini¹
¹Annovis Bio - Malvern (United States)
-  **LP024** A Phase 3 Study of Sublingual Dexmedetomidine for Episodic Treatment of Agitation Associated with Alzheimer's Dementia
Robert Risinger¹, Lavanya Rajachandran¹, Heather Robinson¹, Jeffrey Cummings², George Grossberg³
¹BioXcel Therapeutics - New Haven (United States), ²University of Nevada - Las Vegas (United States), ³St Louis University - St Louis (United States)

POSTER PRESENTATIONS

THEME 11: New therapies and clinical trials

- P042** **Specialized infrastructure in a tertiary hospital to administer disease modifying treatments in Alzheimer's disease**
Talya Nathan¹, Elissa Ash^{1,2,3}, Shir Dror¹, Noa Trubulus¹, Aya Bar-David¹, Mori Hay Levy¹, Galia Wolpe¹, Tamara Shiner^{1,2,3}, Noa Bregman^{1,2,3}
¹Cognitive Neurology Unit, Tel Aviv Sourasky Medical Center - Tel Aviv (Israel), ²Department of Neurology and Neurosurgery, Sackler School of Medicine, Tel Aviv University - Tel Aviv (Israel), ³Sagol School of Neuroscience, Tel Aviv University - Tel Aviv (Israel)
- P043** **Cognitive Verge predicts AD, correlates with CSF biomarkers and improves after digital treatment.**
Hans Supér¹
¹University of Barcelona - Barcelona (Spain)
- P044** **Increasing Representation and Diversity in Clinical Trials of Alzheimer's Disease: Recruitment of Ethnically Diverse Participants with Alzheimer's Disease in the Phase 1 ASCENT Clinical Trials of PRX012**
Chad Swanson¹, Ferenc Martényi¹, Ryan E. Tooker¹, Donna Masterman¹, Courtney Fitzgerald¹, Ann Johnson¹, Lingnan Li¹, Mary E. Quiceno¹, Gene G. Kinney¹, Hideki Garren¹
¹Prothena Biosciences Inc - Brisbane (United States)
- P045** **Advances in Clinical Trials for Alzheimer's Disease in Down Syndrome**
Michael Rafii¹, Juan Fortea², Beau Ances³
¹University of Southern California - San Diego (United States), ²Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ³Washington University - Saint Louis (United States)
- P046** **Clinical experience with amyloid-lowering treatments in an academic dementia specialty practice**
Madeline Paczynski¹, Suzanne Schindler^{1,2}, Erik Musiek^{1,2}, David Holtzman^{1,2}, Tammie Benzinger^{1,2}, Alan Dow³, Sheyda Namazie-Kummer³, Zachary Posey^{1,2}, Dawn Ellington^{1,2}, John Morris^{1,2}, Barbara Snider^{1,2}
¹Washington University School of Medicine - Saint Louis (United States), ²Knight Alzheimer Disease Research Center - Saint Louis (United States), ³Barnes Jewish Corporation - Saint Louis (United States)
- P047** **A randomized, double-blind trial of the effects of a live biotherapeutic product in preclinical Alzheimer's disease**
Kun Ho Lee¹, Kyu Yeong Choi², Sarang Kang¹, Junho H Lee³, Won-Seok Choi³, Jung Hee Lee²
¹Gwangju Alzheimer's & Related Dementia Cohort Research Center, Chosun University - Gwangju (Korea, Republic of), ²Kolab Inc. - Gwangju (Korea, Republic of), ³Chonnam National University - Gwangju (Korea, Republic of)
- P049** **Self-reported sleep quality and amyloid burden in cognitively unimpaired adults from the AMYPAD study.**
Núria Tort-Colet^{1,2}, Laura Stankeviciute¹, Craig Ritchie³, Mercè Boada^{4,5}, Wiesje Van Der Flier⁶, Bernard J Hanseeuw⁷, Pablo Martinez-Lage⁸, Pieter Jelle Visser⁹, Michael Schöhl¹⁰, Giovanni B Frisoni¹¹, Chris Buckley¹², Frank Jessen¹³, Lyduine E. Collij^{9,14}, Frederik Barkhof^{9,14,15}, Oriol Grau-Rivera^{1,2,16,17}
¹BBRC, Pasqual Maragall Foundation - Barcelona (Spain), ²Hospital del Mar Research Institute - Barcelona (Spain), ³Centre for Clinical Brain Sciences, University of Edinburgh - Edinburgh (United Kingdom), ⁴ACE Alzheimer Center Barcelona - Barcelona (Spain), ⁵CIBERNED, Instituto de Salud Carlos III - Madrid (Spain), ⁶Amsterdam UMC Location VUmc - Amsterdam (Netherlands), ⁷IONS, Université Catholique de Louvain - Brussels (Belgium), ⁸Fundacion CITA Alzheimer - San Sebastian (Spain), ⁹Amsterdam University Medical Center, location VUmc - Amsterdam (Netherlands), ¹⁰University of Gothenburg - Gothenburg (Sweden), ¹¹LANVIE, Université de Genève - Geneva (Switzerland), ¹²GE Healthcare - Amersham (United Kingdom), ¹³University Hospital of Cologne - Cologne (Germany), ¹⁴Amsterdam Neuroscience, Brain Imaging - Amsterdam (Netherlands), ¹⁵Centre for Medical Image Computing, and Queen Square Institute of Neurology, UCL - London (United Kingdom), ¹⁶Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), ¹⁷Hospital del Mar - Barcelona (Spain)
- P050** **Phase 1, First-in-human, Single and Multiple Ascending Dose Study of a Novel Orally Administered TREM2 Agonist (VG-3927) in Healthy Volunteers: Interim Results**
Raj Rajagovindan¹, Francois Gaudreault¹, Ryan O'Mara¹, Jade Donaldson¹, Evan Thackaberry¹, Jessica Stromme¹, David Gray¹, Andreas Meier², Petra Kaufmann¹
¹Vigil Neuroscience, Inc - Watertown (United States), ²Formerly Vigil Neuroscience, Inc - Watertown (United States)
- P051** **Interim Safety and Biomarker Data From upLIFT-D, a Phase 1b Trial of PBFT02 in Frontotemporal Dementia and Mutations in the Granulin Gene (FTD-GRN)**
Juan Chavez¹, Tiffini Voss¹, Paulette Triglia¹, Yan Ni¹, Sue Browne¹, Karen Quadri¹, Sarang Rastogi¹, Simon Ducharme², David Irwin³, Isabel Santana⁴, Paul E Schulz⁵, Leonel Takada⁶, Maria Tartaglia⁷, Leonardo Cruz De Souza⁸, Mark S Foreman¹
¹Passage Bio - Philadelphia (United States), ²Douglas Mental Health University Institute and Montreal Neurological Institute, McGill University - Montreal (Canada), ³Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ⁴Centro Hospitalar Universitário de Coimbra - Coimbra (Portugal), ⁵McGovern Medical School, UTHHealth Houston - Houston (United States), ⁶Perelman School of Medicine at the University of Pennsylvania - Sao Paulo (Brazil), ⁷University Health Network, and Tanz Centre for Research in Neurodegenerative Diseases - Toronto (Canada), ⁸Hospital das Clinicas Universidade Federal de Minas Gerais - Belo Horizonte (Brazil)
- P052** **Alzheimer's disease and microbiota: the MICMALZ study**
Germain Busto¹, Lucy Kundura², Sylvaine Artero², Yves Dauvilliers³, Karim Bennys⁴, Sylvie Claeys², Audrey Gabelle¹
¹Center for Memory Resources and Research (CMRR), Department of Neurology, Montpellier University Hospital, Montpellier, INM, University Montpellier, Montpellier, France - Montpellier (France), ²IGF, University Montpellier, CNRS, INSERM, Montpellier, France. - Montpellier (France), ³Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital and INM, University Montpellier, Montpellier, France. - Montpellier (France), ⁴Center for Memory Resources and Research (CMRR), Department of Neurology, Montpellier University Hospital, Montpellier, France. - Montpellier (France)

POSTER PRESENTATIONS

- P053** **TREM2 Agonism Stimulates Human Microglia Responses in the Presence of Amyloid Pathology**
Manuela Polydoro¹, Ivana Geric², Jin Zheng³, Tina Sommer Bisgaard³, Leen Wolfs², Anke Misbaer², Arya Nair², Laura Sans³, Maria Dalby³, Joachim Vilstrup³, Peter Flagstad³, Rita Balice-Gordon⁴, Bart De Strooper^{5,6}, Niels Plath³
¹Muna Therapeutics, Copenhagen, Denmark - Boston (United States), ²Muna Therapeutics, Copenhagen, Denmark - Leuven (Belgium), ³Muna Therapeutics, Copenhagen, Denmark - Copenhagen (Denmark), ⁴Muna Therapeutics, Copenhagen, Denmark - Philadelphia (United States), ⁵UK Dementia Research Institute - London (United Kingdom), ⁶KU Leuven - Leuven (Belgium)
- P054** **Targeting α -Synuclein Fibril's Disordered Region with Small Molecule Inhibitors: A Therapeutic Strategy for Parkinson's Disease**
Shenqing Zhang¹, Huaijiang Xiang², Dan Li¹, Li Tan², Cong Liu²
¹Shanghai Jiao Tong University - Shanghai (China), ²Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Shanghai (China)
- P055** **Different charged biopolymers induce α -synuclein to form fibrils with distinct structures**
Yuxuan Yao¹, Qinyue Zhao¹, Cong Liu², Dan Li³
¹Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University - Shanghai (China), ²Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences - Shanghai (China), ³Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University - Shanghai (China)
- P056** **Development and Efficacy Assessment of a Video-Based Reminiscence Therapy Using Medial Archives for Early-Stage Dementia: A Pilot Study**
Geon Ha Kim¹, Bori R. Kim^{1,2}, Sumin Kim¹, Jee Hyang Jeong³
¹Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine - Seoul (Korea, Republic of), ²Ewha Medical Research Institute, Ewha Womans University - Seoul (Korea, Republic of), ³Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine - Seoul (Korea, Republic of)
- P057** **PreDXClearance, exploring new biomarkers to predict ARIA/CAA and personalize therapy in AD**
Fanni Ujvarosi¹, Line Amundsen¹, Jie Gao¹, Ira Hebold Haraldsen², Fernando Maestú³, Hanna Renvall⁴, Camillo Marra⁵, Paolo M. Rossini⁶, Erik Christensen¹, Maria J. Lagartos¹
¹Pre Diagnostics - Oslo (Norway), ²Oslo University Hospital - Oslo (Norway), ³Universidad Complutense - Madrid (Spain), ⁴HUS - Helsinki (Finland), ⁵Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁶IRCCS San Raffaele - Rome (Italy)
- P058** **Evaluation of square-stepping exercise on plasma amyloid-beta levels and cognitive function in older adults: a randomized controlled trial**
Jeun Yoon¹, Tomohiro Okura¹
¹University of Tsukuba - Tsukuba (Japan)
- P059** **Evaluation of an Upper Alpha Neurofeedback Intervention on Mild Amnesic Cognitive Impairment: A Randomized, Double-blind, Sham-controlled Research Project (ESPERANZA study)**
Esperanza Jubera-García^{1,7}, Carlos Escolano¹, Eduardo López-Larraz¹, Jens Klinzing¹, Jose Ventura¹, Beatriz Hornillos¹, Laura Pampliega¹, Nora Molina-Torres^{2,3}, Jose M. Pérez-Trullén^{2,4}, Elena Lobo^{2,6}, Antonio Lobo², Tristan Beckinschtein⁷, Pedro Modrego^{2,5}, Javier Minguez¹
¹Bitbrain, Zaragoza (Spain), ²Instituto de Investigación Sanitaria de Aragón, Zaragoza (Spain), ³Servicio de Geriatria, Hospital Nuestra Señora de Gracia, Zaragoza (Spain), ⁴Servicio de Neurología, Hospital Nuestra Señora de Gracia, Zaragoza (Spain), ⁵Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza (Spain), ⁶Department of Preventive Medicine and Public Health, Universidad de Zaragoza (Spain), ⁷University of Cambridge, Department of Psychology, Cambridge (United Kingdom)
- P060** **Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer's Disease**
Abigail Silber¹, Amod Athavale¹, Matthew O'Hara¹, Donna Masterman², Preeti S. Bajaj²
¹Trinity Life Sciences - Waltham, MA (United States), ²Prothena Biosciences, Inc - Brisbane, CA (United States)
- P061** **The NANA study: Auditory stimulation during sleep as a symptomatic treatment for mild cognitive impairment**
Jens G. Klinzing¹, Esperanza Jubera-García^{1,6}, Sergio Clemente Jiménez¹, Galit Fierro¹, Eduardo López-Larraz¹, Almudena Robledo-Menéndez¹, Pedro Modrego^{2,3}, Antonio Lobo^{2,4}, Jorge de Francisco Moure^{2,5}, Carmen Almarcegui^{2,5}, Javier Minguez¹
¹Bitbrain, Zaragoza (Spain), ²Instituto de Investigación Sanitaria de Aragón, Zaragoza (Spain), ³Servicio de neurología, Hospital Universitario Miguel Servet, Zaragoza (Spain), ⁴Department of Medicine and Psychiatry, Universidad de Zaragoza (Spain), ⁵Servicio de Neurofisiología Clínica, Hospital Universitario Miguel Servet, Zaragoza (Spain), ⁶University of Cambridge, Department of Psychology, Cambridge (United Kingdom)
-  **P062** **Prospects for the Treatment of Alzheimer's Disease**
Amanda Scarso¹, Gustavo Santos¹, Gabrielle Almeida¹
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil)
- LP025** **Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer's disease**
Cristina Parrado-Fernández^{1,2}, Ruchi Gera³, Veronica Lidell¹, Azita Rasti¹, Sumonto Mitra³, Maria Backlund¹, Gunnar Nordvall^{1,3}, Martin Jönsson^{1,3}, Johan Sandin^{1,4}, Maria Eriksdotter^{3,5}, Pontus Forsell^{1,4}
¹AlzeCure Pharma AB, Hälsovägen 7 - Huddinge (Sweden), ²Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden), ³Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden), ⁴Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm (Sweden) - Stockholm (Sweden), ⁵Theme Inflammation and Aging, Karolinska University Hospital - Stockholm (Sweden)

POSTER PRESENTATIONS

- LP026** **BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies**
Peter Ackerman¹, Nick Kozauer¹, Raj Bhardwaj², Bavani Shankar¹, Bharat Asware¹, Randall Killingsworth¹, Eric Ashbrenner¹, Jo Ann Malatesta², Emily Thompson¹, Dustin Walters¹, Alyssa Cheng¹, Lindsey Lee Lair¹, Richard Bertz¹, Bruce Car¹, Irfan Qureshi¹, Vlad Coric¹
¹Biohaven Pharmaceuticals - New Haven (United States), ²Certara - Radnor (United States)
- LP027** **Blocking the FAM19A5-LRRc4B complex with an anti-FAM19A5 antibody restores lost synapses and reverses cognitive decline in mouse models of Alzheimer's disease**
 Han-Byul Kim¹, Sangjin Yoo¹, Hoyun Kwak¹, Shi-Xun Ma¹, Ryunhee Kim¹, Minhyeok Lee¹, Nui Ha¹, Soonil Pyo¹, Soon-Gu Kwon¹, Eun-Ho Cho¹, Sang-Myeong Lee¹, Juwon Jang¹, Wonkyum Kim¹, Yosub Park¹, Jae Young Seong^{1,2}
¹Neuracle Science Co., Ltd. - Seoul (Korea, Republic of), ²Department of Biomedical Sciences, Graduate School of Medicine, Korea University - Seoul (Korea, Republic of)
- LP028** **Comparison of visually evoked steady-state oscillations between two Spectris™ eyesets**
 Julia Leach¹, Brennan Jackson¹, Miguel Hernandez¹, Olivia Rowe¹, Katharine Kolin¹, David Grant², Roberto Fernandez-Romero², Mihály Hajós^{1,3}, Chandran Seshagiri¹
¹Cognito Therapeutics - Cambridge (United States), ²University of Tennessee Medical Center - Knoxville (United States), ³Yale University School of Medicine - New Haven (United States)
- LP029** **Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease**
 Brian Rash¹, Jeffrey Botbyl¹, Steven Kopcho¹, Zarin Zainul¹, Nataliya Agafonova¹, Lisa McClain-Moss¹, Kevin Ramdas¹, Eric Naioti¹, Brittany Varnado¹, Kevin Peterson¹, Michael Brown¹, Thiago Leal¹, Raul Carballosa², Paayal Patel³, Mark Brody³, Brad Herskowitz³, Ana Fuquay³, Savannah Rodriguez³, Joshua Hare¹
¹Longeveron Inc - Miami (United States), ²First Excellent Research - Miami (United States), ³ERG Clinical - Miami (United States)
- LP030** **Emerging Non-Invasive Brain Stimulation Techniques for Alzheimer's Treatment: Current State and Future Directions**
 Guillaume Blivet¹, Thomas Sacrez², Gizem Temiz³, Michael Weiner⁴, Marwan Sabbagh⁵, Jacques Touchon², Jeffrey Cummings⁶
¹REGEN LIFE - Paris (France), ²University of Montpellier - Montpellier (France), ³TheraPanacea - Paris (France), ⁴University of San Francisco - San Francisco (United States), ⁵Barrow Neurological Institute - Phoenix (United States), ⁶University of Nevada, Las Vegas - Las Vegas (United States)
- LP031** **Phase 2a clinical trial supports therapeutic efficacy of septin modulation in mild-to-moderate Alzheimer's patients**
Jeffrey Cummings¹, Mieke Nuytten², Steven Ramael², Eline Byl², Eveline Debroux², Marieke Voets², Katrien Princen², Marc Fivaz², Gerard Griffioen²
¹Chambers-Grundy Center for Transformative Neuroscience at UNLV - Las Vegas (United States), ²reMYND - Leuven (Belgium)
-  **LP034** **Use of Resveratrol to prevent mild cognitive decline and Alzheimer's Dementia**
 Gustavo Santos^{1,2}, Bruna Fachinelli¹, Mário Roberto Maróstica Junior²
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil), ²Faculty of Food Engineering (FEA), University of Campinas (UNICAMP) - Campinas (Brazil)
-  **LP035** **Lecanemab Experience and ARIA Observations at a Large Community-Based Health Care System**
 Shawn Kile¹
¹Sutter Neuroscience Institute - Sacramento (United States)

THEME 14: Beyond Amyloid and Tau

- P063** **Novel blood-based mitochondrial biomarkers for the prognosis of progression from mild cognitive impairment to Alzheimer's Disease Dementia**
 Jose Luis Mosquera¹, Marta Blanch¹, Nuria Rojo², Jaume Campdelacreu², Joan Bello³, Alberto Lleo⁴, Pablo Martínez-Lage⁵, Adrià Tort-Merino⁶, Raquel Sanchez-Valle⁶, Carlos Cruchaga⁷, Christopher Fowler⁸, Simon Laws⁹, Courosh Mehanian¹⁰, Jordi Gascon-Bayarri², Marta Barrachina¹
¹ADmit Therapeutics - Barcelona (Spain), ²Bellvitge University Hospital - IDIBELL - Barcelona (Spain), ³Complex Hospitalari Moisès Broggi. L'Hospitalet/Sant Joan Despí - Barcelona (Spain), ⁴Institut de Recerca Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona - CIBERNED - Barcelona (Spain), ⁵CITA-alzheimer Foundation - San Sebastián (Spain), ⁶Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona - Barcelona (Spain), ⁷Washington University School of Medicine - Saint Louis (United States), ⁸The Florey Institute, The University of Melbourne - Melbourne (Australia), ⁹Collaborative Genomics and Translation Group, Edith Cowan University - Joondalup (Australia), ¹⁰University of Oregon and Global Health Labs - Eugene (United States)
- P064** **Misfolding of alpha-synuclein as a direct biomarker for Parkinson's Disease and Synucleinopathies**
Klaus Gerwert¹
¹Ruhr-University Bochum - Bochum (Germany)

POSTER PRESENTATIONS

Poster presentations presented **remotely**

are indicated with this icon :



- P065** Phenome-wide Mendelian randomization analysis reveals shared causal risk factors among Alzheimer's disease, vascular dementia, and stroke
Chi-Hun Kim ¹, Jong Hun Kim ², Hyoung Seop Kim ²
¹Hallym University Sacred Heart Hospital - Anyang (Korea, Republic of), ²Ilisan Hospital, National Health Insurance Service - Goyang (Korea, Republic of)
- P066** The N-glycan structure bisecting N-acetylglucosamine predicts cognitive decline in patients from a memory clinic cohort
Robin Zhou ¹, Bengt Winblad ¹, Lars Tjernberg ¹, Sophia Schedin Weiss ¹
¹Karolinska Institutet - Solna (Sweden)
- P067** A phase III, randomized, double-blinded study of the efficacy and safety of LLevetiracetam to prevent Seizures in Symptomatic Alzheimer's Disease in adults with Down syndrome: the LESS-AD trial
María Carmona-Iragui ^{1,2}, Lucía Maure ¹, Beatriz Sánchez Moreno ³, Isabel Barroeta ¹, Gina Paola Mejía ⁴, Miren Altuna ⁵, Joaquín Escobar ⁶, Eloy Rodríguez ⁷, Juan Fortea ^{1,2}, Diego Real De Asúa ³
¹Memory Unit, Alzheimer Down Unit, Neurology Department. Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ²Barcelona Down Medical Center, Fundació Catalana Síndrome de Down - Barcelona (Spain), ³Internal Medicine Department, Adult Down Syndrome Unit, Hospital Universitario de La Princesa - Madrid (Spain), ⁴Clinical Pharmacology Department. Hospital Universitario de La Princesa - Madrid (Spain), ⁵Fundación CITA-Alzheimer Fundazioa - Donostia (Spain), ⁶Neurology Department. Hospital Universitario Virgen de las Nieves - Granada (Spain), ⁷Neurology Department. Hospital Universitario Marqués de Valdecilla - Santander (Spain)
- P068** Association between accelerated epigenetic and inflammatory aging and cognitive function in men and women: a cross-sectional analysis from the INSPIRE-T cohort
Samuel Thuriot ¹, Jason Shourick ¹, Mathilde Strumia ¹, Vanina Bongard ¹, David Furman ², Jean-Marc Lemaître ³, Sophie Guyonnet ¹, Heike Bischoff-Ferrari ¹, Bruno Vellas ¹, Sandrine Andrieu ¹, Laure Rouch ¹
¹IHU HealthAge - Toulouse (France), ²Buck Institute for Research on Aging - Novato (United States), ³INSERM 1183 Institute of regenerative medicine and Biotherapies - Montpellier (France)
- P069** Towards a cortical microstructural signature of neuroinflammation in AD
Gerard Ridgway ¹, Mario Torso ¹, Ian Hardingham ¹, Steven Chance ¹, & For The Alzheimer's Disease Neuroimaging Initiative ²
¹Oxford Brain Diagnostics Ltd - Oxford (United Kingdom), ²Alzheimer's Disease Neuroimaging Initiative - San Francisco (United States)
-  **P070** Associations of LATE-NC with past medical history and medication use: an exploratory analysis using data from the National Alzheimer's Coordinating Center
Davis Woodworth ¹, Joey Wong ¹, Anne-Marie Leiby ¹, S. Ahmad Sajjadi ¹
¹University of California, Irvine - Irvine (United States)
- P071** Association between the long-term use of high anticholinergic drugs and its burden and the incidence of dementia in stroke.
Ahmed Alharthi ^{1,2}, Terry Quinn ¹, Donald Lyall ¹
¹University of Glasgow - Glasgow (United Kingdom), ²Umm Al-Qura University - Makkah (Saudi Arabia)
- P072** Diagnostic Performance of Plasma Alzheimer's Disease Biomarkers for Predicting Amyloid/Tau/Neurodegeneration
Hanna Cho ¹, Han-Kyeol Kim ¹, Jae Hoon Lee ², Jeong-Ha Lee ¹, Joong-Hyun Chun ³, Tim West ⁴, Kris Kerness ⁴, Philip Verghese ⁴, Daniel Connell ⁴, Joel Braunstein ⁴, Young Hoon Ryu ², Chul Hyoung Lyoo ¹
¹Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ²Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ³Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ⁴C2N diagnostics - St Louis (United States)
- P073** Sarcopenia is a predictor for Alzheimer's continuum and related clinical outcomes
Sung Hoon Kang ¹, Yu Jeong Park ¹, Chi Kyung Kim ¹
¹Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of)
- P074** Neuroinflammatory CSF markers associated with cerebrovascular lesions in Alzheimer's disease
Linbin Dai ¹, Qiong Wang ¹, Feng Gao ¹, Yong Shen ¹
¹University of Science and Technology of China - Hefei (China)
- P075** Discovery of a Novel C3-Targeting and CNS Active siRNA as a Potential Therapeutic for Alzheimer's Disease
Tara Barbour ¹, Fay Touti ¹, Yan Li ¹, Anshu Jain ¹, Elisabeth Lonie ¹, Salome Funes ¹, Andrew Carvalho ¹, Maggie Mohr ², Justin Guo ³, Matthew Poulin ⁴, Anke Geick ⁵, Soham Mandal ⁵, Zhouning Zhang ¹, Kate Lane ¹, Lukas Scheibler ¹, David Eyerman ¹
¹Apellis Pharmaceuticals - Waltham (United States), ²Northern Biomedical Research - Norton Shores (United States), ³Synoligo Biotechnologies - Morrisville (United States), ⁴EpigenDx - Hopkinton (United States), ⁵Axolabs GmbH - Kulmbach (Germany)
- LP036** The AGED triad: A vascular aging phenotype and its relationship to AD biomarkers
Adrián Noriega De La Colina ^{1,2}, Caitlin Walker ¹, Meishan Ai ³, Navin Kaushal ⁴, Maiya R. Geddes ^{2,5}
¹Montreal Neurological Institute-Hospital (The Neuro) - Montreal (Canada), ²Department of Neurology and Neurosurgery, McGill University - Montreal (Canada), ³Department of Psychology, Northeastern University - Boston (United States), ⁴School of Health & Human Sciences - Indianapolis (United States), ⁵Montreal Neurological Institute-Hospital (The Neuro) - Montreal (Canada)

POSTER PRESENTATIONS

- LP037 Inhibition of p38 α MAPK pathway in early Alzheimer's disease**
Dominique Gouilly¹, Patrice Péran², Agathe Vrillon³, Elsa Bertrand⁴, Marie Goubeaud⁴, Aurélie Pistono⁵, Alexandre Da Costa², Anne-Sophie Salabert², Johanne Germain⁴, Hélène Catala⁴, Marie Rafiq¹, Deborah Meline¹, Laurence Jasse¹, Benjamine Sarton⁶, Pierre Payoux⁷, Claire Paquet³, Claire Thalams⁴, John Alam⁸, Jérémie Pariente¹
¹Department of Cognitive Neurology, Epilepsy, Sleep and Movement Disorders, CHU Toulouse Purpan- Toulouse (France), ²Toulouse Neuroimaging Center, UMR 1214, Inserm/UPS - Toulouse (France), ³Université de Paris, Cognitive Neurology Center, GHU Nord, APHP, Hospital Lariboisière Fernand Widal- Paris (France), ⁴Center of Clinical Investigation, CHU Toulouse Purpan (CIC 1436)- Toulouse (France), ⁵Université Toulouse 2 Jean Jaurès, - Toulouse (France), ⁶Critical Care Unit, CHU Toulouse Purpan- Toulouse (France), ⁷Department of Nuclear Medicine, CHU Toulouse Purpan- Toulouse (France), ⁸CervoMed Inc - Boston (United States)
- LP039 Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer's disease**
Yu Jin-Tai¹, Guo Yu¹, Huang Yu-Yuan¹
¹Huashan Hospital, Fudan University - Shanghai (China)
- LP040 Relationship Between Caregiving Burden and Alterations in Circadian Rhythm among Spousal Caregivers of cognitive impairment older adults**
 Shin Young Park¹, Jung Been Lee², Take Lee², Yang Hee Won¹, So Yeon Jeon³
¹Chungnam National University Hospital - Daejeon (Korea, Republic of), ²Sun Moon University - Asan (Korea, Republic of), ³Chungnam National University College of Medicine - Daejeon (Korea, Republic of)
-  **LP041 Middle aged and older adults' knowledge, ratings, and preferences for receiving multicomponent lifestyle-based brain health interventions**
Raymond Ownby¹, Gesulla Cavanaugh¹, Joshua Caballero²
¹Nova Southeastern University - Fort Lauderdale (United States), ²University of Georgia - Athens (United States)
- LP041bis Relationship of alpha-synuclein co-pathology to AD biomarkers and clinical progression in MCI and mild AD clinical trials**
Kyle Fraser¹, Roland Brown¹, Kyle Ferber¹, Julie Czerkowiec¹, Amanda Edwards¹, Jessica Collins¹, Gersham Dent¹, Melanie Shulman¹, John O'Gorman¹, Carrie Rubel¹, Danielle Graham¹
¹Biogen - Cambridge (United States)

THEME 15: Clinical Trials Early Career Investigator Showcase

- P076 Bumetanide in Patients with Alzheimer's Disease (BumxAD): A Phase II Clinical Trial**
Kyan Younes¹, Mina Kmiecik¹, Minhtrung Huu Chu¹, Annie Zhou¹, Irina Skylar-Scott¹, Niyatee Samudra¹, Pragya Tripathi¹, Maria Coburn¹, Ted Wilson¹, Zihuai He¹, Francois Haddad¹, Tony Wyss-Coray¹, Sharon J. Sha¹, Michael D. Greicius¹
¹Stanford University - Palo Alto (United States)
- P077 High prevalence of brain amyloidopathy among frail older adults: are they eligible for anti-amyloid treatments? Should they be treated? Evidence from the real-life Cogfrail cohort**
Davide Angioni¹, Sandrine Sourdet¹, Julien Delrieu¹, Gaëlle Soriano¹, Alberta Peluso¹, Gabor Abellan¹, Pierre-Jean Ousset¹, Bruno Vellas¹
¹Institut Hospitalo Universitaire HealthAge, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital - Toulouse (France)
- LP042 Characteristics of patients attending our Alzheimer's disease-modifying therapy clinic in Japan: Implication for clinical trials**
Masanori Kurihara¹, Ryoko Ihara¹, Keiko Hatano¹, Akira Hatakeyama², Fumio Suzuki³, Aya Midori Tokumaru³, Kenji Ishii⁴, Ko Furuta⁵, Atsushi Iwata¹
¹Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ²Dementia Support Center, Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ³Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ⁴Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan), ⁵Department of Psychiatry, Tokyo Metropolitan Institute for Geriatrics and Gerontology - Tokyo (Japan)
- LP043 Novel diagnostic platform enabling protein specific biomarker signature for the diagnosis of AD**
Lawren Vandevrede¹, Rebecca Snell¹, Hilary Heuer¹, Courtney Lane-Donovan¹, Peter Ljubenkov¹, Julio Rojas¹, Adam Boxer¹
¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco - San Francisco (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon : 

POSTER SESSION 2: From Thursday, October 31 - 7:15 a.m. to Thursday, October 31 - 5:00 p.m.

THEME 3: Clinical Trials: imaging

- P079** **Diabetes mellitus-induced differential cerebellar volume reduction across Alzheimer's disease trajectory**
Suhyung Kim¹, Sheng-Min Wang², Dong Woo Kang³, Sunghwan Kim², Hyun Kook Lim², Yoo Hyun Um¹
¹Department of Psychiatry, St.Vincent's Hospital, College of Medicine, The Catholic University of Korea - Suwon (Korea, Republic of), ²Department of Psychiatry, Yeouido St.Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
- P080** **Longitudinal Regional Volume Changes in the Cerebellum Across the Alzheimer's Disease Spectrum**
Um Yoo Hyun¹, Kim Suhyung¹, Wang Sheng-Min¹, Kang Dong Woo¹, Kim Sunghwan¹, Lim Hyun Kook¹
¹College of Medicine, Catholic University of Korea - Seoul (Korea, Republic of)
- P081** **Comparison of accumulation rates of beta-amyloid tracers and their relationship with cognitive changes**
Soo Hyun Cho¹, Heekyoung Kang², Hongki Ham³, Seunghwan Moon⁴, Hyemin Jang⁵, Jihwan Yun⁶, Eun-Hye Lee², Daeun Shin², Sohyun Yim⁷, Hee Jin Kim², Byeong Chae Kim¹, Duk L. Na², Sang Won Seo², Jun Pyo Kim²
¹Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School - Gwangju (Korea, Republic of), ²Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³Neuroscience Center, Samsung Medical Center - Seoul (Korea, Republic of), ⁴Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ⁵Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Jongno-gu - Seoul (Korea, Republic of), ⁶Department of Neurology, Soonchunhyang University Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), ⁷Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of) - Seoul (Korea, Republic of)
- P082** **Data-driven subtypes of white matter lesions are differentially associated with vascular and Alzheimer's pathology**
Lyduine E. Collij^{1,2}, Sophie E. Mastenbroek^{3,2}, Katja Steijn^{3,2}, Carole Sudre⁴, Danielle Van Westen³, Olof Strandberg³, Niklas Mattsson-Carlgrén³, Sebastian Palmqvist³, Erik Stomrud³, Jacob E. Vogel³, Rik Ossenkoppele^{2,3}, Oskar Hansson¹
¹Lund University - Lund (Sweden), ²Amsterdam UMC - Amsterdam (Netherlands), ³Lund University - Lund (Sweden), ⁴King's College London - London (United Kingdom)
- P083** **Neuroimaging data harmonization in multisite studies of Alzheimer's Disease and potential implications on effect sizes in clinical trials.**
Dana Tudorascu¹, Alex Delbene¹, Alexandra Gogola¹, Weiquan Luo¹, Charles Laymon¹, Changlee Chen¹, Mahbaneh Torbati¹, Val Lowe², David Soleimani-Meigooni³, Belen Pascual⁴, Huamee Oh⁵, Brian Gordon⁶, Pedro Rosa-Neto⁷, Tharick Pascoal¹, Suzanne Baker⁸, Davneet Minhas¹
¹University of Pittsburgh - Pittsburgh (United States), ²Mayo Clinic - Rochester (United States), ³University of California at San Francisco - San Francisco (United States), ⁴Houston Methodist - Houston (United States), ⁵Brown University - Providence (United States), ⁶Washington University of St. Louis - St. Louis (United States), ⁷McGill University - Montreal (Canada), ⁸Lawrence Berkeley National Laboratory - Berkeley (United States)
- P084** **Novel regional flortaucipir visual read approaches to stratify subjects by tau spread: Evaluation in TRAILBLAZER-ALZ 2 phase 3 study of donanemab**
Ian Kennedy¹, Min Jung Kim¹, Anupa K. Arora¹, Ming Lu¹, Ilke Tunali¹, Leonardo Iaccarino¹, John R. Sims¹, Emily C. Collins¹, Mark A. Mintun¹, Sergey Shcherbinin¹
¹Eli Lilly and Company - Indianapolis (United States)
- P085** **Multicenter Reader Study Assessing Diagnostic Accuracy of Amyloid-β Detection Comparing Real versus AI-based Amyloid-β PET Generated from Brain MRI**
 Gregory Mathoux¹, Eliliane Pirazzo Andrade Teixeira¹, Phillippe Blanc², Nadya Pyatigorskaya³, Debora-Elisa Peretti⁴, Despoina Ioannidou⁵, Audrey Duran⁵, Gizem Temiz⁵, Shibeshih Belachew⁵, Nikos Paragios⁵, Jacques Touchon⁶, Bruno Vellas⁷, Audrey Gabelle⁶, Pierre Payoux⁸, Giovanni Frisoni⁹, Valentina Garibotto¹⁰
¹Diagnostic Department, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital - Geneva (Switzerland), ²Nuclear Medicine Department, Centre Hospitalier d'Albi - Albi (France), ³Neuroradiology Department, University Hospitals Pitié Salpêtrière - Paris (France), ⁴Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Faculty of Medicine, Geneva University Neurocenter, University of Geneva - Geneva (Switzerland), ⁵Therapancea - Paris (France), ⁶Faculty of Medicine, University of Montpellier - Montpellier (France), ⁷Gérontopôle, Centre Hospitalier Universitaire de Toulouse - Toulouse (France), ⁸Department of Nuclear Medicine, CHU Toulouse Purpan - Toulouse (France), ⁹Department of Rehabilitation and Geriatrics, Memory Clinic, Geneva University Hospitals - Geneva (Switzerland), ¹⁰Diagnostic Department, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, University of Geneva - Geneva (Switzerland)
- P086** **Robustness of visual and quantitative assessment of [18F]PI-2620 PET scans evaluated with different mass doses**
Núria Roé-Vellvé¹, Henryk Barthel², Lorelei Howard¹, Norman Koglin¹, Andre Mueller¹, Audrey Perrotin¹, Aleksandar Jovalekic¹, Franziska Ruth Zientek², Michael Rullmann², Marianne Patt², Andreas Schildan², Tobias Jeschke², Olena Mishchenko², Mathias Berndt², Caroline Papin¹, Johnny Castillo-Meleán¹, Andrew Stephens¹, Osama Sabri², Santiago Bullich¹
¹Life Molecular Imaging GmbH - Berlin (Germany), ²Nuclear Medicine Department, University of Leipzig Medical Center - Leipzig (Germany)
- P087** **Evaluation of a sensitive visual read algorithm for assessing tau PET images**
Ruben Smith¹, Valentina Garibotto², Douglas Hägerström³, Jonas Jögi⁴, Tomas Ohlsson⁵, Olof Strandberg¹, Matteo Tonietto⁶, Shorena Janelidze¹, Sebastian Palmqvist¹, Erik Stomrud¹, Gregory Klein⁶, Oskar Hansson¹
¹Lund University, Clinical Memory Research Unit - Malmö (Sweden), ²Division of Nuclear Medicine and Molecular Imaging, Diagnostic department, University Hospitals of Geneva - Geneva (Switzerland), ³Skåne University Hospital, Department of Clinical Neurophysiology - Lund (Sweden), ⁴Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine - Lund (Sweden), ⁵Skåne University Hospital, Department of Radiation Physics - Lund (Sweden), ⁶Hoffman La Roche Ltd. - Basel (Switzerland)

POSTER PRESENTATIONS

- P088 Regional Cerebral Hypometabolism and Pathological Heterogeneity in Sporadic Early Onset Alzheimer's Disease using Multi-probes PET/CT**
Zhu Zehua¹, Shi Jiong², Wang Shicun³, Lv Xinyi², Shen Yong²
¹Department of Nuclear Medicine, The First Affiliated Hospital of USTC - Hefei (China) - Hefei (China), ²Department of Neurology, The First Affiliated Hospital of USTC - Hefei (China), ³Department of Nuclear Medicine, The First Affiliated Hospital of USTC - Hefei (China)
- P089 First-in-human PET imaging study of intranasal insulin using the Aptar Cartridge Pump System**
Kiran K. Solingapuram Sai¹, Jennifer M. Erichsen¹, Krishna Gollapelli¹, Ivan Krizan¹, Mack Miller¹, Charles Cazzola², Reenal Gandhi², Julie Suman², Suzanne Craft¹
¹Wake Forest School of Medicine - Winston Salem (United States), ²Aptar Pharma - Congers (United States)
- P090 FDG PET Findings according to Wandering Patterns of Patients with Drug-naïve Alzheimer's Disease**
Youngsoon Yang¹
¹Soonchunhyang University College of Medicine - Cheonan (Korea, Republic of)
- P091 Independent Effects of White Matter Hyperintensities on Frailty for Patients with Alzheimer's Dementia**
Won-Myong Bahk¹, Bo-Hyun Yoon², Kwanghun Lee³, Hyung Mo Sung⁴, Sung-Yong Park⁵, Min-Kyu Song⁶, Moon-Doo Kim⁷, Hyun-Ju Yang⁷, Sang-Yeol Lee⁸
¹Professor, Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ²Psychiatrist, Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ³Professor, Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), ⁴Professor, Department of Psychiatry, Soonchunhyang University Gumi Hospital, - Gumi (Korea, Republic of), ⁵Psychiatrist, Department of Psychiatry, Jeyo Hospital - Uiwang (Korea, Republic of), ⁶Psychiatrist, St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of), ⁷Professor, Department of Psychiatry, College of Medicine, Jeju National University - Jeju (Korea, Republic of), ⁸Professor, Department of Psychiatry, Wokwang University School of Medicine - Iksan (Korea, Republic of)
- P092 Olfactory Dysfunction Is Associated with Cerebral Amyloid Deposition and Cognitive Function in the Trajectory of Alzheimer's Disease**
Won-Myong Bahk¹, Bo-Hyun Yoon², Young-Joon Kwon³, Kwanghun Lee⁴, Sang-Yeol Lee⁵, Hyung Mo Sung⁶, Sung-Yong Park⁷, Min-Kyu Song⁸, Sheng-Min Wang¹, Hyun Kook Lim¹
¹Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ²Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ³Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University - Cheonan (Korea, Republic of), ⁴Department of Psychiatry, College of Medicine, Dongguk University, - Gyeongju (Korea, Republic of), ⁵Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁶Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁷Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), ⁸St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)
- P093 Sex-Related Disparities in the Resting State Functional Connectivity of the Locus Coeruleus and Salience Network in Preclinical Alzheimer's Disease**
Kwanghun Lee¹, Hyun Kook Lim², Sheng-Min Wang², Won-Myong Bahk², Bo-Hyun Yoon³, Sang-Yeol Lee⁴, Hyung Mo Sung⁵, Sung-Yong Park⁶, Min-Kyu Song⁷
¹Department of Psychiatry, College of Medicine, Dongguk University - Gyeongju (Korea, Republic of), ²Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ⁴Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁵Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁶Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), ⁷St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of)
- P094 Sex-specific effects of APOE ε4 genotype on longitudinal hippocampal atrophy in mild cognitive impairment due to AD over a 2-year period**
Hyunji Lee¹
¹Pusan National University Hospital - Busan (Korea, Republic of)
- P095 Multicenter study of associations between harmonized tau-PET Centaur values and Alzheimer's disease neuropathology at autopsy: preliminary scope and study design**
Leonardo Iaccarino^{1,2}
¹Eli Lilly and Company - Indianapolis (United States), ²Eli Lilly Italia S.p.A. - Sesto Fiorentino (Italy)
- P096 Sex differences in regional brain volume changes associated with verbal memory in patients with subjective cognitive decline**
Hyuk-Je Lee¹, Bora Yoon¹, Seonghee Ho², Yun Jeong Hong³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁷, Seong Hye Choi⁸, Dong Won Yang¹
¹Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ²Department of Neurology, Hanyang University Hanmaeum Changwon Hospital - Changwon (Korea, Republic of), ³Department of Neurology, College of Medicine, The Catholic University of Korea, Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of), ⁴Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine - Seoul (Korea, Republic of), ⁵Department of Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), ⁶Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ⁷Roa Neurology Clinic - Seongnam (Korea, Republic of), ⁸Department of Neurology, Inha University School of Medicine - Incheon (Korea, Republic of)
- P097 TSPO PET as inflammation biomarker in dementia**
Belen Pascual¹, Quentin Finn¹, Kaitlee Ornelas¹, Alireza Faridar¹, Jon B. Toledo¹, Mohammad O. Nakawah¹, Gustavo C. Roman¹, Joseph C. Masdeu¹
¹Houston Methodist Research Institute - Houston (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely
are indicated with this icon :



- P098 Enhancing the effectiveness of Alzheimer's disease drug development by assessing tau PET as a promising surrogate endpoint within the pre-competitive Critical Path for Alzheimer's Disease (CPAD) consortium**
Yashmin Karten¹, Dries De Witte², Michael Irizarry³, Gregory Klein⁴, Antoine Leuzy^{1,5}, Klaus Romero¹, Eileen Priest¹, Colleen Jacobsen¹, Abad Ariel Alonso^{2,6}, Geert Molenberghs^{2,6}, Diane Stephenson¹
¹Critical Path Institute - Tucson (United States), ²L-Biostat, KU Leuven - Leuven (Belgium), ³Eisai - Nutley (United States), ⁴F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ⁵Enigma Biomedical USA - Knoxville (United States), ⁶I-BioStat, Hasselt University - Hasselt (Belgium)
- P099 Voxel-based morphometric analysis of selected brain regions in MCI subjects treated with choline alphoscerate**
Enea Traini¹, Anna Carotenuto¹, Mohamed Hossein¹, Vincenzo Andreone², Amenta Francesco¹
¹Centro Ricerche Cliniche, Telemedicina e Telefarmacia, Università di Camerino - Camerino (Italy), ²Neurology and Stroke Unit-Neurology, A. Cardarelli Hospital - Napoli (Italy)
- P100 Association between the new sub-classified white matter hyperintensities volume and cognitive function in elderly**
Yoon Bo-Hyun¹, Bahk Won-Myong², Lee Kwanghun³, Lee Sang-Yeol⁴, Sung Hyung Mo⁵, Song Min-Kyu⁶, Park Sung-Yong⁷, Kim Moon-Doo⁸, Yang Hyun-Ju⁸
¹Department of Psychiatry, Naju National Hospital - Naju (Korea, Republic of), ²Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, College of Medicine, Dongguk University, - Gyeongju (Korea, Republic of), ⁴Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine - Iksan (Korea, Republic of), ⁵Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University - Gumi (Korea, Republic of), ⁶St. Mary's Gong-Gam Mental Health Clinic - Siheung (Korea, Republic of), ⁷Department of Psychiatry, Keyo Hospital - Uiwang (Korea, Republic of), ⁸Department of Psychiatry, College of Medicine, Jeju National University - Jeju (Korea, Republic of)
- P101 Allopregnanolone Preserves White Matter Structure Independent of APOE genotype in Early Alzheimer's Disease**
Adam Raikes¹, Gerson Hernandez¹, Claudia Lopez¹, Lon Schneider², Roberta Brinton¹
¹Center for Innovation in Brain Science, University of Arizona - Tucson (United States), ²USC School of Medicine - Los Angeles (United States)
- LP045 Frontal cognitive dysfunction corresponding to severity of cerebral white matter hyperintensities in probable Alzheimer's disease**
Mee Y. Park¹, Hyun J. Han², Jean S. An³, K.Y. Ahn¹
¹Yeungnam Medical University Center - Daegu (Korea, Republic of), ²Ilisanbrin neurology clinic - Ilisan (Korea, Republic of), ³University of Illinois Chicago - Chicago (United States)
- LP046 Concordance between FDA-approved visual interpretation of [18F]flortaucipir PET images and the Centaur scale**
Stamatia Karagianni^{1,2}, Alexis Moscoso^{3,4,5}, Martijn Van Essen⁶, Imini Mainta⁷, Valle Camacho⁸, Omar Rodríguez-Fonseca⁹, Jesús Silva-Rodríguez¹⁰, Andrés Perissinotti^{12,13}, Nicolai Franzmeier^{14,15,4}, Michel J. Grothe^{10,11}, Giovanni B. Frisoni^{16,17}, Valentina Garibotto^{7,18}, Michael Schöll^{19,4,20,17}
¹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg - Gothenburg (Sweden), ²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg - Gothenburg (Sweden), ³Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, - Gothenburg (Sweden), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy - Gothenburg (Sweden), ⁵Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela - Santiago De Compostela (Spain), ⁶Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden, - Gothenburg (Sweden), ⁷Geneva University Hospitals - Geneva (Switzerland), ⁸Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, (Spain), ⁹Nuclear Medicine Department HULA - Lugo (Spain), ¹⁰CIBER-BBN - Madrid (Spain), ¹¹Reina Sofia Alzheimer's Centre, CIEN Foundation, ISCIII, Madrid - Madrid (Spain), ¹²Clínica Barcelona, Barcelona (Spain), ¹³ISCIII, Barcelona (Spain), ¹⁴Institute for Stroke and Dementia Research, LMU - Munich (Germany), ¹⁵Munich Cluster for Systems Neurology (SyNergy) - Munich (Germany), ¹⁶Geneva Memory Center, Geneva University Hospitals - Geneva (Switzerland), ¹⁷LANVIE, University of Geneva - Geneva (Switzerland), ¹⁸Faculty of Medicine, University of Geneva - Geneva (Switzerland), ¹⁹Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg (Sweden), ²⁰Sahlgrenska University Hospital - Gothenburg (Sweden)
- LP047 Functional connectivity, cerebral blood flow, and cortical thickness changes evaluated in patients with Alzheimer's disease receiving anti-amyloid therapy**
Antoine Hone-Blanchet¹, Tao Sun¹, Gersham Dent¹, Carrie Rubel¹, Jonathan Dubois¹, Jennifer Murphy¹, R. Matthew Hutchison¹, John O'gorman¹
¹Biogen - Cambridge (United States)

THEME 04: Clinical trials: biomarkers including plasma

- P102 Determination of plasma biomarkers for the early and specific detection of Alzheimer's disease**
Lourdes Álvarez-Sánchez¹, Carmen Peña-Bautista¹, Laura Ferré-González¹, Laura Cubas², Ángel Balaguer³, Bonaventura Casanova-Estruch², Baquero-Toledo Miguel⁴, Cháfer-Pericás Consuelo⁴
¹Instituto de Investigación Sanitaria La Fe - Valencia (Spain), ²Division of Neuroimmunology, University and Polytechnic Hospital La Fe - Valencia (Spain), ³Math faculty, Universitat de València - Valencia (Spain), ⁴Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe - Valencia (Spain)

POSTER PRESENTATIONS

- P103** **Evaluating the Performance of Plasma Phosphorylated-Tau 181 and Apolipoprotein E4 in Early Detection of Amyloid Pathology in a Multi-Center Study Reflective of Routine Clinical Practice**
 Imke Kirste ¹, Sayuri Hortsch ², Sheila Baez-Torres ³, Mercè Boada ⁴, Monica Crane ⁵, Frederiksen Kristian Steen ⁶, Kevin Hanson ⁷, Jonathan Liss ⁸, Jeffrey Norton ⁹, Marc Suárez-Calvet ¹⁰, Craig Ritchie ¹¹, Stephanie Rutrick ¹², David Watson ¹³, Kelley Yokum ¹⁴, Clara Quijano-Rubio ¹⁵
¹Roche Molecular Solutions - Indianapolis (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³K2 Medical Research Maitland - Maitland (United States), ⁴ACE Alzheimer Center Barcelona - Barcelona (Spain), ⁵Genesis Neuroscience Clinic/Tennessee Memory Disorders Foundation - Knoxville (United States), ⁶Danish Dementia Research Centre, Department of Clinical Medicine - Copenhagen (Denmark), ⁷Eastside Research Associates - Redmond (United States), ⁸Columbus Memory Center - Columbus (United States), ⁹Charter Research Lady Lake - The Villages (United States), ¹⁰Barcelona Beta Brain Research Center - Barcelona (Spain), ¹¹Brain Health Scotland - Edinburgh (United Kingdom), ¹²Adams Clinical - Watertown (United States), ¹³Alzheimer's Research and Treatment Center - Wellington (United States), ¹⁴K2 Medical Research, LLC - Tampa (United States), ¹⁵Roche Diagnostics International Ltd - Rotkreuz (Switzerland)
- P104** **Plasma pTau181 and pTau217 similarly predict asymptomatic amyloid accumulation with performances comparable to amyloid-PET**
 Steffi De Meyer ¹, Jolien Schaevebeke ¹, Emma Luckett ¹, Elena Blujdea ², Patrick Dupont ¹, Koen Van Laere ³, Jeroen Vanbrabant ⁴, Erik Stoops ⁴, Eugene Vanmechelen ⁴, Guglielmo Di Molfetta ⁵, Henrik Zetterberg ⁵, Nicholas Ashton ⁵, Charlotte Teunissen ⁶, Koen Poesen ³, Rik Vandenberghe ³
¹KU Leuven - Leuven (Belgium), ²UMC Amsterdam - Amsterdam (Netherlands), ³UZ Leuven - Leuven (Belgium), ⁴ADx NeuroSciences - Ghent (Belgium), ⁵Sahlgrenska Academy - Mölndal (Sweden), ⁶UMC Amsterdam - Amsterdam (Sweden)
- P105** **Use of Non- genetically Modified Natural Killer Cells (SNK01) With Enhanced Activity in Subjects with Active Alzheimer's Disease. Further Biomarker Analysis and Implications for Use in Prevention.**
 Paul Song ¹, Clemente Humberto Zúñiga Gil ², Blanca Isaura Acosta Gallo ³, Cesar Alejandro Amescua ³, Rufino Menchaca Díaz ³, Sean Hong ¹, Juan Mata ¹, Katia Betito ¹, Hank Lee ¹, Yoonmi Kang ¹, Lucia Hui ¹
¹NKGen Biotech - Santa Ana (United States), ²Tijuana General Hospital - Tijuana (Mexico), ³Hospital Angeles - Tijuana (Mexico)
- P106** **Analytical validation of an ultrasensitive immunoassay for detection of phosphorylated Tau217 in human biofluids**
 Jacqueline Surls ¹, Kolby Janzen ¹, Hannah Rawlins ¹, Robyn Vega Ibanez ¹, Lindsey Brown ¹, Joshua Kemp ¹
¹Rules-Based Medicine, a Q Squared Solutions Company - Austin (United States)
- P107** **Plasma p-tau217 Concentrations in Patients Undergoing Evaluation for Anti-Amyloid Therapy**
 Alicia Algeciras-Schimmich ¹, Susan Ashrafzadeh Kian ¹, Joshua Bornhorst ¹, Daniel Figdore ¹, Jonathan Graff-Radford ¹, Ronald Petersen ¹, Vijay Ramanan ¹
¹Mayo Clinic - Rochester (United States)
- P108** **Integrative analysis of clinical stages, plasma biomarkers, and cognitive trajectories according to AT classification in Alzheimer's disease related cognitive impairment, subcortical vascular cognitive impairment, and frontotemporal dementia**
 Soyeon Yoon ¹, Min Young Chun ², Jihwan Yun ³, Daeun Shin ¹, Eun Hye Lee ¹, Hyemin Jang ⁴, Jun Pyo Kim ¹, Hee Jin Kim ¹, Duk L Na ¹, Sang Won Seo ¹
¹Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Gangnam-Gu, Seoul (Korea, Republic of), ²Department of Neurology, Yonsei University College of Medicine - Seoul (Korea, Republic of), ³Department of Neurology, Soonchunhyang University Bucheon Hospital - Gyeonggi-Do (Korea, Republic of), ⁴Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine - Jongno-Gu, Seoul (Korea, Republic of)
- P109** **Association of plasma Aβ42/Aβ40 with brain amyloidosis and conversion to mild cognitive impairment after a 5-year follow-up in individuals with subjective cognitive decline: data from the FACEHBI cohort.**
 José Antonio Allué ¹, María Pascual-Lucas ¹, Leticia Sarasa ¹, Noelia Fandos ¹, Jorge Loscos ¹, Juan Pablo Tartari ², Ángela Sanabria ^{2,3}, Montserrat Alegret ², Óscar Sotolongo-Grau ², Lluís Tàrraga ^{2,3}, Agustín Ruiz ^{2,3}, María Eugenia Sáez ⁴, Marta Marquí ^{2,3}, Jose Terencio ^{1,5}, Mercè Boada ^{2,3}
¹Araclon Biotech-Grifols - Zaragoza (Spain), ²Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya - Barcelona (Spain), ³CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases. National Institute of Health Carlos III. - Madrid (Spain), ⁴CAEBI, Centro Andaluz de Estudios Bioinformáticos. - Sevilla (Spain), ⁵Grifols S.A. - Barcelona (Spain)
- P110** **Prediction of Alzheimer's disease using an AI driven screening platform: PREDICTOM study design**
 Anna-Katharine Brem ¹, Zunera Khan ¹, Mark Ashworth ¹, Nicholas Ashton ¹, Sigurd Brandt ², Anne Corbett ³, Ana Diaz ⁴, Holger Fröhlich ⁵, Martha Therese Gjestsén ⁶, Dianne Gove ⁴, Sandeep Kaushik ⁷, Gaby Marquardt ⁸, Matthias Müllenborn ⁹, Spiros Nikolopoulos ¹⁰, Dag Aarsland ¹
¹King's College London - London (United Kingdom), ²GN Hearing - Copenhagen (Denmark), ³University of Exeter - Exeter (United Kingdom), ⁴Alzheimer Europe - Luxembourg (Luxembourg), ⁵Fraunhofer SCAI - Bonn (Germany), ⁶Stavanger University - Stavanger (Norway), ⁷Alzheimer GE Healthcare - Munich (Germany), ⁸Siemens Healthineers - Erlangen (Germany), ⁹Novo Nordisk - Copenhagen (Denmark), ¹⁰CERTH - Thessaloniki (Denmark)
- P111** **Cerebrospinal fluid levels of VAMP-2 and SNAP-25 are associated with executive function in dementia with Lewy bodies, an effect that is cofounded by Alzheimer comorbidity**
 Alba Cervantes González ^{1,2}, Julie Goossens ³, Nele Dewit ⁴, Laia Lidón ^{1,2}, Danna Perlaza ^{1,2}, Juan Fortea ^{1,2}, Daniel Alcolea ^{1,2}, Alberto Lleó ^{1,2}, Eugene Vanmechelen ³, Olivia Belbin ^{1,2}
¹Sant Pau Memory Unit, Neurology Department and IIB-Sant Pau, Hospital de La Santa Creu i Santa Pau, Universitat Autònoma de Barcelona - Barcelona (Spain), ²Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), - Madrid (Spain), ³ADx NeuroSciences NV, Zwijnaarde - Ghent (Belgium), ⁴Medpace Reference Laboratories (A.A.), Flow Cytometry Unit - Louvain (Belgium)

POSTER PRESENTATIONS

Poster presentations presented **remotely**

are indicated with this icon :



- P113** **Novel plasma assay for p-Tau217: Evaluation in a cohort of individuals with cerebral amyloidosis and Alzheimer's disease.**
Etienne Mondesert ¹, Anne Marie Dupuy ¹, Paul Wynveen ², Corey Carlson ², Miklos Szabo ², Kevin Ley ², Chris Knutson ², Jean-Sebastien Blanchet ³, Constance Delaby ¹, Germain Busto ⁴, Christophe Hirtz ¹, Jean-Paul Cristol ⁵, Sylvain Lehmann ¹
¹LBPC-PPC, University Montpellier, CHU Montpellier, INM INSERM, Montpellier, France - Montpellier (France), ²Beckman Coulter Diagnostics - Chaska (United States), ³Beckman Coulter France - Villepinte (France), ⁴CMRR, University Montpellier, CHU Montpellier, INM INSERM - Montpellier (France), ⁵Biochimie Lapeyronie, University Montpellier, CHU Montpellier - Montpellier (France)
- P114** **Plasma p-tau217 measurement as a screening tool for future AD neuropathology proxy status in dementia-free individuals from the British 1946 birth cohort**
Ashvini Keshavan ¹, William Coath ¹, David M. Cash ¹, Frederik Barkhof ^{2,3,4}, Amanda Heslegrave ⁵, Henrik Zetterberg ^{5,6,7,8}, Jonathan M. Schott ¹
¹Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), ²Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centre - Amsterdam (Netherlands), ³Centre for Medical Image Computing, University College London - London (United Kingdom), ⁴Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square - London (United Kingdom), ⁵UK Dementia Research Institute, University College London, London - London (United Kingdom), ⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg - Molndal (Sweden), ⁷Hong Kong Center for Neurodegenerative Diseases, Science Park - Hong Kong (China), ⁸School of Medicine and Public Health, University of Wisconsin-Madison - Madison, Wisconsin (United States)
- P115** **Levels of p-tau217 in blood and its capacity to predict patterns change of cognitive trajectories in elderly: 10 years follow-up Vallecas Project.**
Elizabeth Valeriano Lorenzo ^{1,2}, Sonia Wagner ¹, David García ³, Alicia Ruiz ¹, Ana Belén Pastor ¹, Belén Frades ¹, Meritxell Valentí ¹, Mario Ricciardi ¹, Maria Ascension Zea ¹, Marta Antón ¹, Teodoro Del Ser ¹, Pascual Sánchez-Juan ¹
¹Fundacion CIEN - Madrid (Spain), ²Universidad Autónoma de Madrid - Madrid (Spain), ³Universidad Complutense de Madrid - Madrid (Spain)
- P116** **Using neural derived EV-bound biomarkers in blood for the accurate classification of alpha synuclein aggregation in the brain**
Nicholas Rui Yuan Ho ¹, Rasheed Samat ¹, Gladys Ho ¹, Peter Maimonis ², Mario Morken ², Marc Cantillon ²
¹Sunbird Bio - Singapore (Singapore), ²Sunbird Bio - Cambridge, Ma (United States)
- P117** **Plasma pTau181 predicts clinical progression in mild Alzheimer's Disease in a randomized controlled trial**
Dana Hilt ¹, Jack Taylor ¹, Mark Jaros ², Christopher Chen ³, John Harrison ^{4,5,6}
¹Actinogen Medical - Sydney (Australia), ²Summit Analytical - Chicago (United States), ³Memory Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), ⁴Scottish Brain Sciences, Edinburgh, United Kingdom - Edinburgh (United Kingdom), ⁵King's College - London (United Kingdom), ⁶Alzheimercentrum, AUMC - Amsterdam (Netherlands)
- P118** **Introduction of multi-dimension biomarkers application for a randomized, double-blind, single-simulated clinical trial of sodium oligomannate on Alzheimer's disease**
Wang Qiong ¹, Dai Linbin ², Gao Feng ², Shi Jiong ², Shen Yong ²
¹The first Affiliated Hospital of USTC - Hefei (China), ²The first Affiliated hospital of USTC - Hefei (China)
- P119** **Plasma p-tau and Amyloid biomarkers discrimination accuracy of biologically-defined Alzheimer's disease in a memory clinic setting: a head-to-head study**
Federica Anastasi ¹, Aida Fernández-Lebrero ¹, Nicholas J. Ashton ², Paula Ortiz-Romero ¹, Esther Jiménez-Moyano ¹, Javier Torres-Torronteras ¹, Marta Milà-Alomà ¹, José Contador ¹, Greta García-Escobar ³, Oriol Grau-Rivera ¹, Henrik Zetterberg ², Marta Del Campo ¹, Kaj Blennow ², Albert Puig-Pijoan ³, Marc Suárez-Calvet ¹
¹BarcelonaBeta Brain Research Center - Barcelona (Spain), ²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden - Gothenburg (Sweden), ³Hospital del Mar Research Institute, Barcelona, Spain
- P120** **Associations of dementia risk scores with glucose and lipid-related metabolic blood biomarkers in the persons at-risk of dementia**
Sabsil Ana Lopez Rocha ¹, Ruth Stephen ¹, Alina Solomon ², Tiia Ngandu ³, Jenni Lehtisalo ³, Tiina Laatikainen ³, Patrizia Mecocci ⁴, Jaakko Tuomilehto ⁵, Miia Kivipelto ¹, Francesca Mangialasche ¹
¹Karolinska Institutet - Stockholm (Sweden), ²University of Eastern Finland - Kuopio (Finland), ³Finnish Institute for Health and Welfare - Helsinki (Finland), ⁴Università di Perugia - Perugia (Italy), ⁵University of Helsinki - Helsinki (Finland)
- P121** **Acceleration of epigenetic age as a biomarker for cognitive impairment: findings from the Diet and Healthy Aging cohort**
Kaisy Ye ¹
¹National University of Singapore - Singapore (Singapore)
- P122** **The clinical impact of blood-based biomarkers: the PLASMAR study**
Gianmarco Iaccarino ^{1,2}, José Miguel Contador ^{1,3,4}, Isabel Estragués ^{5,3,6}, Leydi Dayana Martinez ^{7,4,3}, Aida Fernandez Lobrero ^{5,8,3}, Irene Navalpotro-Gomez ⁵, Greta García-Escobar ³, Rosa Maria Manero ⁹, Oriol Grau-Rivera ^{5,4,10}, Juan Jose Hernandez-Sanchez ¹¹, Anna Padrós-Fluvià ¹¹, Paula Ortiz-Romero ⁵, Javier Torres-Torronteras ⁵, Marta Del Campo ^{5,12,3}, Albert Puig-Pijoan ^{3,4}, Marc Suárez-Calvet ^{5,3,4,10}
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain) - Barcelona (Spain), ²Università Campus Bio-Medico - Roma (Italy), ³Hospital del Mar Research Institute - Barcelona (Spain), ⁴Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ⁵BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ⁶Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ⁷BarcelonaBeta Brain Research Center (BBRC) - Barcelona (Spain), ⁸Cognitive Decline and Movement Disorders Unit, Neurology Department - Barcelona (Spain), ⁹Hospital del Mar Research Institute - Barcelona (Spain) - Barcelona (Spain), ¹⁰Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III - Madrid (Spain), ¹¹Laboratori de Referència de Catalunya - Barcelona (Spain), ¹²Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities - Madrid (Spain)

POSTER PRESENTATIONS

- P123** **Is serum p-tau217 a viable blood source as a biomarker for Alzheimer's disease?**
Andrea L. Benedet¹, Burak Arslan¹, Kubra Tan¹, Hanna Hulbert¹, Ilaria Pola¹, Guglielmo Di Molfetta¹, Kaj Blennow¹, Henrik Zetterberg¹, Nicholas J. Ashton²
¹Gothenburg University - Gothenburg (Sweden), ²Banner Health - Phoenix (United States)
- P124** **A Two-Stage Approach to Risk Stratification in Early-Stage Alzheimer's Disease: Utilizing MRI and Plasma p-Tau217**
Sohyun Yim¹, Henrik Zetterberg^{2,3,4,5}, Kaj Blennow^{2,3,6,7}, Hyemin Jang⁸, Junpyo Kim⁹, Heejin Kim^{9,10,11,12}, Duk L Na^{9,10}, Sungbum Park¹³, Sangwon Seo^{9,3,11,12}, Kichang Kwak¹³
¹Department of Neurology, Samsund - Seoul (Korea, Republic of), ²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), ³Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Gothenburg (Sweden), ⁴Department of Neurodegenerative Disease, UCL Institute of Neurology - London (United Kingdom), ⁵UK Dementia Research Institute at UCL - London (United Kingdom), ⁶Paris Brain Institute, ICM, Pitie-Salpetriere Hospital, Sorbonne University - Paris (China), ⁷Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (Sweden), ⁸Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine - Seoul (Korea, Republic of), ⁹Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ¹⁰Alzheimer's Disease Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), ¹¹Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University - Seoul (Korea, Republic of), ¹²Neuroscience Center, Samsung Medical Center - Seoul (Korea, Republic of), ¹³R&D Center, BeauBrain Healthcare - Seoul (Korea, Republic of)
- P125** **Fluid biospecimens and genetic data collection and dissemination: new pipelines to serve the dementia research community from the UCSF Memory and Aging Center**
Argentina Lario Lago¹, Julia Webb¹, Taylor Young¹, Kristina Noyes¹, Rose George¹, Karen Smith¹, Ana Tyler¹, Eliana Ramos², Hilary Heuer¹, Mary Koestler¹, Lawren Vandevred¹, Renaud Lajoie¹, Gil Rabinovici¹, Bruce Miller¹, Julio Rojas¹, Kaitlin Casaletto¹, Jennifer Yokoyama¹, Adam Boxer¹
¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. - San Francisco (United States), ²Department of Neurology, University of California Los Angeles. - Los Angeles (United States)
- P126** **Associations between Cognitive Impairment, ApoE genotype and Plasma p-tau Biomarkers in European MCI Populations: Insights from the AI-Mind Project**
Guido Maria Giuffrè^{1,2}, Ana Perez³, Soraya Alfonsin^{4,5}, Christoffer Hatlestad-Hall³, Timo Saarinen⁶, Naïke Caraglia¹, Erik Christensen⁷, Gwendlyn Kollmorgen⁸, Kaj Blennow^{9,10}, Henrik Zetterberg^{9,10}, Fernando Maestú^{4,5}, Hanna Renvall^{6,11}, Ira Hebold Haraldsen³, Paolo Maria Rossini¹², Camillo Marra^{1,2}
¹Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ²Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), ³Department of Neurology, Oslo University Hospital - Oslo (Norway), ⁴Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁵Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Pozuelo De Alarcón (Spain), ⁶BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), ⁷Pre Diagnostics AS - Oslo (Norway), ⁸Roche Diagnostics GmbH - Penzberg (Germany), ⁹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ¹⁰Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹¹Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), ¹²Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)
- P127** **Fully automated ultrasensitive Simoa assay for brain-derived tau: enhancing the characterization of Alzheimer's disease-related neurodegeneration in blood**
 Jing Shi¹, Casey Sheehy¹, Julio Herrera¹, David Wilson¹, Prasad Gawande¹, Mike Miller¹, Kishore Malyavantham¹
¹Quanterix - Billerica (United States)
- P128** **Evaluation of the effects of repeated lumbar punctures on Alzheimer's Disease CSF and blood biomarkers**
Anne Biever¹, Yixuan Zou¹, Cassandra Arneja¹, Schauer Stephen¹, Calderon Emilia¹, Cenicerio Ryan¹, Gwendlyn Kollmorgen², Tobias Bittner³, Lyle Jew⁴, Thomas Kremer³, Venissa Machado³, Bastian Zinnhardt³, Cross Nicholas⁵, Kaj Blennow⁶, Edmond Teng¹
¹Genentech Inc - San Francisco (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³Roche - Basel (Switzerland), ⁴Genentech Inc - San Francisco (Switzerland), ⁵New Zealand Clinical Research - Christchurch (New Zealand), ⁶Department of Psychiatry and Neurochemistry - Gothenburg (Sweden)
- P129** **Concordance between the updated Elecsys CSF immunoassays and amyloid PET for the diagnosis of Alzheimer's disease: Findings from the Apollo study**
Henrik Schinke¹, Magnus Förnvik Jonsson^{2,3}, Mayme Gummesson², Rikard Nilsson², Stefanie Gaupp¹, Ekaterina Manuilova¹, Silja McIlwrick¹, Margherita Carboni⁴, Erik Stormrud^{5,6}
¹Roche Diagnostics GmbH - Penzberg (Germany), ²Department of Clinical Chemistry and Pharmacology, Skåne University Hospital - Lund (Sweden), ³Department of translational medicine, Lund university - Lund (Sweden), ⁴Roche Diagnostics Int. AG - Rotkreuz (Switzerland), ⁵Clinical, Memory Research Unit, Department of Clinical Sciences Malmö - Malmö (Sweden), ⁶Memory Clinic, Skåne University Hospital - Malmö (Sweden)
- P130** **Unraveling the Enigma in Cerebral Amyloid Angiopathy, Plasma Alzheimer's Downstream Markers, and Cognitive Decline: in relation to amyloid uptakes**
Sung Hoon Kang¹, Eun Hye Lee², Jun Pyo Kim², Sang Won Seo²
¹Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of)
- P131** **Detection of Cerebral Amyloid Angiopathy (CAA) in Alzheimer's Disease (AD) using blood biomarkers.**
Mario Ricciardi¹, Elizabeth Valeriano-Lorenzo¹, María Ascensión Zea-Sevilla¹, Meritxell Valentí¹, Belén Frades¹, Alicia Ruiz-González¹, Ana Belén Pastor¹, Francisco López-González¹, Paloma Ruiz¹, Laura Saiz¹, Iván Burgueño-García¹, María José López-Martínez¹, Alberto Rábano¹, Teodoro Del Ser¹, Pascual Sánchez-Juan¹
¹Alzheimer's Centre Reina Sofía-CIEN Foundation-ISCIII - Madrid (Spain)

POSTER PRESENTATIONS

Poster presentations presented **remotely**

are indicated with this icon :



- P132 Davos Alzheimer's Collaborative Healthcare System Preparedness: Accurate Diagnosis Project Methodology**
Amy Deckert¹, Katherine J. Selzler¹, Monica Zigman Suchsland¹, Tim Macleod¹, Alissa Kurzman¹, Karen Weyrauch¹
¹Davos Alzheimer's Collaborative - Wayne (United States)
- P133 Preliminary evaluation of plasma ALZpath p-tau217 for detecting amyloid pathology in a diverse community-based cohort**
Michelle Mielke¹
¹Wake Forest University School of Medicine - Winston Salem (United States)
- P134 Advancing Detection of Neurological Biomarkers in Blood Using a Novel Ultrasensitive Single Molecule Counting Technology**
Renee Tobias¹, Peter Wagner¹, Johanna Sandlund¹, Kazushige Moriyama², Masayasu Imaizumi², Yukina Kawada², Kumiko Hamano², Frank Zaugg¹, Gipshu Dave¹, Daigo Inaoka¹, Hayato Kimura¹, Ko Kobayashi¹, Valerie Brachet¹
¹Fluxus, Inc. - Sunnyvale (United States), ²Fujirebio, Inc. - Tokyo (Japan)
- P135 A two-stage machine learning model predicts amyloid β positivity accurately and cost effectively**
Wenjun Zhu¹, Li Sun¹, So-Youn Shin¹, Joseph Donahue¹, Jeanne Latourelle¹
¹Aitia - Somerville (United States)
- P136 Use of CSF sTREM2/total-tau ratio as a potential prognostic biomarker to identify fast progressors in early Alzheimer's disease**
Jennifer Sorinas¹, Neva Coello², Nicole Pezous², Edward Khokhlovich³, Alexandra Rogojina², Jelena Curcic¹, Harsha Kocherla², Kristin Hannesdottir³
¹Biomedical Research, Novartis - Basel (Switzerland), ²Novartis Pharma AG - Basel (Switzerland), ³Biomedical Research, Novartis - Cambridge (United States)
- P137 Exploring the association between p-tau217 and performance-based digital assessment of cognitive functioning in mild cognitive impairment**
Ana Perez^{1,2}, Soraya Afonsin^{3,4}, Guido Giuffrè⁵, Erik Christensen^{6,2}, Fernando Maestú^{3,7}, Hanna Renvall^{8,4}, Camillo Marra⁵, Paolo Rossini⁹, Christoffer Hatlestad-Hall¹, Ira Haraldsen^{1,10}
¹Department of Neurology, Oslo University Hospital - Oslo (Norway), ²Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Madrid (Spain), ³Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁴Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), ⁵Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁶Pre Diagnostics AS - Oslo (Norway), ⁷BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science, - Helsinki (Finland), ⁸Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), ⁹Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy), ¹⁰Institute of Clinical Medicine, Faculty of Medicine, University of Oslo - Oslo (Norway)
- P138 New high-throughput, fully automated immunoassay for plasma neurofilament light chain**
Jeff Todtleben¹, Dusten Unruh¹, Miklos Szabo¹, Corey Carlson¹, Kara Curtis¹, Katie Hoffmann¹, Laura Mediger¹, James Mendoza¹, Mikaela Nichova-Doseva¹
¹Beckman Coulter Inc - Chaska, Mn (United States)
- P139 Clinical and analytical validation of LucentAD Complete, multi-marker algorithmic lab developed test (LDT) for high accuracy plasma detection of amyloid pathology**
David Wilson¹, Karen Copeland², Meenakshi Khare¹, Michele Wolfe¹, Patrick Sheehy¹, Lyndal Hesterberg³, Ann-Jeanette Vasko¹, Wiesje van der Flier⁴, Argonde van Harten⁴, Inge Verberk⁴, Charlotte Teunissen⁴, Mike Miller¹
¹Quanterix Corporation - Billerica (United States), ²Boulder Statistics - Steamboat Springs (United States), ³HCS, Inc - Denver (United States), ⁴Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam, (Netherlands)
- P140 The diagnostic impact of plasma p-tau217 combined with structural magnetic resonance imaging in a memory clinic cohort.**
Jonas Jarholm^{1,2}, Sandra Tecelão¹, Bjørn-Eivind Kirsebom^{3,4}, Fernando Gonzalez-Ortiz^{5,6}, Lene Pålhaugen^{1,2}, Berglind Gísladóttir¹, Henrik Zetterberg^{5,6,7,8}, Kaj Blennow^{5,6,9,10}, Per Selnes^{1,2}, Tormod Fladby^{1,2}
¹Department of Neurology, Akershus University Hospital - Lørenskog (Norway), ²Institute for Clinical Medicine, University of Oslo - Oslo (Norway), ³Department of Neurology, University Hospital of North Norway - Tromsø (Norway), ⁴Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway - Tromsø (Norway), ⁵Inst. of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), ⁶Clinical Neurochemistry Lab, Sahlgrenska University Hospital - Mölndal (Sweden), ⁷Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square - London (United Kingdom), ⁸UK Dementia Research Institute at UCL - London (United Kingdom), ⁹Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University - Paris (France), ¹⁰Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC - Hefei (China)
- P141 Geographic Access to Amyloid PET Scans in the U.S.: Implications for Clinical Trials and Real-World Treatment**
Mark Hanson¹, Ying Liu¹, Hao Yin¹, Soeren Mattke¹
¹University of Southern California - Los Angeles (United States)
- P142 Implementation of p-tau181/A β 42 and total-tau/A β 42 Roche Elecsys ratios: Evaluation of cut-offs for p-tau181, total-tau and A β 42**
Jessica Colon-Franco¹, Lynn Bekris², Sarah Zilka¹, Katie Troike¹, Maria Khrestian², Tousei Babak³, Elizabeth Tuason², James Leverenz³
¹Laboratory Medicine, Diagnostic Institute, Cleveland Clinic - Cleveland (United States), ²Genomic Medicine Institute, Cleveland Clinic - Cleveland (United States), ³Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic - Cleveland (United States)
- P143 Exploring the utility of plasma microRNA for early diagnosis of Alzheimer's disease.**
Joanna Williams¹, Diane Guevremont¹, Chris Fowler², Colin Masters², Ralph Martins³, Wickliffe Abraham¹, Warren Tate¹, Nicholas Cutfield¹
¹University of Otago - Dunedin (New Zealand), ²The Florey Institute - Melbourne (Australia), ³Macquarie University - New South Wales (Australia)
-  **P144 The Plasma pTau181/217 ratio is highly sensitive to discriminate Alzheimer's disease from other dementias – a pilot study in a memory clinic population**
Michaela Defrancesco¹, Alex Hofer¹, Christian Humpel¹
¹Medical University of Innsbruck - Innsbruck (Austria)

POSTER PRESENTATIONS

- LP048 Plasma Oligomer Beta-Amyloid is Associated with Disease Severity and Cerebral Amyloid Deposition in Alzheimer's Disease Spectrum**
Sheng-Min Wang¹, Dong Woo Kang¹, Yoo Hyun Um¹, Sunghwan Kim¹, Chang Uk Lee¹, Philip Scheltens¹, Hyun Kook Lim Lim¹
¹Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
- LP049 A Multiomic Blood Biomarker Panel to Enhance AD Patient Selection and Therapy Outcomes**
 Benoit Souchet¹, Elodie Fountis², Robert Popp³, Adriano M. C. Pimenta⁴, Baptiste Billoir¹, Evgeniy V. Petrotchenko⁴, Christoph H. Borchers⁴, Dimitri Petinataud², Jerome Braudeau¹
¹AgenT - Paris (France), ²Inovio - Marseille (France), ³MRM proteomics - Montreal (Canada), ⁴McGill University - Montreal (Canada)
- LP050 Development of Blood-Based pTau217 Assay Using a Novel Ultrasensitive Single-Molecule Counting Technology**
 Kumiko Hamano¹, Yukina Kawada¹, Masayasu Imaizumi¹, Gipshu Dave², Ko Kobayashi², Mariya Soban², Hayato Kimura², Kazushige Moriyama¹, Katsumi Aoyagi¹, Frank Zaugg², Peter Wagner², Johanna Sandlund², Renee Tobias², Valerie Brachet²
¹Fujirebio, Inc., Tokyo (Japan), ²Fluxus, Inc. - Sunnyvale (United States)
- LP051 Analytical Performance of the Lumipulse G pTau 217/ β -Amyloid 1-42 Plasma Ratio**
Luna Buitrago¹, Francesca I. De Simone¹, Natalya Benina¹, Rachel R. Radwan¹, Jessica Junfola¹, Andie Graney¹, Natalie Goepfert¹, Eric Jones¹, M. Craig Miller², Abhay Moghekar³, William T. Hu⁴, Diana Dickson¹
¹Fujirebio Diagnostics Inc. - Malvern, Pa (United States), ²Statistical Consultant, Fujirebio Diagnostics Inc. - Quakertown, Pa (United States), ³Department of Neurology, Johns Hopkins School of Medicine - Baltimore, Md (United States), ⁴Department of Neurology, Rutgers-Robert Wood Johnson Medical School and Center for Healthy Aging, Rutgers Institute for Health, Health Care Policy, and Aging Research - New Brunswick, Nj (United States)
- LP052 Exploring the association between blood-based biomarkers and cognitive-related oculomotor behaviours in asymptomatic carriers of the autosomal dominant mutation E280A-PSEN1.**
 Mario Parra¹, Yakeel Quiroz², David Aguillon³, Francisco Lopera³, Danilo Verge⁴, Gerardo Fernandez⁵
¹Glasgow University - Glasgow (United Kingdom), ²Harvard - Massachusetts (United States), ³Universidad de Antioquia - Medellin (Colombia), ⁴ViewMind - Copenhagen (Denmark), ⁵ViewMind - Bahia Blanca (Argentina)
- LP053 Impact of preanalytical factors on the Lumipulse G pTau 217/ β -Amyloid 1-42 Plasma Ratio**
Luna Buitrago¹, Francesca I. De Simone¹, Natalya Benina¹, Rachel R. Radwan¹, Amanda Calabro¹, Jessica Junfola¹, Natalie Goepfert¹, Abhay Moghekar², Diana Dickson¹
¹Fujirebio Diagnostics Inc. - Malvern, Pa (United States), ²Department of Neurology, Johns Hopkins School of Medicine - Baltimore, Md (United States)
- LP054 Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)**
Eden Barragan¹, Hilary Heuer¹, Rachel Nosheny^{2,3}, Monica Camacho^{2,4}, Krista Navarra^{2,4}, Paul Aisen⁵, Annalise Rahman-Filipiak⁶, J. Scott Roberts^{6,7}, Adeyinka Ajayi⁸, Desiree Byrd⁹, Monica Rivera-Mindt^{8,10}, Gil Rabinovici¹, Adam Boxer¹
¹Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco - San Francisco (United States), ²VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center - San Francisco (United States), ³Department of Psychiatry, University of California San Francisco - San Francisco (United States), ⁴Northern California Institute for Research and Education (NCIRE) - San Francisco (United States), ⁵VA Advanced Alzheimer's Therapeutic Research Institute, University of Southern California Imaging Research Center, San Francisco Veteran's Administration Medical Center - San Diego (United States), ⁶Michigan Alzheimer's Disease Research Center, University of Michigan Alzheimer's Therapeutic Research Institute, University of Southern California Imaging Research Center, San Francisco Veteran's Administration Medical Center - Ann Arbor (United States), ⁷Department of Health Behavior and Health Education, School of Public Health, University of Michigan - Ann Arbor (United States), ⁸Department of Neurology, Icahn School of Medicine at Mount Sinai - New York (United States), ⁹Department of Psychology, Queens College - Flushing (United States), ¹⁰Departments of Psychology, Latin American Latino Studies, and African and African American Studies, Fordham University - New York (United States)
- LP055 Clinical performance of the Lumipulse G pTau 217/ β -Amyloid 1-42 Plasma Ratio**
 Francesca I. De Simone¹, Luna Buitrago¹, Natalya Benina¹, Jessica Junfola¹, Stephen Menkes¹, James Koch¹, Douglas Hawkins², James Rock³, Oskar Hansson^{4,5}, Erik Stomrud^{4,5}, Richard C. Mohs⁶, Elaine Peskind^{7,8}, Jefferson Kinney⁹, Sterling Johnson¹⁰, Rachel R. Radwan¹
¹Fujirebio Diagnostics Inc. - Malvern, Pa (United States), ²Scottsdale Scientific LLC - Austin, Tx (United States), ³AriBio Co., Ltd - La Jolla, Ca (United States), ⁴Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), ⁵Memory Clinic, Skane University Hospital - Malmö (Sweden), ⁶Global Alzheimer's Platform Foundation - Washington, Dc (United States), ⁷Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System - Seattle, Wa (United States), ⁸Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle, Wa, ⁹Department of Brain Health, University of Nevada - Las Vegas, Nv (United States), ¹⁰Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health - Madison, Wi (United States)
- LP057 Investigating personalized genomic profiling in Alzheimer's Disease using synchronized cells from autopsy-validated skin and blood samples**
Florin Chirila¹, Daniel L. Alkon²
¹Spot Dx - Morgantown (United States), ²Synaps Dx - Rockville (United States)
- LP059 Non-Invasive Detection of Dementia using Plasma Cell-Free DNA sequencing and Artificial Intelligence**
Jonathan Wan¹, Jay Ganbat¹, Tim Liu¹, Hannah Thompson¹, Henrik Zetterberg¹, Sofia Tonniolo¹, Husain Masud¹, Ivan Koychev¹, Ravi Solanki¹
¹CFDX - London (United Kingdom)

POSTER PRESENTATIONS

- LP060 Plasma p-tau217, PET and cognition in an African American Sample: Results from the AA-FAIM study**
Rebecca Langhough ¹, Lianlian Du ², Rachael Wilson ¹, Ramiro Reyes ¹, Gilda Ennis ¹, Fabu Carter ¹, Nia Norris ¹, Diane Gooding ³, Lauren Mclester-Davis ¹, Carol Van Hulle ¹, Nathaniel Chin ¹, Megan Zuelsdorff ⁴, Henrik Zetterberg ¹, Sterling Johnson ¹, Carey Gleason ¹
¹University of Wisconsin School of Medicine and Public Health - Madison (United States), ²Rush University - Chicago (United States), ³Dept of Psychology, University of Wisconsin, Madison - Madison (United States), ⁴University of Wisconsin School of Nursing - Madison (United States)
- LP061 NULISA Assays for Inflammatory Markers in Fecal Samples from Patients with or at Risk for AD**
Sandra Harding ¹, Barbara Bendlin ¹, Margo Heston ¹, Jea Woo Kang ¹, Alfred Bracerros ¹, Joseph Luke Wheeler ¹, Sushma Shankar ¹, Alyssa Mickol ¹, Hana Chow ¹, Eric Zhang ¹, Eleanor Clements ¹, Faith Taylor ¹, Aaliyah Mushtaque ¹, Darby Peter ¹, Sterling Johnson ¹, Sanjay Asthana ¹, Henrik Zetterberg ², Blennow Kaj ², Tyler K Ulland ¹, Federico Rey ¹
¹University of Wisconsin - Madison (United States), ²University of Gothenburg - Gothenburg (Sweden)
- LP062 Advancing Alzheimer's Disease Stratification: Integrating APOE Genotyping with AI-Driven Biomarker Analysis**
Miguel Casanova ¹, Seval Kuhl ¹, Nicolas Scalzitti ², Lucas Pham-Van ¹, Gabriel Sanchez ³, Stéphanie Boutillier ¹, Jean-Christophe Bier ⁴, Tamer Demiralp ⁵, Frédéric Blanc ⁶, François Sellal ⁷, Bruno Dubois ⁸, Hüseyin Firat ¹
¹AMONETA - Huningue (France), ²FIRALIS - Huningue (France), ³FMP - Huningue (France), ⁴ERASME Hospital - Bruxelles (Belgium), ⁵Istanbul Faculty of Medicine - Istanbul (Turkey), ⁶CHU Strasbourg - Strasbourg, France (France), ⁷Hopitaux civils de colmar - Colmar (France), ⁸AP-HP, Hôpitaux de Paris - Paris (France)
- LP063 Elevated P-Tau217 is More Strongly Associated with Changes in Tau-PET and Cognition in Younger Adults: Findings from the A4 and LEARN studies.**
Gillian Coughlan ¹, Hannah Klinger ¹, Mabel Seto ¹, Colin Birkenbihl ¹, Michelle Farrell ¹, Robert Rissman ², Michael Properzi ¹, Diana Townsend ¹, Hyun-Sik Yang ¹, Keith Johnson ¹, Oliver Langford ², Michael Donohue ², Reisa Sperling ¹, Rachel Buckley ¹, Study Team A4/learn ¹
¹Mass General Hospital/Harvard Medical School - Boston (United States), ²Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)
- LP064 Plasma pTau217 as a single rule-in biomarker to diagnose underlying AD in early dementia patients.**
Thomas Wegehaupt ¹, Patrick Sommer ¹, Oliver Goldhardt ¹, Josef Priller ¹, Dennis Hedderich ¹, Igor Yakushev ¹, Timo Grimmer ¹
¹Technical University of Munich, School of Medicine and Health, TUM University Hospital - Munich (Germany)
- LP065 Revamping Alzheimer's Disease Diagnostics: Evaluating Future IVD Plasma p-Tau 181 and ApoE4 Immunoassays for Amyloid Detection in a Multi-Center Study Reflective of Routine Clinical Practice**
Imke Kirste ¹, Sayuri Hortsch ², Sheila Baez-Torres ³, Mercè Boada ⁴, Monica Crane ⁵, Frederiksen Kristian Steen ⁶, Kevin Hanson ⁷, Jonathan Liss ⁸, Jeffrey Norton ⁹, Marc Suárez-Calvet ¹⁰, Craig Ritchie ¹¹, Stephanie Rutrick ¹², David Watson ¹³, Kelley Yokum ¹⁴, Clara Quijano-Rubio ¹⁵
¹Roche Molecular Solutions - Indianapolis (United States), ²Roche Diagnostics GmbH - Penzberg (Germany), ³K2 Medical Research - Maitland (United States), ⁴ACE Alzheimer Center - Barcelona (Spain), ⁵Genesis Neuroscience Clinic/Tennessee Memory Disorders Foundation - Knoxville (United States), ⁶Danish Dementia Research Centre, Department of Clinical Medicine - Copenhagen (Denmark), ⁷Eastside Research Associates - Redmond (United States), ⁸Columbus Memory Center - Columbus (United States), ⁹Charter Research Lady Lake - The Villages (United States), ¹⁰Barcelona Beta Brain Research Center - Barcelona (Spain), ¹¹Brain Health Scotland - Edinburgh (United Kingdom), ¹²Adams Clinical - Watertown (United States), ¹³Alzheimer's Research and Treatment Center - Wellington (United States), ¹⁴K2 Medical Research, LLC - Tampa (United States), ¹⁵Roche Diagnostics International Ltd - Rotkreuz (Switzerland)
- LP066 Novel β -synuclein specific assays**
Julie Goossens ¹, Charlotte De Rocker ¹, Sherif Bayoumy ², Megan De Pauw ¹, Shreyasee Das ¹, Wiesje Van Der Flier ², Inge M. Verberk ², Charlotte Teunissen ², Eugeen Vanmechelen ¹
¹ADx NeuroSciences - Gent (Belgium), ²Amsterdam UMC - Amsterdam (Netherlands)
- LP067 High-throughput, fully automated immunoassay for detecting zygosity of apolipoprotein $\epsilon 4$ (APOE $\epsilon 4$) in EDTA plasma**
Brian Engel ¹, Miklos Szabo ¹, Katie Hoffmann ¹, Ben Schlichtmann ¹, Kara Curtis ¹, Laura Mediger ¹, Corey Carlson ¹, James Mendoza ¹, Mikaela Nickkova-Doseva ¹
¹Beckman Coulter, Inc. - Chaska, Mn (United States)
- LP068 Plasma pTau-217 versus plasma pTau-217/A β 1-42 ratio performance in predicting amyloid positivity compared to CSF A β 42/40 ratio or PET in a screening cohort from a phase 3 registration study: Implications for a triage model**
Sharon Sha ¹, James Rock ², Fred Kim ², Rachel Radwan ³, Francesca De Simone ³, Natalya Benina ³, Douglas Hawkins ⁴
¹Neurology & Neurological Sciences, Stanford University - Palo Alto (United States), ²AriBio Co., Ltd. - San Diego (United States), ³Fujirebio Diagnostics, Inc. - Malvern (United States), ⁴Scottsdale Scientific LLC - Austin (United States)
- LP069 Head-to-head comparison of the fully automated Elecsys pTau217 plasma assay and the Lumipulse pTau217 plasma assay**
Robert Perneczky ^{1,2,3,4,5}, Laura Stoeckl ⁶, Margherita Carboni ⁷, Sayuri Hortsch ⁶, Christina Rabe ⁸, Alexander Jethwa ⁶, Tobias Bittner ^{9,8}
¹University Hospital of Munich - Munich (Germany), ²German Center for Neurodegenerative Diseases - Munich (Germany), ³Munich Cluster for Systems Neurology - Munich (Germany), ⁴Ageing Epidemiology Research Unit, - London (United Kingdom), ⁵Sheffield Institute for Translational Neuroscience - Sheffield (United Kingdom), ⁶Roche Diagnostics GmbH - Penzberg (Germany), ⁷Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ⁸Genentech Inc. - San Francisco (United States), ⁹F. Hoffmann-La Roche Ltd - Basel (Switzerland)
- LP070 Biomarkers of Neuropathology in Patients screened for clinical trials who have cognitive impairment but are Amyloid PET negative**
Richard Mohs ¹
¹Global Alzheimer's Platform Foundation - Washington Dc (United States)

POSTER PRESENTATIONS

- LP071** **Gllymphatic dysfunction affects plasma downstream markers for Alzheimer's disease and clinical progression.**
Sung Hoon Kang ¹, Seongmi Kim ^{2,3}, Beonseok Sohn ⁴, Sang Won Seo ^{2,5,6,7}
¹Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine - Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³Alzheimer's disease convergence research center, Samsung Medical Center - Seoul (Korea, Republic of), ⁴Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, - Seoul (Korea, Republic of), ⁵Alzheimer's Disease Convergence Research Center, Samsung Medical Center, - Seoul (Korea, Republic of), ⁶Department of Digital Health, SAIHST, Sungkyunkwan University, - Seoul (Korea, Republic of), ⁷Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, - Seoul (Korea, Republic of)
-  **LP072** **CAPS Plus: A clinical biomarker scoring system to predict Aβ positivity and facilitate enrolment in anti-amyloid clinical trials**
Durjoy Lahiri ¹, Jennifer Cooper ², Bruna Seixas-Lima ³, Carlos Roncero ³, Cheryl Wellington ², Howard Chertkow ³
¹Queen's University - Kingston (Canada), ²University of British Columbia - Vancouver (Canada), ³University of Toronto - Toronto (Canada)
- LP073** **Introduction of multi-dimension biomarkers application for a randomized, double-blind, singlesimulated clinical trial of sodium oligomannate on Alzheimer's disease**
Qiong Wang ¹, Linbin Dai ¹, Feng Gao ¹, Jiong Shi ¹, Yong Shen ¹
¹The first Affiliated Hospital of USTC - Hefei (China), ²The first Affiliated hospital of USTC - Hefei (China) - Hefei (China)
- LP074** **Biomarker data showed buntanetap reduced neurotoxic proteins, improved axonal integrity, reduced inflammation, and neuronal functions in Alzheimer's clinical studies.**
Cheng Fang ¹, David Feng ², Melissa Gaines ¹, Eve Damiano ¹, Maria Maccacchini ¹
¹Annovis Bio - Malvern (United States), ²TCM - Princeton (United States)
- LP075** **Levels of age-related CD8 T cells binding HLA track with Alzheimer's disease status in HLA-A2+ and HLA-A2- patients: expansion of a flow cytometric blood biomarker assay to all patients.**
Christopher Wheeler ¹, Debbie Van Dam ², Yannick Vermeiren ², Hans De Reu ³, Paul De Deyn Peter ²
¹T-Neuro Pharma, Inc. (United States), ²Institute Born-Bunge - Antwerp (Belgium), ³Faculty of Medicine and Health Sciences, Vaccine and Infectious Disease Institute, Laboratory of Experimental Hematology, - Antwerp (Belgium)
- LP076** **Monitoring treatment effects of sodium selenate in Alzheimer's disease and behavioural variant frontotemporal dementia using fluid biomarkers.**
Fernando Gonzalez-Ortiz ¹, Cassandra Marotta ², Henrik Zetterberg ¹, Michael Turton ³, Peter Harrison ³, Christopher M. Hovens ⁴, Terence J. O'Brien ², Kaj Blennow ¹, Lucy Vivash ⁴
¹Gothenburg University - Gothenburg (Sweden), ²Monash University - Melbourne (Australia), ³Bioventix - Farnham (United Kingdom), ⁴University of Melbourne - Parkville (Australia)
- LP077** **Exploring the link between differences in spectral power across ocular states in resting-state EEG and p-tau181 levels in mild cognitive impairment**
Christoffer Hatlestad-Hall ¹, Lukas Gemein ², Federico Ramirez-Torano ^{3,4}, Ricardo Bruña ^{3,5}, Gwendlyn Kollmorgen ⁶, Margherita Carboni ⁶, Jörg Hipp ², Kaj Blennow ^{7,8}, Henrik Zetterberg ^{7,8}, Fernando Maestú ^{3,4}, Hanna Renvall ^{9,10}, Camillo Marra ^{11,12}, Paolo Maria Rossini ¹³, Denis Engemann ², Ira Hebold Haraldsen ¹
¹Dept. of Neurology, Oslo University Hospital - Oslo (Norway), ²Roche Pharma Research and Early Development, Neuroscience and Rare Diseases, F. Hoffmann-La Roche Ltd. - Basel (Switzerland), ³Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁴Department of Experimental Psychology, Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Pozuelo De Alarcón (Spain), ⁵Department of Radiology, Rehabilitation and Physiotherapy, School of Medicine, Universidad Complutense de Madrid - Madrid (Spain), ⁶Roche Diagnostics GmbH - Penzberg (Germany), ⁷Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), ⁸Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ⁹BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), ¹⁰Department of Neuroscience and Biomedical Engineering, Aalto University - Helsinki (Finland), ¹¹Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ¹²Department of Neuroscience, Catholic University of the Sacred Heart - Rome (Italy), ¹³Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)

THEME 12: Proof of concept/Translational research for Alzheimer Drug Development interventions

- P145** **APOE-Targeted Epigenome Therapy for Alzheimer's Disease**
Boris Kantor ¹, Bernadette O'Donovan ¹, Elena Korsakova ², Joseph Rittiner ¹, Elaine Hamm ², Ornit Chiba-Falek ¹
¹Duke - Durham (United States), ²CLAIRGene - Durham (United States)
- P146** **Nasal Immunotherapy clears intracellular tau pathology through TRIM21 and improves cognitive functions in aged tauopathy mice**
Rakez Kaye ¹
¹University of Texas Medical Branch - Galveston (United States)
- P147** **Mediation of beta-amyloid pathology for the association between serum cortisol, neurodegeneration, and cognitive impairment**
Gihwan Byeon ¹, Jeongsim Kim ², Dahyun Yi ³, Hyejin Ahn ³, Gijung Jung ³, Joon Hyung Jung ⁴, Yoon Young Chang ⁵, Kyungtae Kim ⁶, Hyeji Choi ⁶, Jeongmin Choi ⁶, Yu Kyeong Kim ², Jun young Lee ², Koung Mi Kang ⁶, Chul-Ho Sohn ⁶, Yun sang Lee ⁶, Min Soo Byun ⁶, Dong Young Lee ⁶
¹Seoul St. Mary's Hospital - Seoul (Korea, Republic of), ²SMG SNU Boramae Medical Center - Seoul (Korea, Republic of), ³Institute of Human Behavioral Medicine, Medical Research Center Seoul National University - Seoul (Korea, Republic of), ⁴Chungbuk National University Hospital - Cheongju (Korea, Republic of), ⁵Inje University Sanggye Paik Hospital - Seoul (Korea, Republic of), ⁶Seoul National University Hospital - Seoul (Korea, Republic of)
- P148** **Brain Health Services for the prevention of dementia: evidence from pilot experiences**
Federica Ribaldi ¹, Giovanni B Frisoni ¹
¹UNIGE - Geneva (Switzerland)

POSTER PRESENTATIONS

- P149 De novo designed TfR1 binding peptide to shuttle antibody therapeutics across blood brain barrier**
Hao Wu¹, Yibo Qiu¹, Fei Sheng¹, Yue Wu¹
¹ChainGen Bio - Shanghai (China)
- P150 Tau PET Measures Optimized for Detecting Treatment Effects on Tau Spread in Alzheimer Disease**
Janice Wong¹, Tina Wang², Ritobrato Datta², Dave Henley^{3,4}, Hartmuth C. Kolb², Ziad S. Saad²
¹Janssen Research & Development, LLC - Cambridge, Massachusetts (United States), ²Janssen Research & Development, LLC - La Jolla, California (United States), ³Janssen Research & Development, LLC - Titusville, New Jersey (United States), ⁴Indiana University School of Medicine, Psychiatry - Indianapolis, Indiana (United Kingdom)
- P151 Prediction of cognitive outcome and progression to dementia using Polyunsaturated fatty acids Omega6/3 ratio**
Victor Andrade^{1,2}, Luca Kleineidam^{3,4}, Holger Wagner-Thelen⁵, Rafael Campos⁵, Tommaso Ballarini^{2,6}, Sarah Egert⁷, Pamela Martino-Adami¹, Leonie Weinhold⁸, Sophie Guyonnet⁹, Bruno Vellas¹⁰, Frank Jessen^{6,11}, Matthias Schmid^{8,6}, Anja Schneider^{4,6}, Michael Wagner^{4,6}, Alfredo Ramirez^{1,2}
¹Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical faculty Köln (Germany), ²Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn - Bonn (Germany), ³Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical faculty - Köln (Germany), ⁴Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn - Bonn (Germany), ⁵Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Medical faculty - Köln (Germany), ⁶DZNE - Bonn (Germany), ⁷Department of Nutrition and Food Sciences, Nutritional Physiology, University of Bonn - Bonn (Germany), ⁸Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn - Bonn (Germany), ⁹Centre d'Epidémiologie et de Recherche en santé des POPulations de Toulouse - Toulouse (France), ¹⁰Gérontopôle, Toulouse University Hospital - Toulouse (France), ¹¹Department of Psychiatry, Medical Faculty, University of Cologne - Köln (Germany)
- P152 MRI monitoring of Alzheimer disease patients in the new era of disease-modifying therapies: a real-world case study**
Salvatore Napoli¹, Celine Maes², Rafay Khan², An Tanghe², Silvina Catuara Solarz², Jill Claes², Nuno Pedrosa De Barros², Diana Sima², Wim Van Hecke², Dirk Smeets², Annemie Ribbens²
¹Neurology and Infusion Center of New England - Foxborough (United States), ²icometrix - Leuven (Belgium)
- P154 Mild behavioral impairment: building the killifish-mouse-human pipeline in the INSPIRE-t cohort.**
Emmanuel Gonzalez-Bautista^{1,2,3}, Bruno Guiard^{3,4}, Isabelle Ader^{3,5}, Sophie Guyonnet^{3,2}, Jason Shourick⁶, Adelaide De Mauleon¹, Estelle Dubus¹, Marie Mommeja¹, Jean-Philippe Pradere^{3,5}, Maria Soto^{1,2,3}
¹Research and Clinical Alzheimer's Disease Center, CMRR, CHU Toulouse - Toulouse (France), ²Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier - Toulouse (France), ³IHU HealthAge, Inserm, CHU Toulouse - Toulouse (France), ⁴Equipe REMEMBeR. Centre de Recherches sur la Cognition Animale, CRCA, Univ. P. Sabatier - Toulouse (France), ⁵Institut RESTORE - UMR 1301 - Inserm/5070-CNRS/EFS/ Université Paul Sabatier - Toulouse (France), ⁶Maintain Aging Research team, CERPOP, Inserm, Université Paul Sabatier - Toulouse (France)
- P155 ADDITION-MCI: A clinical trial to fully exchange the blood plasma of older cognitively impaired individuals with young donor plasma.**
Sara Nygaard^{1,2}, Lana Nagmadin Karim³, Andreas Engvik⁴, Håkon Ihle-Hansen⁵, Petter Holland¹, Arne Sørhaas¹
¹Dept. of Microbiology, Oslo University Hospital - Oslo (Norway), ²Dept. of Acute Medicine, Oslo University Hospital - Oslo (Norway), ³Dept. of Immunology and Transfusion Medicine, Oslo University Hospital - Oslo (Norway), ⁴Dept. of Endocrinology, Obesity and Preventive Medicine, Oslo University Hospital - Oslo (Norway), ⁵Dept of Medicine, Bærum Hospital, Vestre Viken Hospital Trust - Drammen (Norway)
- P156 Expanding IMPACT-AD to include international trainees: A pilot program**
Margaret D. Mastrolorenzo¹, Rema Raman¹, Joshua Grill², Maria Carrillo³, Heather Snyder³
¹Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California - San Diego, Ca (United States), ²Institute of Memory Impairment and Neurological Disorders, Department of Psychiatry & Human Behavior, Department of Neurobiology & Behavior, University of California at Irvine - Irvine, Ca (United States), ³Alzheimer's Association - Chicago, IL (United States)
- P157 Implantable device for intrathecal pseudodelivery of immunotherapies: preclinical testing of a prototype for humans**
Ester Perez-Martin¹, Maria Rodriguez-Cañon¹, Gabriel Alvarez¹, Catuxa Prado¹, Cristina Tomas-Zapico^{2,3}, Manuel Menendez-Gonzalez^{2,3,4}
¹Neuroscience Innovative Technologies - Llanera (Spain), ²Universidad de Oviedo - Oviedo (Spain), ³Instituto de Investigación Sanitaria del Principado de Asturias - Oviedo (Spain), ⁴Hospital Universitario Central de Asturias - Oviedo (Spain)
- P158 ONESTX-01, a potent inhibitor of Steroid Sulphatase (STS), that restores neuron cholinergic activity and decreases cognitive impairment: design of a phase IIa clinical study.**
Viñas Andrés-Simón¹, Javier Valle-Galisteo², Juan Antonio Fernández-Cabrera³, Almudena Ramos-Pozo², José María Hernández-Curiel³, Sandra Gavalda-Martín¹, Cristina García-Gutierrez², Inés Sánchez Romero³, Mercedes Pérez-Jiménez², Elena Rodríguez Sandoval³, Antonio Aires-Trapote¹, Manuel Jesús Muñoz-Ruiz², Ángel Manuel Carrión³, Ángel Cebolla-Ramírez¹
¹Olavide Neuron STX SL - Seville (Spain), ²Universidad Pablo de Olavide, Centro Andaluz de Biología del Desarrollo (CABD), CSIC, JA - Seville (Spain), ³Universidad Pablo de Olavide, Department of Physiology, Anatomy and Cellular Biology - Seville (Spain)
- P159 Novel Cyclodextrins with Reduced Cellular Toxicity: Application in Treating Pathologic Tau-Related Lipid Accumulations**
Ji-Yeong Lee¹, Heegon Kim², Sun Ah Park^{1,3,4}
¹Lab of Neurodegenerative Dementia, Department of Anatomy, Ajou University School of Medicine - Suwon (Korea, Republic of), ²Renatus - Daejeon (Korea, Republic of), ³Neuroscience Graduate Program, Department of Biomedical Sciences, Ajou University Graduate School of Medicine - Suwon (Korea, Republic of), ⁴Department of Neurology, Ajou University School of Medicine - Suwon (Korea, Republic of)
- P160 Enhanced Imaging Techniques for ARIA Detection and Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer's Disease**
Jude-Patrick N. Okafor¹, Jacob Stefanko¹, Hope Shimony¹, Austin Mccullough¹, Nayid Jana¹, Nelly Joseph-Mathurin¹, Stephen Jarman¹, Edmond Knopp², Tammie Benzinger¹
¹Washington University School of Medicine - Saint Louis (United States), ²Hyperfine Inc. - Guilford (United States)
- P161 CRISPR-Cas9-Mediated Upregulation of Melatonin Receptor 1 Attenuates Cognitive Impairment in Alzheimer's Disease**
Jongpil Kim¹
¹Dongguk University - Seoul (Korea, Republic of)

POSTER PRESENTATIONS

- LP078 Brain Shuttles to Novel Receptors to Overcome Liabilities of First-Generation Shuttled Anti-Amyloid Therapeutics**
Shane Lofgren¹
¹Manifold Bio - Boston (United States)
- LP080 Therapeutic potential of novel GAS6 fusion protein (GAIA) - Overcoming neuroinflammation via efferocytosis in anti-Aβ immunotherapies**
Jin Kyung Lee¹, Soomin Ji¹, Sanghoon Park¹, Chan Hyuk Kim², Won-Suk Chung³
¹Illim Therapeutics, Inc. - Seoul (Korea, Republic of), ²College of Pharmacy, Seoul National University - Seoul (Korea, Republic of), ³Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST) - Daejeon (Korea, Republic of)
- LP081 Targeting Disulfide-Linked Protein Aggregation with Small Molecules: A Potential Strategy for Neurodegenerative Disease Therapy**
Nataliia Lukianenko^{1,2}, Lim Sungsu¹, Yun Kyung Kim^{1,2}
¹Center for Brain Disorders, Korea Institute of Science and Technology, Seoul, Republic of Korea - Seoul (Korea, Republic of), ²Division of Bio-Medical Science & Technology, University of Science and Technology (UST), Daejeon, Republic of Korea - Daejeon (Korea, Republic of)

THEME 15: Clinical trials Early Career Investigator Showcase

- P162 PET Imaging of Microtubules in Cognitively Normal and Impaired Older Adults: A Pilot Study**
 Bhuvanachandra Bhoopal¹, Mack Miller¹, Naresh Damuka¹, Krishna Gollapelli¹, Ivan Krizan¹, Samuel Lockhart¹, Akiva Mintz², Suzanne Craft¹,
Kiran K. Solingapuram Sai¹
¹Wake Forest School of Medicine - Winston Salem (United States), ²Columbia University School of Medicine - New York (United States)
- LP082 Effect of EGb761 on blood markers of inflammation and oxidative stress in a cohort of patients with Mild Cognitive Impairment (ACE-2020-EGb761)**
Xavier Morató¹, Juan Pablo Tartari¹, Maria Eugenia Saez², Maria Capdevila-Bayo¹, Amanda Cano¹, Laia Montoliu-Gaya³, Hanna Huber³, Asuncion Lafuente¹, Marta Ibarria¹, Susana Diego Gullon¹, Yahveth Cantero Fortiz¹, Nuria Aguilera¹, Sara Jofresa¹, Laia Cañada¹, Natalia Tantinya¹, Marta Marquié¹, Sergi Valero¹, Henrik Zetterberg³, Agustin Ruiz¹, Mercè Boada¹
¹FUNDACIO ACE - Barcelona (Spain), ²Andalusian Bioinformatics Research Centre (CAEBI) - Sevilla (Spain), ³University of Gothenburg - Mölndal (Spain)
-  **LP083 Differentiating underlying pathologies in early Alzheimer's clinical phenotypes: Interest of acoustic markers for predicting CSF biomarkers and clinical evolution**
Eloïse Da Cunha^{1,2,3}, Valeria Manera^{1,3}, Raphaël Zory⁴, Auriane Gros^{1,5,3}
¹CoBTeK (Cognition, Behaviour, Technology) Laboratory, Université Côte d'Azur - Nice (France), ²3IA Côte d'Azur (Interdisciplinary Institute of Artificial Intelligence) - Nice (France), ³Speech and Language Pathology department of Nice, Faculty of Medicine, Université Côte d'Azur - Nice (France), ⁴LAHMESS Laboratory, Université Côte d'Azur - Nice (France), ⁵Centre Mémoire Ressources et Recherche, CHU de Nice - Nice (France)
- LP084 Potential role of MRI to optimize the design of clinical trials for PSP and CBD**
Ignacio Illán-Gala¹, Jesus García-Castro¹, Lawren Vandevredde², Hillary Heuer², Rema Raman³, Michael Donohue³, Barragan Eden², Julio Rojas², Anne-Marie Wills⁴, Irene Litvan⁵, Adam Boxer²
¹Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ²Memory and Aging Center, University of California San Francisco - San Francisco (United States), ³Alzheimer's Therapeutic Research Institute (ATRI) Keck School of Medicine, University of Southern California - San Diego (United States), ⁴Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ⁵Department of Neurosciences, University of California San Diego - San Diego (United States)

POSTER SESSION 3: From Friday, November 1 – 7:15 a.m. to Friday, November 1 – 5:00 p.m.

THEME 5: Clinical trials: Cognitive and functional endpoints

- P163** **Impairments of visual information processing in dementia**
Mark Stemmler¹, Monika Daseking²
¹Friedrich-Alexander University of Erlangen-Nuremberg - Erlangen (Germany), ²Helmut-Schmidt-University Hamburg - Hamburg (Germany)
- P164** **Home-based transcranial alternating current stimulation over the precuneus in Alzheimer's disease: a double-blind, randomized, placebo-controlled trial followed by an open label phase**
Valentina Cantoni¹, Elias Paolo Casula², Chiara Cupidi³, Daniele Altomare⁴, Enrico Premi⁵, Elisa Zummo³, Romina Esposito², Nadine Huber⁶, Eino Solje^{7,8}, Maria Sofia Cotelli¹, Alessandro Martorana⁹, Giacomo Koch^{2,10,11}, Annakaisa Haapasalo¹², Alberto Benussi¹³, Barbara Borroni^{1,10}
¹Department of Continuity of Care and Frailty, ASST Spedali Civili of Brescia - Brescia (Italy), ²Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS - Rome (Italy), ³Neurology Unit, Fondazione Istituto G. Giglio - Cefalù (Italy), ⁴Department of Clinical and Behavioral Neurology, Santa Lucia Foundation IRCCS - Brescia (Italy), ⁵Stroke Unit, ASST Spedali Civili of Brescia - Brescia (Italy), ⁶A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, - Kuopio (Finland), ⁷Institute of Clinical Medicine, University of Eastern Finland, - Kuopio (Finland), ⁸Neuro center, Neurology - Kuopio (Finland), ⁹Department of Systems Medicine, Memory Clinic, University of Rome Tor Vergata, - Rome (Italy), ¹⁰Department of Clinical and Experimental Sciences, University of Brescia - Brescia (Italy), ¹¹Department of Neuroscience and Rehabilitation, University of Ferrara, and Center for Translational Neurophysiology of Speech and Communication (CTNSC), Italian Institute of Technology (IIT), - Ferrara (Italy), ¹²A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland - Kuopio (Finland), ¹³Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste - Trieste (Italy)
- P165** **Assessing informal caregivers' self-perceived sense of competence in Mild Cognitive Impairment: Psychometric evaluation of the 7-item Sense of Competence Questionnaire (SCQ)**
Pascual Sanchez-Juan¹, Elena Garcia-Arcelay², Mircea Balasa³, Gerard Piñol-Ripoll⁴, Mercè Boada⁵, Lamberto Landete⁶, Eloisa Navarro⁷, Inmaculada Abellán⁸, Angel Berbel⁹, Beatriz Espejo¹⁰, Mariló Almagro¹¹, Jesús Rodrigo¹¹, Jorge Maurino², Sagrario Manzano-Palomo⁷, Javier Ballesteros¹²
¹Fundación CIEN - Madrid (Spain), ²Roche Farma - Madrid (Spain), ³Hospital Clinic, IDIBAPS - Barcelona (Spain), ⁴IRBLLeida - Lleida (Spain), ⁵Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁶Hospital Universitario Dr. Peset - Valencia (Spain), ⁷Hospital Universitario Infanta Leonor, - Madrid (Spain), ⁸Hospital San Vicente del Raspeig, - Alicante (Spain), ⁹Hospital de la Cruz Roja Madrid - Madrid (Spain), ¹⁰Unit Hospital Clínico San Cecilio - Granada (Spain), ¹¹CEAFA - Madrid (Spain), ¹²UPV/EHU, CIBERSAM - Leioa (Spain)
- P166** **The effect of high-definition transcranial direct current stimulation (HD-tDCS) on cognitive function in patients with mild cognitive impairment: a randomized, triple-blind, sham-controlled, study**
Che-Sheng Chu¹, Chih-Chuan Pan¹, Cheng-Ho Chang¹, Yung-Chih Chiang¹, Hsin-Ya Kuo¹, Shiou-Lan Chen², Cheng-Sheng Chen²
¹Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan - Kaohsiung (Taiwan, Republic of China), ²Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan - Kaohsiung (Taiwan, Republic of China)
- P167** **The longitudinal relationship between cardiorespiratory fitness, amyloid- β , and cognitive performance in adults at risk for Alzheimer's disease.**
Adam J. Paulsen^{1,2}, Brianne M. Breidenbach^{1,2}, Matthew Glittenberg^{1,2}, Sanjay Asthana^{1,2,4}, Sterling C. Johnson^{1,2}, Tobey J. Bethausen¹, Dane B. Cook^{5,6}, Ozioma C. Okonkwo^{1,2,4}
¹Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health - Madison (United States), ²Wisconsin Alzheimer's Institute, Madison - Madison (United States), ⁴Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital - Madison (United States), ⁵Department of Kinesiology, University of Wisconsin-Madison - Madison (United States), ⁶William S. Middleton Memorial Veterans Hospital - Madison (United States)
- P168** **Evaluating the Performance of Participant-Report, Study Partner-Report, and Performance-Based Assessments of Daily Functioning in Older Adults as Functional Endpoints in Alzheimer's Disease Clinical Trials**
Hannah Truitt^{1,2}, Rebecca Amariglio^{1,3,2}, Sharon Wang³, Onyinye Udeogu³, Ariel Brathwaite³, Dorene Rentz^{1,2}, Gad Marshall^{1,3,2}, Mark Dubbelman^{1,3,2}
¹Brigham and Women's Hospital - Boston (United States), ²Harvard Medical School - Boston (United States), ³Massachusetts General Hospital - Boston (United States)
- P169** **Mapping Alzheimer's disease progression via changes in the CDR-Global for accurate clinical trial design**
Rodrigo Canovas¹, Christopher Fowler², Simon Laws^{3,4,5,6}, Stephanie Rainey-Smith^{7,8,9,10}, Colin Masters², Ralph Martins^{7,11}, Paul Maruff², James Doecke¹²
¹Australian E-Health Research Centre, CSIRO - Parkville (Australia), ²Florey Institute, The University of Melbourne - Parkville (Australia), ³Centre for Precision Health, Edith Cowan University - Joondalup (Australia), ⁴Collaborative Genomics and Translation Group, Edith Cowan University, - Joondalup (Australia), ⁵School of Medical and Health Sciences, Edith Cowan University, - Joondalup (Australia), ⁶Curtin Medical School, Curtin University - Bentley (Australia), ⁷School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ⁸School of Psychological Science, University of Western Australia - Crawley (Australia), ⁹Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), ¹⁰Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), ¹¹Department of Biomedical Sciences, Macquarie University - Macquarie (Australia), ¹²Australian E-Health Research Centre, CSIRO - Herston (Australia)

POSTER PRESENTATIONS

- P170 Time-saved due on treatment: validation in a real-world population study**
Rodrigo Canovas ¹, Marcela Cespedes ², Christopher Fowler ³, Stephanie Rainey-Smith ^{4,5,6,7}, Colin Masters ³, Ralph Martins ^{4,8}, Paul Maruff ³, James Doecke ²
¹Australian E-Health Research Centre, CSIRO - Parkville (Australia), ²Australian E-Health Research Centre, CSIRO - Herston (Australia), ³Florey Institute, The University of Melbourne - Parkville (Australia), ⁴School of Medical and Health Sciences, Edith Cowan University - Joondalup (Australia), ⁵School of Psychological Science, University of Western Australia - Crawley (Australia), ⁶Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Murdoch (Australia), ⁷Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute - Nedlands (Australia), ⁸Department of Biomedical Sciences, Macquarie University - Macquarie (Australia)
- P171 Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning-Enabled Digital Cognitive Assessment**
Ali Jannati ¹, Karl Thompson ¹, Claudio Toro-Serey ¹, Connor Higgins ¹, Russell Banks ¹, Jeff Pobst ¹, John Showalter ¹, David Bates ¹, Sean Tobyne ¹, Pascual-Leone Alvaro ¹
¹Linus Health - Boston (United States)
- P173 Neurogenesis Hypothesis- Clinical Trials of NA-831 for Alzheimer's Disease and NA-901 for Major Depressive Disorder**
Lloyd Tran ¹, Fern Vu ¹, Zung Tran ¹
¹Biomed Industries, Inc. - San Jose (United States)
- P174 Preliminary Findings on the Effects of Donepezil on Visuospatial Abilities in amyloid PET-positive Mild Cognitive Impairment Assessed Using Eye-Tracking**
Ko Woon Kim ¹, Qi Wang ², Su Jeong Wang ³, Byoung-Soo Shin ³
¹Jeonbuk National University Medical School and Hospita - Jeonju (Korea, Republic of), ²Jeonbuk National University Medical School - Jeonju (Korea, Republic of), ³Jeonbuk National University Hospital - Jeonju (Korea, Republic of)
- P175 Understanding the Early Alzheimer's Disease Experience: Perspectives from Patients and Caregivers**
Jennifer Dine ¹, Jae Lee ², Anand Shewale ², Jonathan Stokes ², Bonita Basnyat ¹, Michelle Brown ¹, Amy Greenblatt ¹, Elaheh Shirneshan ²
¹RTI International - Research Triangle Park (United States), ²AbbVie - North Chicago (United States)
- P176 Impact of Rater Change on Clinical Dementia Rating Data: A Retrospective Analysis**
David Miller ¹, Xingmei Wang ¹, Alan Kott ²
¹Signant Health - Blue Bell, Pa (United States), ²Signant Health - Prague (Czech Republic)
- P177 A strategic approach to rigorous clinical endpoint strategies in drug development – An example from a phase 2 trial in early Alzheimer's disease (EXPLAIN-AD)**
Flavia Loreto ¹, Alex Sverdlow ², Nicole Pezous ¹, Neva Coello ¹, Alex Murphy ³, Peggy Allred ⁴, Peter Rock ¹, Gul Erdemli ³, Joann Whittle ⁵, Jaffar Saleh Subaie ⁶, Jon G. Snædal ⁷, Jelena Curcic ⁸, Kristin Hannesdottir ⁴
¹Novartis - Basel (Switzerland), ²Novartis - East Hanover (United States), ³Novartis - Cambridge (United States), ⁴Novartis Biomedical Research - Cambridge (United States), ⁵Novartis Biomedical Research - Chicago (United States), ⁶Novartis - Mexico City (Mexico), ⁷National University Hospital of Iceland | LSH - Department of Geriatrics - Reykjavik (Iceland), ⁸Novartis Biomedical Research - Basel (Switzerland)
- LP085 Cognitive Assessment and Wearable Sensor-Based Gait and Balance Assessment in Studies of Alzheimer's Disease and Mild Cognitive Impairment: A Preliminary Review.**
Prateek Verma ¹
¹Clario - London (United Kingdom)
- LP086 Associations between central and peripheral biomarkers for Alzheimer's disease in community-dwelling older adults at risk of dementia.**
Mario Parra ¹, Alfredis Gonzalez Hernandez ², Jasmin Bonilla Santos ², Rodrigo Gonzalez Montealegre ², Yisela Cala ², Danilo Verge ³, Gerardo Fernandez ⁴
¹Glasgow University - Glasgow (United Kingdom), ²Surcolombiana - Neiva (Colombia), ³ViewMind - Copenhagen (Denmark), ⁴ViewMind - Bahia Blanca (Argentina)
- LP087 The effect of education on ATN biomarkers of Alzheimer's disease**
Kim Yeshin ¹, Kim Sunghoon ¹, Kim Sungheon ¹
¹Kangwon National University Hospital - Chuncheon (Korea, Republic of)
- LP089 Validation of a precision measure of cognitive change in a phase II clinical trial in early AD: The Early and Mild Alzheimer's Cognitive Composite (EMACC)**
Sarah Barnum ¹, Judith Jaeger ², Lisle Kingery ³
¹Cognition Metrics LLC - Lake Orion (United States), ²Cognition Metrics LLC - Hixson (United States), ³Consultant Neuropsychologist - Geneva (United States)
- LP090 Pilot study of a conversational AI voicebot to administer the autobiographical recall questions of the Clinical Dementia Rating**
Rachel Nosheny ¹, Jack Weston ², Emil Fristed ², Juliet Fockler ¹, Joseph Eichenbaum ¹, Derek Flenniken ¹, Krista Moulder ³, John Morris ³, Michael Weiner ¹
¹University of California, San Francisco - San Francisco (United States), ²Novoic, Ltd. - London (United Kingdom), ³Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine - St. Louis (United States)

POSTER PRESENTATIONS

Poster presentations presented remotely are indicated with this icon : 

- LP091** **Clinical meaningfulness of cognitive decline measured using the Preclinical Alzheimer's Disease Cognitive Composite score (PACC), in the preclinical stage of Alzheimer's disease**
Rodrigo Canovas ¹, Rosita Shishegar ¹, Marcela Cespedes ², Christopher Fowler ³, Hamid Sohrabi ⁴, Jurgen Fripp ², Yen Ying Lim ⁵, Jason Hassenstab ⁶, Paul Maruff ⁷, James Doecke ², Adopic Research Group ⁸
¹Australian E-Health Research Centre, CSIRO, - Melbourne (Australia), ²Australian E-Health Research Centre, CSIRO, - Brisbane (Australia), ³The University of Melbourne - Melbourne (Australia), ⁴Murdoch University - Perth (Australia), ⁵Monash University - Melbourne (Australia), ⁶Washington University - Saint Louis (United States), ⁷Cogstate - Melbourne (Australia), ⁸ADOPIC - Melbourne (Australia)
- LP092** **Incorporating personally defined brain health priorities in clinical trials outcomes: the electronic Person Specific Outcome Measure approach in the US**
Stina Saunders ^{1,2}, Ali Jannati ^{1,3}, Shane Sheehan ², Sean Tobyn ¹, Álvaro Pascual-Leone ^{1,3,4}
¹Linus Health - Boston (United States), ²Usher Institute, University of Edinburgh - Edinburgh (United Kingdom), ³Department of Neurology, Harvard Medical School - Boston (United States), ⁴Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)

THEME 6: Cognitive assessment and clinical trials

- P178** **Neuropsychological Testing in Patients with Converted and Stable Mild Cognitive Impairment**
Yunjin Lee ¹, June Sic Kim ², Hee-Jin Kim ¹
¹Hanyang University - Seoul (Korea, Republic of), ²Konkuk University Medical Center - Seoul (Korea, Republic of)
- P179** **Longitudinal analysis of the factor structure of a multidomain cognitive task battery in ageing and preclinical AD**
Nicholas Taptiklis ¹, Michele Veldsman ¹, Francesca Cormack ¹, Alex Kaula ¹, Nora Stang ², Ana Perez ², Soraya Alfonsi ³, Timo Saarinen ⁴, Fernando Maestú ³, Hanna Renvall ⁴, Camillo Marra ⁵, Paolo Rossini ⁶, Christoffer Hatlestad-Hall ², Ira Haraldsen ²
¹Cambridge Cognition - Cambridge (United Kingdom), ²Department of Neurology, Oslo University Hospital - Oslo (Norway), ³Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁴BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), ⁵Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁶Department of Neurosciences & Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)
- P180** **Interpersonal Effects of AD/DR Screening on older primary care patients and their family members wellbeing: Results from the Caregiver Outcomes of Alzheimer's Disease Screening (COADS) Trial**
Nicole Fowler ¹, Yifan Lou ², Christina Baucco ³, Malaz Boustani ¹, Joan Monin ²
¹Indiana University School of Medicine - Indianapolis (United States), ²Yale University - New Haven (United States), ³IU Center for Aging Research - Indianapolis (United States)
- P181** **Advancements in identifying stage 2 preclinical Alzheimer's disease: reliable methods to define objective memory decline associated with cerebrospinal fluid and plasma biomarkers**
David López-Martos ¹, Marc Suárez-Calvet ¹, Armand González-Escalante ¹, Marta Milà-Alomà ¹, Juan Domingo Gispert ¹, Carolina Minguillon ¹, Clara Quijano-Rubio ², Gwendlyn Kollmorgen ³, Henrik Zetterberg ⁴, Kaj Blennow ⁴, Oriol Grau-Rivera ¹, Gonzalo Sánchez-Benavides ¹
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ²Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ³Roche Diagnostics GmbH - Penzberg (Germany), ⁴Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden)
- P182** **Identification of Cognitive Impairment in Alzheimer's Disease with Drawing and Speech-Based Assessments and Metrics**
Tanya Talker ¹, Karl Thompson ¹, Ali Jannati ^{1,2}, Russell Banks ¹, John Showalter ¹, David Bates ¹, Alvaro Pascual-Leone ^{1,2,3}, Sean Tobyn ¹
¹Linus Health - Boston (United States), ²Department of Neurology, Harvard Medical School - Boston (United States), ³Hinda and Arthur Marcus Institute for Aging Research and Deanna and Sidney Wolk Center for Memory Health, Hebrew SeniorLife - Boston (United States)
- P183** **Exploring Novel RT-Based Measures Calculated from Detailed Paired Associate Learning Task Data: Preliminary Analyses**
Alexander Kaula ¹, Nick Taptiklis ¹, Francesca Cormack ^{1,2}, Nora Stang ³, Ana Perez ³, Soraya Alfonsi ⁴, Timo Saarinen ⁵, Fernando Maestú ⁴, Hanna Renvall ⁵, Camillo Marra ⁶, Paolo Rossini ⁷, Christoffer Hatlestad-Hall ³, Ira Haraldsen ³
¹Cambridge Cognition - Cambridge (United Kingdom), ²Department of Psychiatry, University of Cambridge - Cambridge (United Kingdom), ³Dept. of Neurology, Oslo University Hospital - Oslo (Norway), ⁴Centre for Cognitive and Computational Neuroscience, Universidad Complutense de Madrid - Madrid (Spain), ⁵BioMag Laboratory, HUS Medical Imaging Centre, Helsinki University Hospital, Helsinki University and Aalto University School of Science - Helsinki (Finland), ⁶Memory Clinic, Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁷Department of Neurosciences & Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)
- P184** **The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Detect the Presence of Amyloid in Clinical Samples with Cognivue Clarity®**
James Galvin ¹, Michael Kleiman ¹, Paul Estes ², Heather Harris ², Ernest Fung ²
¹University of Miami Miller School of Medicine - Boca Raton (United States), ²Cognivue, Inc - Victor (United States)
- P185** **Evaluating Cognition across Latin America: Insights from the LatAm-FINGERS Study**
Lucia Crivelli ¹, Nicolás Corvalán ¹, Ricardo F. Allegri ¹, Ismael L. Calandri ¹, Paulo Caramelli ², Mark A. Espeland ³, Francisco Lopera ⁴, Ricardo Nitrini ⁵, Kathryn V. Papp ⁶, Gustavo E. Seivler ¹, Rosa María Salinas ⁷, Ana Luisa Sosa ⁷, Claudia Kimie Suemoto ⁸, Monica Sanches Yassuda ⁹, Laura Baker ¹⁰
¹Fleni - Buenos Aires (Argentina), ²Faculty of Medicine - Universidade Federal de Minas Gerais - Belo Horizonte (Brazil), ³Departments of Internal Medicine and Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem - North Carolina (United States), ⁴Grupo de Neurociencias de Antioquia, Universidad de Antioquia - Medellín (Colombia), ⁵Cognitive and Behavioral Neurology Unit - University of São Paulo - São Paulo (Brazil), ⁶Brigham and Women's Hospital, Harvard Medical School - Massachusetts (United States), ⁷Dementias Laboratory, National Institute of Neurology and Neurosurgery - Ciudad De México (Mexico), ⁸Division of Geriatrics, Department of Internal Medicine, University of São Paulo Medical School - São Paulo (Brazil), ⁹University of São Paulo - São Paulo (Brazil), ¹⁰Wake Forest University School of Medicine - Winston-Salem, North Carolina (United States)

POSTER PRESENTATIONS

- P186** Exploring the role of education on cognitive outcomes in Hispanic/Latino Adults in Southern California: Insights from Community Based Intervention, SERVE-OC
Alissa Kurzman ¹, Bruce Albala ¹, Aryanna Chavez ¹, Jeffrey Wing ², Desiree Gutierrez ³, Darnisha Draughter ³, Bernadette Boden-Albala ³
¹University of California Irvine - Irvine (United States), ²Ohio State University - Columbus (United States), ³University of California, Irvine - Irvine (United States)
- P187** Longitudinally defined objective subtle memory decline in cognitively unimpaired individuals is associated with tau deposition in Braak I/II regions
Gonzalo Sánchez-Benavides ^{1,2,3}, David López-Martos ^{1,2}, Mahnaz Shekari ¹, Edilio Borroni ⁴, Gregory Klein ⁴, Matteo Tonietto ⁴, Marc Suarez-Calvet ^{1,2,3,5}, Juan Domingo Gispert ^{1,2}, Oriol Grau-Rivera ¹
¹BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), ²Hospital del Mar Medical Research Institute (IMIM) - Barcelona (Spain), ³Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, - Madrid (Spain), ⁴Roche Pharma Research and Early Development, Neuroscience and Rare Disease, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain)
- P188** Severe COVID-19 leads to accelerated dementia onset
Sasha Mukhija ^{1,2,3}, Max Sunog ^{1,2}, Colin Magdamo ^{1,2}, Mark W. Albers ^{1,2}
¹Harvard Medical School - Boston (United States), ²Massachusetts General Hospital - Boston (United States), ³University Hospital of Zurich - Zurich (Switzerland)
- P189** Effect of disease stage and amyloid level on harmonized data from neuropsychological tests in three natural history studies.
Rosita Shishegar ¹, Vincent Dore ¹, Pierrick Bourgea ², Simon Laws ³, Tenielle Porter ³, Samantha Burnham ⁴, Azadeh Feizpour ⁵, Michael Weiner ⁶, Jason Hassenstab ⁷, Christopher Row ⁵, Victor Villemagne ⁸, Colin Masters ⁵, Jurgen Frapp ², James Doecke ², Hamid Sohrabi ⁹, Paul Maruff ¹⁰
¹The Australian e-Health Research Centre, CSIRO - Melbourne (Australia), ²The Australian e-Health Research Centre, CSIRO - Brisbane (Australia), ³School of Biomedical Sciences, Faculty of Health Sciences, Curtin University - Perth (Australia), ⁴Avid, Eli Lilly and Company - Boston (United States), ⁵Florey Institute of Neuroscience and Mental Health, The University of Melbourne - Melbourne (Australia), ⁶Center for Imaging of Neurodegenerative Diseases, University of California-San Francisco - San Francisco, (United States), ⁷Institute of Clinical and Translational Sciences, Washington University School of Medicine - St Louis (United States), ⁸Department of Psychiatry, University of Pittsburgh - Pittsburgh (United States), ⁹Centre for Healthy Ageing, Health Futures Institute, Murdoch University - Perth (Australia), ¹⁰Cogstate Ltd - Melbourne (Australia)
- P191** ClinCloud Successfully Democratizes POLARIS-AD Phase 3 Early Alzheimer's Disease Study to Maximize Trial Exposure to Diversified and Underserved Populations
Maria Biban ¹, James Rock ², Jessica Branning ¹, Caroline Skirrow ³, Geraldine Marino ¹, Landon Estes ¹, Karem Sapp ¹, Natalie Gadea ¹
¹ClinCloud, LLC - Maitland (United States), ²AriBio Co., LTD - San Diego (United States), ³Novoic LTD - London (United Kingdom)
- P192** Associations between body composition metrics, Clinical Dementia Rating Scale (CDR[®]) scores, gender, and race/ethnicity among older adults with and without cognitive impairment
Giovanna Pilonieta ¹, David Geldmacher ¹
¹The University of Alabama at Birmingham - Birmingham (United States)
- P193** Relationship between body composition metrics and performance on the Dementia Rating Scale (DRS-2) in older adults with and without cognitive impairment.
David Geldmacher ¹, Giovanna Pilonieta ¹
¹The University of Alabama at Birmingham - Birmingham (United States)
- P194** Effects of the Davos Alzheimer's Collaborative Early Detection of Cognitive Impairment Program on Clinician Attitudes and Confidence
Soeren Matthe ¹, Tabasa Ozawa ¹, Valeria Baldivieso ², Otelo Corrêa Dos Santos Filho ³, Ishtar Govia ⁴, Hisatomo Kowa ⁵, Mariana Lopez-Ortega ⁶, Alison Mckean ⁷, Amy Deckert ⁸, Katherine Selzler ⁸
¹University of Southern California - Los Angeles (United States), ²AdventHealth - Orlando (United States), ³State University of Rio de Janeiro - Rio De Janeiro (Brazil), ⁴Jamaica Mental Health Advocacy Network - Kingston (Jamaica), ⁵Kobe University - Kobe (Japan), ⁶National Institute of Geriatrics - Mexico City (Mexico), ⁷Brain Health Scotland - Edinburgh (United Kingdom), ⁸Davos Alzheimer's Collaborative - Wayne (United States)
- P195** Davos Alzheimer's Collaborative Healthcare System Preparedness Early Detection Program: Key Roles for Successful DCA Implementation
Amy Deckert ¹, Katherine J. Selzler ¹, Laura Chavira-Razo ¹, Alissa Kurzman ¹, Tim Macleod ¹
¹Davos Alzheimer's Collaborative - Wayne (United States)
- P196** Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) changes anchored with CDR progression in a preclinical AD population
Catarina Cunha ¹, Raymond Blattner ¹, Barbara Echevarria ¹, Selam Negash ¹, Christopher Randolph ¹
¹WCG Clinical Research Solution - Princeton (United States)
- P197** An Assessment of the Utility of the Montreal Cognitive Assessment (MoCA) in predicting Amyloid PET Positivity in Alzheimer's Disease (AD) Clinical Trials
Elizabeth Sosa ¹
¹Irvine Clinical Research - Irvine (United States)

POSTER PRESENTATIONS

Poster presentations presented **remotely** are indicated with this icon: 

- P198** **Development and validation of a 4-years all-cause dementia prediction tool based on sleep-related symptoms using a score risk prediction model**
Hyukjun Lee¹, Ji Won Han¹, Jong Bin Bae¹, Dong Gyu Moon¹, Jin Shin², Dae Jong Oh³, Eunji Lim⁴, Bong Jo Kim⁵, Dong Woo Lee⁶, Jeong Lan Kim⁷, Joon Hyuk Park⁸, Jung Jae Lee⁹, Kyung Phil Kwak¹⁰, Seok Bum Lee⁹, Ki Woong Kim¹¹
¹Department of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ²Department of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ³Workplace Mental Health Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ⁴Department of Neuropsychiatry, Gyeongsang National University Changwon Hospital - Changwon (Korea, Republic of), ⁵Department of Psychiatry, Gyeongsang National University, School of Medicine - Jinju (Korea, Republic of), ⁶Department of Neuropsychiatry, Inje University Sanggye Paik Hospital - Seoul (Korea, Republic of), ⁷Department of Psychiatry, School of Medicine, Chungnam National University - Daejeon (Korea, Republic of), ⁸Department of Neuropsychiatry, Jeju National University Hospital - Jeju (Korea, Republic of), ⁹Department of Psychiatry, Dankook University Hospital - Cheonan (Korea, Republic of), ¹⁰Department of Psychiatry, Dongguk University Gyeongju Hospital - Gyeongju (Korea, Republic of), ¹¹Department of Psychiatry, Seoul National University, College of Medicine - Seoul (Korea, Republic of)
- P199** **Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease in AdventHealth**
Valeria Baldovino¹, Steven R. Smith¹, Richard E. Pratley¹, Magda Baksh¹, Gayle Shepherd¹, Janice Lopez¹
¹AdventHealth - Orlando (United States)
- P200** **Clinical Management during the Davos Alzheimer's Collaborative Early Detection of Cognitive Impairment Program in Six Countries**
Soeren Matthe¹, Tabasa Ozawa¹, Jiahe Chen¹, Valeria Baldovino², Otelo Corrêa Dos Santos Filho³, Ishtar Govia⁴, Hisatomo Kowa⁵, Mariana Lopez-Ortega⁶, Alison McKean⁷, Deanna Willis⁸, Amy Deckert⁹, Katherine Selzler⁹
¹University of Southern California - Los Angeles (United States), ²AdventHealth - Orlando (United States), ³State University of Rio de Janeiro - Rio De Janeiro (Brazil), ⁴Jamaica Mental Health Advocacy Network - Kingston (Jamaica), ⁵Kobe University - Kobe (Japan), ⁶National Institute of Geriatrics - Mexico City (Mexico), ⁷Brain Health Scotland - Edinburgh (United Kingdom), ⁸Indiana University School of Medicine - Indianapolis (United States), ⁹Davos Alzheimer's Collaborative - Wayne (United States)
- P201** **Accounting for Wordlist Feature Differences across Alternate Forms of the ADAS-Cog Word Recall Test**
Jason Bock^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Tushar Mangrola¹, Michael Lee²
¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)
- LP093** **Comparability and Usability of Cambridge Neuropsychological Test Automated Battery (CANTAB®) tests delivered via a smartphone**
Emily Thorp¹, Alexander Kaula¹, Nick Taptiklis¹, Elizabeth Wragg¹, Francesca Cormack^{1,2}
¹Cambridge Cognition Ltd. - Cambridge (United Kingdom), ²Department of Psychiatry, University of Cambridge - Cambridge (United Kingdom)
- LP094** **Evaluation of a multicomponent PFAS assay in blood samples to assess the impact of cognitive function**
Heesoo Eun¹, Hiroshi Hata¹, Mayumi Ohnishi-Kameyama¹, Jieun Yoon²
¹National Agriculture and Food Research Organization (NARO) - Tsukuba (Japan), ²University of Tsukuba - Tsukuba (Japan)
- LP095** **Psychometric Validity of Neurocognitive Biomarkers from ViewMind: insights from Classical Cognitive Screenings**
Gerardo Fernandez¹, Alfreidis Gonzalez Hernandez², Jasmin Bonilla Santos², Rodrigo Gonzalez Montealegre², Yisela Cala², Valentin Barco¹, Danilo Verge³, Mario Parra⁴
¹ViewMind - Bahia Blanca (Argentina), ²SurColombiana - Neiva (Colombia), ³ViewMind - Copenhagen (Denmark), ⁴Glasgow University - Glasgow (United Kingdom)
- LP096** **Remote and unsupervised digital monitoring of memory decline in patients with mild cognitive impairment**
Sarah Polk¹, Kristin Basche², Luca Kleindam³, Wenzel Glanz¹, Robert Pernecky⁴, Annika Spottke³, Anja Schneider³, Jens Wiltfang⁵, Stefan Teipel⁶, Michael Wagner³, Sterling Johnson², Lindsay Clark², Frank Jessen³, Emrah Düzel¹, David Berron¹
¹German Center for Neurodegenerative Diseases (DZNE) - Magdeburg (Germany), ²University of Wisconsin School of Medicine and Public Health - Madison (United States), ³German Center for Neurodegenerative Diseases (DZNE) - Bonn (Germany), ⁴German Center for Neurodegenerative Diseases (DZNE) - München (Germany), ⁵German Center for Neurodegenerative Diseases (DZNE) - Göttingen (Germany), ⁶German Center for Neurodegenerative Diseases (DZNE) - Rostock (Germany)

THEME 7: Behavioral disorders and clinical trials

- P202** **EHR-Based Identification and Pre-qualification of Patients with Behavioral Symptoms of Alzheimer's Disease for Neuropsychiatric Clinical Trials**
Sahaj Mahesh¹, Erin Beck¹, Daniel Gautieri¹
¹SiteRx - New York (United States)
- P203** **Baseline Demographics of the ECT-AD Trial: Electroconvulsive Therapy for the Management of Treatment-Refractory Agitation and Aggression in Advanced Dementia**
Maria Lapid¹, Martina Mueller², Adriana Hermida³, George Petrides⁴, Louis Nykamp⁵, Anthony Chatham³, David Harper⁶, Simon Kung¹, Sandeep Pagali¹, Regan Patrick⁶, Cristina Pritchett³, Patricio Riva Posse³, Sohag Sanghani⁷, Steve Seiner⁶, Brent Forester⁸
¹Mayo Clinic - Rochester (United States), ²Medical University of South Carolina - Charleston (United States), ³Emory University School of Medicine - Atlanta (United States), ⁴RWJBarnabas Health System, Trinitas Regional Medical Center - Elizabeth (United States), ⁵Pine Rest Christian Mental Health Services - Grand Rapids (United States), ⁶McLean Hospital - Belmont (United States), ⁷Northwell - New Hyde Park (United States), ⁸Tufts University School of Medicine - Boston (United States)
- P204** **Caregiving-related depression increases neuroinflammation in spousal caregivers of individuals with cognitive impairment: a longitudinal study**
So Yeon Jeon¹, Hee Won Yang¹, Jeong Lan Kim¹
¹Chungnam National University Hospital - Daejeon (Korea, Republic of)

POSTER PRESENTATIONS

- P205 Predicting suicide risk in individuals with cognitive decline: integrating sociodemographic and clinical predictors**
 Eva Vidovic ¹, Jernej Rudi Finžgar ², Anja Kokalj Palandacic ¹, Polona Rus Prelog ^{1,3}
¹University Psychiatric Clinic Ljubljana - Ljubljana (Slovenia), ²Technical University Munich, School of CIT, Department of Computer Science - Garching (Germany), ³Faculty of Medicine, University of Ljubljana - Ljubljana (Slovenia)

THEME 8: Health economics and clinical trials

- P206 Risk prediction models of mild cognitive impairment using electronic health record data**
 Gang Li ¹, Viswanath Devanarayan ¹, Rachel Halpern ², Stephane Borenstein ¹, Susan Desanti ¹, Jo Vandercappellen ¹, Ara Khachaturian ³, Richard Crislip ², Jeffrey Meyerhoff ², Joanne Bell ¹, Mattke Soeren ⁴, Harald Hampel ¹
¹Eisai - Nutley (United States), ²Optum - Prairie (United States), ³PAD2020 - Washington (United States), ⁴University of Southern California - Los Angeles (United States)
- P207 Development of a simulation model of Alzheimer's Disease to evaluate disease modifying treatments in a memory clinic population**
 Pieter Van Der Veere ^{1,2,3}, Hana Broulikova ^{4,5}, Jeroen Hoogland ⁶, Jort Vijverberg ^{1,3}, Wiesje Flier ^{1,2,3}, Hans Berkhof ²
¹Alzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), ²Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands), ³Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands), ⁴Department of Health Science, Faculty of Science, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), ⁵Department of Public Mental Health, National Institute of Mental Health - Klecany (Czech Republic), ⁶Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University Medical Center - Amsterdam (Netherlands) - Amsterdam (Netherlands)
- P208 Estimation of Long-term Care Utilization and Lifetime Distribution of Medical Cost for Dementia in Korea**
 Jun Hong Lee ¹
¹NHIS Ilsan Hospital - Goyang-Si (Korea, Republic of)
- P209 Use of a Mobile Research Unit to Address Health Disparities in Alzheimer's Clinical Trials**
 Santiago Santelis ¹, Sandra Carmona Torres ¹, Rachel Rittichier ¹, Gisel Kautz ¹, Lucy Lenox ¹, Brina Quaning ²
¹K2 Medical Research - Orlando (United States), ²MetroHealth Inc. - Orlando (United States)
- LP097 Cost-effectiveness of diagnosing and treating patients with early Alzheimer's Disease with anti-amyloid treatment**
 Anders Wimo ¹, Ron Handels ², Kaj Blennow ³, Jaka Bon ⁴, Andreja Emersic ⁴, Bjørn-Eivind Kirsebom ⁵, Fernando Gonzalez-Ortiz ³, Milica Gregoric Kramberger ⁴, Andreja Speh ⁴, Per Selnes ⁶, Anders Sködlunger ¹, Santiago Timón-Reina ⁶, Pieter Jelle Visser ², Ellen Vromen ⁷, Bengt Winblad ¹, Tormod Fladby ⁶
¹Karolinska Institutet - Solna (Sweden), ²Maastricht University - Maastricht (Netherlands), ³University of Gothenburg - Gothenburg (Sweden), ⁴University Medical Centre Ljubljana - Ljubljana (Slovenia), ⁵The Arctic University of Norway - Tromsø (Norway), ⁶University of Oslo - Oslo (Norway), ⁷Vrije Universiteit Amsterdam - Amsterdam (Netherlands)
- LP098 Assessing the Adequacy and Distribution of US Clinical Trial Sites for Alzheimer's Disease: Addressing Regulatory, Diversity, Equity, and Inclusion Challenges**
 Sean Stanton ¹, John Ahn ², Sandra Torres ¹, Stephanie Cassidy ¹, Kerry Lovelace ¹, Seth Goodman ¹, Daniel Gautiera ¹
¹K2 Medical Research - Orlando (United States), ²K2 Medical Research - San Francisco (United States)

THEME 9: Epidemiology and clinical trials

- P210 Impact of Physical Activity on Risk of Dementia in Pre-Menopausal and Post-Menopausal Women**
 Lim Eunye ¹, Cho Ahyun ¹
¹Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea - Seoul (Korea, Republic of)
- P211 Evaluating ICD-10 Medicare Claims Data as a Method of Identifying Persons Living with Dementia**
 Joya Bhattacharyya ¹, Yi Chen ², Kan Gianattasio ³, Francine Grodstein ³, Bryan James ², Ali Moghtaderi ¹, Christina Prather ¹, David Rein ³, Raj Shah ², Emma Stapp ¹, Melinda Power ⁴
¹George Washington University - Washington, Dc (United States), ²Rush University - Chicago, Il (United States), ³NORC - Chicago, Il (United States), ⁴George Washington University - Washington (United States)
- P212 Use of Medications in Patients with Alzheimer's Disease Before and After Diagnosis**
 Olga Sánchez-Solís ¹, Yael Barer ², Sivan Gazit ², Lisa Vinikoor-Imler ¹, Gabriel Chodick ²
¹AbbVie - North Chicago (United States), ²Maccabi Institute for Research and Innovation, Maccabi Healthcare Services - Tel Aviv (Israel)
- P214 The Dementia Datahub: Development of a National Surveillance System of Diagnosed Dementia in the United States**
 David Rein ¹, Kan Giannattasio ², John Wittenborn ³, Samuel Knisely ⁴, Carrie Bao ⁴, Qian Gu ⁴, Melinda Power ⁵
¹NORC at the University of Chicago - Atlanta (United States), ²NORC at the University of Chicago - Bethesda (United States), ³NORC at the University of Chicago - Raleigh (United States), ⁴KPMG - Mclean (United States), ⁵KPMG - Washington District Of Columbia (United States)

POSTER PRESENTATIONS

Poster presentations presented **remotely**
are indicated with this icon : 

- P215 **Impact of Helicobacter pylori eradication on age-specific risk of incident dementia in patients with peptic ulcer disease: A nationwide population-based cohort study**
Kang Dong Woo¹
¹Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea - Seoul (Korea, Republic of)
- P216 **Epidemiological Survey of Dementia in the Korean Elderly Population**
Im Seok Koh^{1,2}, Jeewon Suh^{1,2}, Mookyoung Oh², Jungrea Lee², Hyunsung Cho², Se Jin Kim³
¹Department of Neurology, National Medical Center - Seoul (Korea, Republic of), ²National Institute of Dementia, National Medical Center - Seoul (Korea, Republic of), ³Korea Institute for Health and Social Affairs - Sejong (Korea, Republic of)
- P217 **All-cause mortality increased with intracerebral hemorrhage in the United States Medicare Beneficiaries 65 years or older with mild cognitive impairment or Alzheimer's dementia**
Haixin Zhang¹, Babak Haji¹, Gao Ran¹, Michael Irrizary¹, Quanwu Zhang¹, Amir Abbas Tahami Monfared¹
¹Eisai - Nutley (United States)
-  P219 **Epidemiological study of hospital morbidity due to Alzheimer's disease in Brazil from 2008 to 2023: a contribution to clinical trials.**
Julia Fahd¹, Gabriel Betez¹, Gustavo Santos¹, Julia Grilo¹, Isabelle Borges¹
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil)
-  P220 **The importance of cognitive reserve in maintaining brain health in Alzheimer's disease**
Gabrielle Almeida¹, Gustavo Santos², Amanda Scarso², Beatriz Hara², Larissa Rubim², Giovana Villar², Fabiola Moraes²
¹Faculdade Sao Leopoldo Mandic de Araras, Medical School - Araras (Brazil), ²Faculdade Sao Leopoldo Mandic de Araras, Medical School - Louveira (Brazil)
- LP099 **Diversity amongst the Phase 3 HOPE study participants is reflective of the real-world Alzheimer's Disease (AD) population**
Lily Lee¹, John Dwyer¹, Celine Houser¹, Alex Konisky¹, Evan Hempel¹, Tamiko Magee-Rodgers¹, Michael Hull¹, Christian Howell¹, Ralph Kern¹
¹Cognito Therapeutics - Cambridge, Ma (United States)
- LP100 **Estimating by race and APOE ε4 carrier status counts of US adults with subjective cognitive decline with preclinical Alzheimer's disease**
Cai Gillis¹, Sharda Showell¹, Nancy Maserejian¹
¹Biogen - Cambridge (United States)
- LP101 **Regional disparities in adherence of anti-dementia medications**
Young-Gun Lee¹, Eunyong Lee², Sungwoo Kang³
¹Inje University College of Medicine - Goyang (Korea, Republic of), ²Borame Medical Center - Seoul (Korea, Republic of), ³Yonsei University College of Medicine - Seoul (Korea, Republic of)
-  LP103 **Global estimates of number of persons across key subgroups of the Alzheimer continuum**
Nicholas Norton¹, Anders Gustavsson^{1,2}, Aiman Afaque¹
¹Quantify Research - Stockholm (Sweden), ²Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden)

POSTER PRESENTATIONS

THEME 10: Animal model

- P221** **Nanoscale imaging of pT217-tau in aged rhesus macaque entorhinal and dorsolateral prefrontal cortex: Evidence of interneuronal trafficking and early-stage neurodegeneration**
Dibyadeep Datta¹, Isabella Perone¹, Denethi Wijegunawardana¹, Feng Liang², Yuri Morozov¹, Jon Arellano¹, Alvaro Duque¹, Zhongcong Xie², Christopher Van Dyck¹, Mary Kate Joyce¹, Amy Arnsten¹
¹Yale University - New Haven (United States), ²Massachusetts General Hospital and Harvard Medical School - Boston (United States)
- P222** **2D3A8 a p53 Conformation-Specific Antibody Reacts with Alzheimer's Disease-positive Tissue in human brain samples.**
Shmuel Agus¹, David Lynch², Madison Samples², Rakez Kaye², Simona Picciarelli³, Paul Kinnon³
¹Diadem SpA - Rosindale (United States), ²Mitchell Center for Neurodegenerative diseases, University of Texas Medical Branch (UTMB) - Galveston (United States), ³Diadem Srl - Milano (Italy)
- P225** **Cryo-EM Structures of Amyloid- β Fibrils from Alzheimer's Disease Mouse Models**
Fernanda Salome Peralta Reyes¹, Mara Zielinski², Lothar Gremer^{2,3}, Gunnar F. Schröder^{2,4}
¹Institut für Physikalische Biologie, Heinrich Heine Universität Düsseldorf - Düsseldorf (Germany), ²Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich - Düsseldorf (Germany), ³Institut für Physikalische Biologie, Heinrich Heine Universität Düsseldorf - Düsseldorf (Germany) - Düsseldorf (Germany), ⁴Physics Department, Heinrich Heine University Düsseldorf - Düsseldorf (Germany)

THEME 13: Digital health/E-trials

- P226** **Retinal AI-based Alzheimer's Disease Detection Model Identifies Poor Brain Health in Cognitively Unimpaired Subjects**
 Vincent Chung Tong Mok¹, Ho Ko¹, Bonnie Yin Ka Lam¹, Huijing Zheng¹, Yuen Ting Ng¹, Lisa Wing Chi Au¹, Alex Yuk Lun Lau¹, Alan Hiu Fung Lam², Anran Ran³, Xiaoyan Hu³, Ha Ying Chiu⁴, Carol Yim Lui Cheung³
¹Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), ²Department of Mechanical and Automation Engineering, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), ³Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR - Hong Kong (Hong Kong), ⁴The Charles Kao Foundation for Alzheimer's Disease - Hong Kong (Hong Kong)
- P227** **Cognitive therapy software for improving cognitive function for patients with MCI**
Hojin Choi¹, Jong Hyun Jeon¹, Yangki Minn², Chi Kyung Kim³
¹Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), ²Department of Neurology, Kangnam Sacred Heart Hospital - Seoul (Korea, Republic of), ³Department of Neurology, Korea University Guro Hospital - Seoul (Korea, Republic of)
- P229** **Earlier is better: Clinical Trial Simulator SimulAD quantifies the relationship between amyloid/tau load severity and the amplitude of cognitive benefits of anti-amyloid treatments.**
Anna Custo^{1,2}, Marco Lorenzi³, Giovanni Frisoni⁴, Valentina Garibotto^{1,2,5}
¹Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University - Geneva (Switzerland), ²Neurocenter and Faculty of Medicine, University of Geneva - Geneva (Switzerland), ³Inria Sophia Antipolis, Université Côte d'Azur - Sophia Antipolis (France), ⁴Geneva Memory Center, Geneva University Hospitals and Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva - Geneva (Switzerland), ⁵Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals and CIBM Center for Biomedical Imaging, Geneva University Hospitals - Geneva (Switzerland)
- P230** **The CAN-THUMBS UP Brain Health Support Program: Outcome completion rates in a fully remote online intervention study**
Howard Feldman^{1,2}, Nicole Anderson³, Sylvie Belleville^{4,5}, Paul Brewster⁶, Andrew Lim⁷, Manuel Montero-Odasso^{8,9}, Haakon Nygaard¹⁰, January Durant^{1,2}, Jody-Lynn Lupo^{1,2}, Penelope Slack¹⁰, Howard Chertkow³
¹Department of Neurosciences, University of California San Diego - La Jolla (United States), ²Alzheimer's Disease Cooperative Study, University of California San Diego - La Jolla (United States), ³Rotman Research Institute, Baycrest Academy for Research and Education; University of Toronto - Toronto (Canada), ⁴Centre de recherche de l'Institut Universitaire de gériatrie du CIUSSS du Centre-Sud-de-l'Île-de-Montréal - Montréal (Canada), ⁵Université de Montréal - Montréal (Canada), ⁶Cognition & Technology Research Group, Institute on Aging and Lifelong Health, University of Victoria - Victoria (Canada), ⁷Sunnybrook Research Institute - Toronto (Canada), ⁸Gait and Brain Laboratory, Lawson Health Research Institute, Parkwood Institute - London (Canada), ⁹Schulich School of Medicine and Dentistry, Department of Medicine (Geriatrics), University of Western Ontario - London (Canada), ¹⁰Division of Neurology, University of British Columbia - Vancouver (Canada)
- P231** **Digital Assessment of Cognition for Optimizing Neuropsychology Workflow**
 Ali Jannati¹, Karl Thompson¹, Claudio Toro-Serey¹, Russell Banks¹, Connor Higgins¹, Jeff Pobst¹, John Showalter¹, David Bates¹, Sean Tobyne¹, David Libon¹, Rod Swenson¹, Alvaro Pascual-Leone¹
¹Linus Health - Boston (United States)
- P232** **Comparing Eye-Tracking Metrics for Figure-Copying in Amyloid-Negative and Amyloid-Positive Mild Cognitive Impairment**
Ko Woon Kim¹, Qi Wang², Su Jeong Wang³, Byoung-Soo Shin¹
¹Jeonbuk National University Medical School and Hospital - Jeonju (Korea, Republic of), ²Jeonbuk National University Medical School - Jeonju (Korea, Republic of), ³Jeonbuk National University Hospital - Jeonju (Korea, Republic of)
- P233** **Validation of a Lifestyle Risk Assessment 'Smart Tracker' tool**
Larissa Mcketton¹, Angela Troyer^{2,3}, Nicole Anderson^{1,3,4}
¹Rotman Research Institute, Baycrest Academy for Research and Education - Toronto (Canada), ²Neuropsychology and Cognitive Health, Baycrest - Toronto (Canada), ³Department of Psychology, University of Toronto - Toronto (Canada), ⁴Department of Psychiatry, University of Toronto - Toronto (Canada)

POSTER PRESENTATIONS

Poster presentations presented **remotely**

are indicated with this icon :



- P234 Agreement between Altoida's Digital Biomarker Platform and standard neuropsychological tests in individuals with subjective memory complaints**
M. Florencia Iulita¹, Alberto Ferrari¹, Gonzalo Sanchez Benavides², Victoria Brugada Ramentol¹, Silvia Fallone¹, Nicholas Griffin¹, Emmanuel Streeel¹, Oriol Grau-Rivera², Carolina Minguillon², Claudia Porta-Mas², Mylea Charvat¹, Ioannis Tarnanas¹
¹Altoida Inc. - Washington Dc (United States), ²BarcelonaBeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain)
- P235 Reliability and validity of a tablet-based neuropsychological test (the Hellocog) for screening dementia**
Hee Won Yang¹, Daniel Hahnsam Seok², Ki Woong Kim²
¹Chungnam national university hospital - Daejeon (Korea, Republic of), ²Seoul National University - Seoul (Korea, Republic of)
- P236 Virtual reality-based cognitive training improves cognitive function in alzheimer's disease patients**
Ho-Won Lee¹, Dohun Kim²
¹Dep. of Neurology, School of Medicine, Kyungpook National University - Daegu (Korea, Republic of), ²G-L Co, Ltd - Daegu (Korea, Republic of)
- P237 The effectiveness of a virtual reality-based cognitive training program for mild cognitive impairment: A pilot study**
Eek-Sung Lee¹, Seung-Keun Lee¹, Tae-Kyeong Lee¹, Seuonghee Na², Yang Ho Kim³
¹Soonchunhyang University Bucheon Hospital - Bucheon (Korea, Republic of), ²Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea - Incheon (Korea, Republic of), ³Tenetus Co. - Seoul (Korea, Republic of)
- P238 Memory features obtained through automated phone calls associate to the intensity of subjective cognitive decline in cognitively unimpaired individuals**
Clàudia Porta-Mas^{1,2}, Gonzalo Sánchez-Benavides^{1,2,3}, Elisa Mallick⁴, Johannes Tröger⁴, Nicklas Linz⁴, Alexandra König⁴, Andreea Radoi¹, Carlota Medina¹, Alba Cañas-Martínez¹, Anna Brugulat-Serrat¹, Lidia Canals-Gispert¹, Isabel Pérez-Gutiérrez¹, Marc Suárez-Calvet^{1,2,3,5}, Juan Domingo Gispert^{1,2,3}, Oriol Grau-Rivera^{1,2,3,5}
¹BarcelonaBeta Brain Research Center - Barcelona (Spain), ²Hospital del Mar Research Institute (IMIM) - Barcelona (Spain), ³Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III - Madrid (Spain), ⁴ki:elements - Saarbrücken (Germany), ⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain)
- P239 Quantifying Prediction Confidence in AI Models for EEG Analysis**
Mats Tveter^{1,2}, Thomas Tveitstøl^{1,2}, Ana Perez^{1,2}, Christoffer Hatlestad-Hall¹, Hanna Renvall^{3,4}, Fernando Maestú^{5,6,7}, Camillo Marra^{8,9}, Paolo Maria Rossini¹⁰, Ira R. J. Hebold Haraldsen¹
¹Oslo University Hospital - Oslo (Norway), ²Faculty of Medicine, University of Oslo - Oslo (Norway), ³Aalto University - Helsinki (Finland), ⁴BioMag Laboratory, Helsinki University and Aalto University School of Science - Helsinki (Finland), ⁵Universidad Complutense de Madrid - Madrid (Spain), ⁶Department of Experimental Psychology, Universidad Complutense de Madrid Madrid (Spain), ⁷IdISSC, San Carlos University Hospital - Madrid (Spain), ⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁹Catholic University of the Sacred Heart - Rome (Italy), ¹⁰IRCCS San Raffaele - Rome (Italy)
- P240 Self-supervised learning for feature extraction in EEG**
Thomas Tveitstøl^{1,2}, Mats Tveter^{1,2}, Christoffer Hatlestad-Hall¹, Camillo Marra^{3,4}, Hanna Renvall^{5,6}, Fernando Maestú^{7,8,9}, Paolo Maria Rossini¹⁰, Ira R. J. Hebold Haraldsen¹
¹Oslo University Hospital - Oslo (Norway), ²Faculty of Medicine, University of Oslo - Oslo (Norway), ³Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ⁴Catholic University of the Sacred Heart - Rome (Italy), ⁵Aalto University - Helsinki (Finland), ⁶BioMag Laboratory, Helsinki University and Aalto University - Helsinki (Finland), ⁷Universidad Complutense de Madrid - Madrid (Spain), ⁸Cognitive Psychology and Speech and Language Therapy, Universidad Complutense de Madrid - Madrid (Spain), ⁹IdISSC, San Carlos University Hospital - Madrid (Spain), ¹⁰IRCCS San Raffaele - Rome (Italy)
- P241 All-cause mortality in patients with mild cognitive impairment or Alzheimer's dementia who experienced intracerebral hemorrhage**
Ying Wang^{1,2}, Peter Morin^{3,2}, Vanesa Arasa^{3,4}, Brant Mittler⁵, Joel Reisman^{2,6}, Raymond Zhang⁷, Amir Abbas Tahami Monfared^{7,8}, Quanwu Zhang⁷, Weiming Xia^{2,6,3}
¹Wentworth Institute of Technology - Boston (United States), ²VA Bedford Healthcare System - Bedford (United States), ³Boston University - Boston (United States), ⁴VA Boston Healthcare System - Boston (United States), ⁵VA South Texas Healthcare System - San Antonio (United States), ⁶University of Massachusetts - Lowell (United States), ⁷Eisai, Inc - Nutley (United States), ⁸McGill University - Montreal (Canada)
- P241bis All-cause mortality in patients with mild cognitive impairment or Alzheimer's dementia who experienced seizure**
Myriam Abdennadher¹, Ying Wang^{2,3}, Peter Morin^{1,3}, Vanesa Arasa^{1,4}, Brant Mittler⁵, Joel Reisman^{3,6}, Raymond Zhang⁷, Amir Abbas Tahami Monfared^{7,8}, Michale Irizarry⁷, Quanwu Zhang⁷, Weiming Xia^{3,6,1}
¹Boston University - Boston (United States), ²Wentworth Institute of Technology - Boston (United States), ³VA Bedford Healthcare System - Bedford (United States), ⁴VA Boston Healthcare System - Boston (United States), ⁵VA South Texas Healthcare System - San Antonio (United States), ⁶University of Massachusetts - Lowell (United States), ⁷Eisai, Inc - Nutley (United States), ⁸McGill University - Montreal (Canada)
- P242 Screening for Dementia Using Acoustic Feature and Machine Learning of Free Conversation**
Toshiro Horigome¹, Kuo-Ching Liang¹, Taishiro Kishimoto¹
¹Keio University School of Medicine - Tokyo (Japan)

POSTER PRESENTATIONS

- P243** **The HOGAR study: Home-based brain monitoring with a self-managed EEG to study cognitive decline in the ageing population**
Eduardo López-Larraz¹, Almudena Robledo-Menéndez¹, Esperanza Jubera-García^{1,2}, Olga Gelonch³, Jorge de Francisco Moure^{4,5}, José María Marín^{4,6}, Nora Molina-Torres^{4,7}, Jose M. Pérez-Trullén^{4,8}, Elena Muñoz Farjas⁹, Rosario Osta^{4,10}, Elena Lobo^{4,11}, Antonio Lobo^{4,12}, Pedro Modrego^{4,13}, Rosa Magallón-Botaya^{4,14}, Javier Minguez¹
¹Bitbrain, Zaragoza, Spain. ²University of Cambridge, UK, Department of Psychology ³Clinical Research Group for Brain, Cognition and Behavior, Hospital de Terrassa, Consorci Sanitari de Terrassa, Spain. ⁴Instituto de Investigación Sanitaria de Aragón, Zaragoza, Spain. ⁵Servicio de neurofisiología Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. ⁶Servicio de neumología, Hospital Universitario Miguel Servet, Zaragoza, Spain. ⁷Servicio de geriatría, Hospital Nuestra Señora de Gracia, Zaragoza, Spain. ⁸Servicio de neurología, Hospital Nuestra Señora de Gracia, Zaragoza, Spain. ⁹Servicio de neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. ¹⁰Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, Spain. ¹¹Department of Preventive Medicine and Public Health, Universidad de Zaragoza, Spain. ¹²Department of Medicine and Psychiatry, Universidad de Zaragoza, Spain. ¹³Servicio de neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain. ¹⁴Department of Medicine, Psychiatry and Dermatology, Faculty of Medicine, University of Zaragoza, Spain.
- P244** **Seizure in patients with mild cognitive impairment or Alzheimer's dementia who experienced intracerebral hemorrhage**
 Myriam Abdennadher^{1,2}, Ying Wang^{3,4}, Peter J. Morin⁴, Vanesa Carlota Andreu Arasa^{5,6}, Brant Mittler⁷, Joel Reisman^{8,9}, Zhang Raymond¹⁰, Amir Abbas Tahami Monfared^{10,11}, Michael Irizarry¹⁰, Quanwu Zhang¹⁰, Weiming Xia^{9,12,13}
¹Boston Medical Center - Boston (United States), ²Boston University Chobanian & Avedisian School of Medicine - Boston (United States), ³Wentworth Institute of Technology - Boston (United States), ⁴Research Service, VA Bedford Healthcare System - Bedford (United States), ⁵Neuroradiology, VA Boston Healthcare system - Boston (United States), ⁶Radiology, Boston Chobanian & Avedisian School of Medicine - Boston (United States), ⁷Geriatric Research Education & Clinical Center, VA South Texas Healthcare System - San Antonio (United States), ⁸Center for Healthcare Organization & Implementation, VA Bedford Healthcare System - Bedford (United States), ⁹Department of Biological Sciences, University of Massachusetts Lowell - Lowell (United States), ¹⁰Alzheimer's Disease & Brain Health, Eisai Inc. - Nutley (United States), ¹¹McGill University - Montreal (Canada), ¹²Geriatric Research Education and Clinical Center - Bedford, (United States), ¹³Pharmacology, Physiology and Biophysics, Boston University Chobanian & Avedisian School of Medicine - Boston (United States)
- P245** **Big Data from Smart Ecosystems Targeting Cognitive Impairment**
Razvan Ioan Trasca^{1,2}, Mircea Dan Marzan^{1,2}, Luiza Spiru^{1,2}
¹"Carol Davila" University of Medicine and Pharmacy - Bucharest (Romania), ²Ana Aslan International Foundation - Bucharest (Romania)
- P246** **MRI imaging biomarker prediction using Alzheimer's disease characteristic acoustic speech features**
Seonki Chung¹, Hyunsun Ham², Minju Bae², Hyeonjin Kim², Keun You Kim², Jun-Young Lee^{2,1}
¹Seoul National University College of Medicine - Seoul (Korea, Republic of), ²SMG-SNU Boramae Medical Center, Department of Psychiatry - Seoul (Korea, Republic of)
- P248** **Analysis of Connectivity in Al-Mind Data using Graph Neural Networks**
Mohamed Radwan¹, Pedro G. Lind¹, Rabindra Khadka¹, Asma Belhadi¹, Ira Haraldsen², Paolo Rossini³, Camillo Marra⁴, Fernando Maestu⁵, Hanna Renvall⁶, Erik Christensen⁷, Anis Yazidi¹
¹Oslo Metropolitan University - Oslo (Norway), ²Oslo University Hospital - Oslo (Norway), ³Università Cattolica del Sacro Cuore - Milan (Italy), ⁴IRCCS San Raffaele Pisana - Rome (Italy), ⁵Universidad Politécnica de Madrid - Madrid (Spain), ⁶Helsinki University Hospital - Helsinki (Finland), ⁷Pre Diagnostics AS - Oslo (Norway)
- P249** **EEG-JEPA: Self-Supervised Learning from EEG Signals with a Joint-Embedding Predictive Architecture**
Rabindra Khadka¹, Pedro G. Lind^{1,2}, Christoffer Hatlestand-Hall³, Mohamed Radwan¹, Asma Belhadi¹, Gustavo Mello¹, Michael A. Riegler^{1,4}, Erik Christensen⁵, Hanna Renvall^{6,7}, Fernando Maestu^{8,9}, Camillo Marra^{10,11}, Paolo M. Rossini¹², Ira H. Haraldsen³, Anis Yazidi¹
¹Oslo Metropolitan University - Oslo (Norway), ²Simula - Oslo (Norway), ³University of Oslo - Oslo (Norway), ⁴Simulamet - Oslo (Norway), ⁵Pre Diagnostics AS - Oslo (Norway), ⁶Aalto University, Helsinki, Finland - Helsinki (Finland), ⁷Helsinki University Hospital - Helsinki (Finland), ⁸Universidad Complutense de Madrid - Madrid (Spain), ⁹San Carlos University Hospital - Madrid (Spain), ¹⁰Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome (Italy), ¹¹Catholic University of the Sacred Heart - Rome (Italy), ¹²Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele - Rome (Italy)
- LP104** **Identification, Enrichment, and Longitudinal Tracking of Alzheimer's Disease Patients via the SiteRx CNS Disease Registry**
Sahaj Mahesh¹, Daniel Gautieri¹
¹SiteRx - New York (United States)
- LP105** **Can an AI voice agent (Grove AI) successfully recruit participants into Alzheimer's Clinical Trials?**
Stephanie Cassidy¹, Kerry Lovelace¹, Tran Le², Sohith Gatiganti², Anthony Riley², Sandra Torres¹, Phuc Truong³, Michael Isaac¹, Gina Cedano¹, Michelle Montone¹, Brandon Lenox¹, Natalia Torres¹, Dennis Moya¹, Stanton Sean¹
¹K2 Medical Research - Orlando (United States), ²Grove AI - San Francisco (United States), ³Vision Cycles - Boston (United States)
- LP106** **Differential Diagnosis of Alzheimer's disease and frontotemporal dementia using multimodal Deep Learning**
 Gianmarco Guarnier^{1,2}, Janis Reinelt¹, Eóin N. Molloy¹, Paul Glad Mihai¹, Pegah Einaliyan¹, Sofie Valk^{3,4,5}, Augusta Modestino¹, Matteo Ugolini¹, Aroma Dabas^{1,6}, Rhys Agombar¹, Karsten Mueller^{3,7}, Wu Qiong³, Anahit Babayan², Marco Castellaro⁸, Arno Villringer^{3,9}, Konstantin Thierbach^{1,3}, Matthias L. Schroeter^{3,9}
¹AICURA medical GmbH - Berlin (Germany), ²Max Planck Institute for Human Cognitive and Brain Sciences - Leipzig (Germany) - Leipzig (Germany), ³Max Planck Institute for Human Cognitive and Brain Sciences - Leipzig (Germany), ⁴Institute of Neuroscience and Medicine, Brain & Behaviour (INM-7), - Jülich (Germany), ⁵Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf - Düsseldorf (Germany), ⁶Max Planck Institute for Human Cognitive and Brain Sciences - Leipzig, ⁷Department of Neurology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague - Prague (Czech Republic), ⁸Department of Information Engineering, University of Padua - Padua (Italy), ⁹Clinic for Cognitive Neurology, University Hospital Leipzig - Leipzig (Germany)

POSTER PRESENTATIONS

Poster presentations presented **remotely**
are indicated with this icon: 

- LP107** **Xpress0: a digital cognitive self-evaluation for population screening**
Willem Huijbers¹, Johanna Gruber¹, Hans-Aloys Wischmann², Murray Gillies¹, Ziad Nasreddine¹
¹MoCA Cognition - Montreal (Canada), ²Charité – Universitätsmedizin Berlin - Berlin (Germany)
- LP108** **Prescribing remote digital self-testing for suspected mild cognitive impairment: results of the re.cogni.ze study on feasibility and acceptance with the neotivCare app**
Emrah Düzel^{1,2}, Claudia Bartels³, Dirk Czesnik⁴, Thomas Duning⁵, Andreas Lüscho⁶, Gereon Nelles⁷, Gerd Reifschneider⁸, Michael Schöttler⁹, Björn Hendrik Schott³, Martin Griebel¹⁰
¹Deutsche Zentrum für Neurodegenerative Erkrankungen (DZNE) - Magdeburg (Germany), ²Institut für Kognitive Neurologie und Demenzforschung, Otto von Guericke Universität - Magdeburg (Germany), ³Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin Göttingen - Deutschland (Germany), ⁴Gemeinschaftspraxis für Neurologie - Göttingen (Germany), ⁵Klinik für Neurologie - Klinikum Bremen-Ost (Germany), ⁶MVZ Campus Benjamin Franklin - Charité Berlin (Germany), ⁷Neuromed-Campus - Köln (Germany), ⁸NeuroCentrum Odenwald - Erbach (Germany), ⁹Roche Pharma AG - Grenzach-Wyhlen (Germany), ¹⁰Neurologische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg - Heidelberg (Germany)
- LP109** **Pilot program of digital cognitive testing by Primary Care Clinicians in a large Health System**
Darren Gitelman^{1,2,3}, Jennifer Mishos¹, Michael Malone^{4,5}
¹Advocate Health - Downers Grove (United States), ²Rosalind Franklin University of Medicine and Science - Chicago (United States), ³Northwestern University - Chicago (United States), ⁴Aurora Health Care - Milwaukee (United States), ⁵University of Wisconsin School of Medicine & Public Health - Madison (United States)
- LP110** **Defining clinical contexts of use and performance standards for digital cognitive assessments: Recommendations from the Global CEO Initiative on Alzheimer's Disease**
Louisa Thompson¹, A.M. Barrett², Sol Fittipaldi^{3,4}, Barak Gaster⁵, Dustin Hammers⁶, Christopher Butler⁷
¹Brown University - Providence (United States), ²University of Massachusetts Chan Medical School - Massachusetts (United States), ³Universidad Adolfo Ibáñez - Santiago (Chile), ⁴University of California San Francisco - San Francisco (United States), ⁵University of Washington - Seattle (United States), ⁶Indiana University School of Medicine - Indianapolis (United States), ⁷Imperial College London - London (United Kingdom)
- LP111** **Real-World Care of Alzheimer's Disease Patients (n=2,153) in Germany: Insights from Registry of the Neurologists Network NeuroTransData (NTD) using the Physician/Patient Platform (DESTINY)**
Arnfried Bergmann¹, Stefan Braune¹, Oliver Fasold¹, Heidi Dikow¹, Niloofar Tavakoli¹
¹NeuroTransData GmbH, NTD Study Group, Neuburg an der Donau - Neuburg An Der Donau (Germany)

THEME 15: Clinical Trials Early Career Investigator Showcase

- P250** **The risk factors affecting CDR-SOB changes in amyloid-beta negative individuals with mild cognitive impairment and subjective memory impairment**
Hyunji Lee¹
¹Pusan National University Hospital - Busan (Korea, Republic of)
- P251** **Association of Alzheimer's disease biomarkers and emotional states: analysis of individuals with and without preclinical Alzheimer's disease in the A4 trial**
Taimur Kouser¹, James Kelbert², Ingrid Luo¹, Zihuai He³, Irina Skylar-Scott¹
¹Stanford University - Palo Alto (United States), ²University of Arizona - Phoenix (United States), ³University of Arizona - Palo Alto (United States)
- P252** **Changes in cognitive and neural markers of Alzheimer's disease in response to aerobic and non-aerobic exercise among cognitively healthy older African Americans: The role of body composition, genetics, and sex**
Bernadette Fausto¹
¹Rutgers-The State University of New Jersey - Newark (United States)
- P253** **Association between cognitive performance and emotional states: analysis from the A4 trial**
James Kelbert¹, Taimur Kouser², Ingrid Luo², Christina Young², Zihuai He², Irina Skylar-Scott²
¹University of Arizona - Phoenix, ²Stanford University - Palo Alto (United States)
- LP112** **Discrepancies in Dementia Self-Awareness: Correlations with Well-Being Across Daily Challenges**
Haruaki Horie¹, Fumiya Nakai¹, Taishiro Kishimoto¹, Masaru Mimura¹, Toshiro Horigome¹
¹Keio University Hospital - Tokyo (Japan)

CTAD would like to thank its 2024 privileged partners
for their continued support.

Ultimate Sponsor



Alzheimer's
Drug Discovery
Foundation

Platinum Sponsor



Gold Sponsors





Practical Details

Conference Venue

Madrid Marriott Auditorium Hotel & Conference Center

Avda de Aragon 400 - 28022 Madrid (Spain)



Airport shuttle: a complimentary shuttle is available to/from the airport.

The timetable is available on the mobile app and at the registration desk

ROOM LOCATOR

> Meeting Room

> Conference Room

All sessions will be held in the Auditorium in the Conference Center at Lobby Level.

> Posters Sessions and Coffee Breaks

Poster sessions will be held in the Italian Rooms - Meet our poster presenters during the coffee breaks. A poster assistance desk will be available to locate the posters.

> Registration desk opening hours:

- October 28: 04:00 p.m. to 06:00 p.m.
- October 29: 10:00 a.m. to 07:00 p.m.
- October 30: 07:30 a.m. to 06:00 p.m.
- October 31: 07:30 a.m. to 06:00 p.m.
- November 1: 07:30 a.m. to 05:45 p.m.



> Cloakroom opening hours:

- October 29: 02:00 p.m. to 10:00 p.m.
- October 30: 07:30 a.m. to 10:30 p.m.
- October 31: 07:30 a.m. to 10:30 p.m.
- November 1: 07:30 a.m. to 06:00 p.m.

> Lunch bags



Lunch bags will be available in the Poster Hall, Atrium Bar and Buffet Madrid on Wednesday, Thursday and Friday (see floorplan).

In your badge holder you have 3 lunch tickets with different colors corresponding to a different day, please hand the correct one to the catering staff to get your lunch bag.

> CTAD Networking Event with the Support of the Alzheimer's Association

Tuesday, October 29 from 7:00 p.m. to 8:00 p.m.

in the conference center.



Practical Details

POSTER WALKING TOUR

Enjoy a morning coffee while touring the posters from 7:30 a.m. to 8:30 a.m. on Wednesday, Thursday and Friday.

New at CTAD this year

CTAD is dedicated to promoting the professional development of early career investigators to ensure their success and career advancement. Join us for the “flash session presentations” in the poster area during morning and afternoon coffee breaks and discover their exciting research work (see the program for the scheduled sessions).



Free WiFi available at CTAD

Login to: MarriotBonvoy_Conference no password needed

> Mobile App

Download the VFairs mobile app on the Apple Store or Google Play. Login with the email address used to register, then click on CTAD2024 and enjoy the conference at your fingertips, you can watch the livestream from the Ballroom, access the virtual poster hall and connect with your colleagues!



vFAIRS

> CTAD24 digital platform

To access our digital platform simply go to www.ctad24.com and enter with your email address.



CTAD 2024

Clinical Trials on Alzheimer's Disease

> Keep in touch!

Follow us on social media!



[@CTADConference](https://twitter.com/CTADConference)
[#CTAD24](https://twitter.com/CTADConference)



[CTAD Conference](https://www.facebook.com/CTADConference)



[CTAD Alzheimer](https://www.linkedin.com/company/CTAD-Alzheimer)

CTAD Congress > Email: ctad@ant-congres.com
www.ctad-alzheimer.com

CTAD

2025

Clinical Trials on Alzheimer's Disease

<https://www.notion.so/Rejoignez-nous-Toul>

December 1-4, 2025

San Diego, CA, USA

Montpellier '08 • Las Vegas '09 • Toulouse '10 • San Diego '11 • Monte Carlo '12 • San Diego '13
Philadelphia '14 • Barcelona '15 • San Diego '16 • Boston '17 • Barcelona '18 • San Diego '19
Virtual '20 • Boston '21 • San Francisco '22 • Boston '23 • Madrid '24

www.ctad-alzheimer.com

Email: ctad@ant-congres.com

JPAD
The Journal of Prevention of Alzheimer's Disease